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SUMMARY
The present in vitro studies employed a radioassay, incorporating tritiated [^H] 
thymidine, to measure phagocytic uptake of Staphylococcus aureus (S. aureus) 
by polymorphonuclear leucocytes (PMNs) of patients with rheumatoid arthritis 
(RA) and healthy controls.
An intrinsic defect was detected in the phagocytic capacity of peripheral blood 
(PB) PMNs from patients with RA. Serum from RA patients and normals had a 
similar inhibitory effect on PMN phagocytosis. However, synovial fluid (SF) from RA patients 
was found to impair phagocytic ability by acting directly on the PMN. 
Furthermore, these SF significantly impaired PMN uptake as compared to SF 
from patients with various other arthritides. No correlation was found between 
defective phagocytosis and age, disease activity, drug therapy, the amount of 
circulating immune complexes (ICs) or rheumatoid factor (RF). Also, the lack 
of correlation between clinical parameters such as titres of RF and complement 
components, suggests factors other than ICs may be involved in this inhibitory 
activity.
Complement levels and heat-labile opsonic activity were lower in SF from RA 
patients than SF from other forms of arthritis or normal serum. Nevertheless, 
none of the RA sera or SF tested lacked opsonic activity.
Interleukin 1 (IL-1) production by monocytes of RA patients and normal 
subjects were studied both spontaneously and after lipopolysaccharide (LPS) 
and S. aureus stimulation. Interleukin 1 activity was measured using the LBRM 
TG-6/HT2 bioassay system. Rheumatoid arthritis monocytes spontaneously 
produced more IL-1 than the controls and this difference was maintained after
x
stimulation. When paired PB and SF monocytes were compared, SF cells 
produced less IL-1 than corresponding PB monocytes, but more than normal PB 
monocytes. This was similarly observed after stimulation. These findings 
suggest that this line of host defence is not impaired in RA patients. However, 
a high concentration of IL-1 may be detrimental to the PMNs migrating into 
the SF from the PB.
Hydrocortisone sodium phosphate was found to inhibit IL-1 
production. This is not true for the other anti-rheumatic drugs studied.
Thus, the findings of these studies suggest that the increased incidence of 
bacterial infection in RA patients is the consequence of impaired PMN 
phagocytosis. The mechanism underlying this defect could be intrinsic to the 
cell, and amplified by extracellular inhibitory factors present in SF, as yet to be 
characterised.
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OBJECTIVES
1. To investigate the possible intrinsic phagocytic defect in peripheral blood
polymorphonuclear leucocytes from patients with rheumatoid arthritis.
2. To investigate the effect of serum upon phagocytic uptake by normal and
rheumatoid arthritis peripheral blood polymorphonuclear leucocytes.
3. To investigate the effect of synovial fluid, from patient with and without
rheumatoid arthritis, upon phagocytic uptake by normal peripheral blood 
polymorphonuclear leucocytes.
4. To investigate the opsonic activity of serum and synovial fluid from patient
with rheumatoid arthritis.
5. To establish optimum in vitro conditions for production of interleukin 1
supemantants, to be used as a routine procedure in the laboratory.
6. To study interleukin 1 production by peripheral blood and synovial fluid
monocytes from patients with rheumatoid arthritis, both spontaneously and in 
response to stimulation by different stimuli; lipopolysaccharide (as soluble 
stimulus) and Staphylococcus aureus (as particulate stimulus).
7. To investigate the effect of anti-rheumatic drugs on polymorphonuclear
leucocyte phagocytosis and monocyte interleukin 1 production.
8 . To relate host susceptibility to infection to the presence or absence of cellular
dysfunction in vitro.
xv
CHAPTER ONE - GENERAL INTRODUCTION
1.1 RHEUMATOID ARTHRITIS
1.1.1 Historical and clinical aspects
The term ’rheumatoid arthritis’ was coined by Sir Alfred Baring Garrod in 
1876. One of the most intriguing aspects of the disease is its apparent scarcity 
prior to the 18th century, in contrast to osteoarthritis, gout, and infectious 
arthritis, which are diseases of antiquity. Because of the lack of convincing 
historical evidence, Boyle and Buchanan (1971) postulated that RA is a disease 
of the modem era. The first convincing description of RA is that of Landre- 
Beauvais in 1800 (Parish, 1963).
Rheumatoid Arthritis is a chronic systemic disease manifested most prominently 
by an inflammatory, symmetric polyarthritis but it can begin in a single joint 
(monoarticular RA). The onset is generally between 20 and 60 years of age, 
with peaks in the 5th and 6th decades of life. It shows a predilection to involve 
the proximal interphalangeal (PIP), metacarpophalangeal (MCP), wrist, elbow, 
shoulder, ankle, knee, hip, metatarsophalangeal (MTP) and tempromandibular 
joints (Fig I). Also involvement of the cervical spine is more common than 
generally recognised (Martel, 1977). The most frequent clinical manifestation of 
cervical spine involvement is painful limitation of neck movement.
The principal extra-articular manifestation is subcutaneous nodules. These 
nodules tend to occur over traumatised areas such as elbows, extensor surface 
of arms, knees, knuckles, heels, bridge of nose and buttocks. Approximately 
20% to 25% of all RA patients manifest such nodules eventually. They are
1
-P em p om a n di b u l a r  (Jaw)
Shoulder
Wris
MCI
• P I P
D I P
K n ee
A n k l e
l ; i g .  I Rhe uma to i d  a r t hr i t i s  -  d i s t r i b u t i o n  o f  target  j o i nt s .
generally firm, non-tender, mobile and may spontaneously vary in size. Other 
manifestations, such as vasculitis, scleritis and neuropathy do occur, although 
less frequently than the aforementioned nodules.
In the majority of patients, the disease starts gradually and insidiously. 
However in a few it can be acute. The early symptoms include malaise, 
tiredness, weight loss, fever, vague pain and morning stiffness. These tend to 
abate after the patient has ’limbered up’, but as the disease advances they tend 
to become progressively more severe and persistent. Swelling of the involved 
joints is prominent, accompanied by limitation of movement and, consequently, 
a diffuse wasting of adjacent muscles. This ultimately results in total loss of 
joint function.
Over 80% of patients follow a characteristic course of remissions and 
exacerbations, with 20% having a complete remission following the initial 
episode with neither recurrent nor residual inflammation.
Rheumatoid arthritis is divided into two categories; seropositive and 
seronegative disease, depending on the presence or absence of RFs respectively, 
in the patients’ serum. These RFs are antibodies of immunoglobulin G (IgG), 
IgA and IgM classes directed against native IgG as the autoantigen. In the early 
stages of RA many patients are classified as seronegative but convert to 
seropositive with time, others convert, either spontaneously or while receiving 
remissive agents, from positive to negative.
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1.1.2 Incidence and prognosis
Rheumatoid Arthritis is relatively common in Western communities. The 
prevalence of RA in the adult population is approximately 1%, females being 
affected more frequently than males, in a ratio of 3 to 1. No clear explanation 
for the apparent female preponderance is available.
An estimated 30% of patients do not consult a physician due to the mild nature 
of the disease. On the other hand, chronic progressive RA has long been felt to 
be associated with a reduced life expectancy. Debility and increased 
susceptibility to infection probably play some role. Those who are female and 
young at the time of an insidious onset have a less favourable prognosis than an 
older male with an acute onset. Patients who live within the limitations of their 
disease and who persist in active range-of-motion exercises along with a 
positive attitude appear to do better than those who refuse to help themselves.
1.1.3 HLA and disease association
The principal known immunogenetic association with RA is the class II human 
leucocyte histocompatability antigen, HLA-Dw4, as determined by the mixed 
lymphocyte reaction or the related HLA-DR4 allotype on lymphocytes (Panayi, 
Wooley and Batchelor, 1979). H LA-Dwl4 is also associated with susceptibility 
to RA (Nepom et al- 1987). Investigations have shown that 70% of patients 
with RA possess the HLA-DR4 locus and calculations indicate that an 
individual with the HLA antigen is six to twelve times more likely to develop 
the disease than one who is negative (Panayi and Chapel, 1987). The specificity
3
of this locus for RA is by no means as strong as the HLA-B27 locus for 
ankylosing spondylitis.
It is possible that this HLA-DR4 antigen is a marker for genes which regulate 
either the development of autoimmunity to such self components as IgG or 
IgM, or an abnormal host response to an environmental agent. It is worth 
noting that although some 25% of Caucasians are HLA-DR4 positive, only some 
5% at the most of such populations have RA (Panayi and Chapel, 1987), so 
clearly other factors are involved in causing the disease.
Moreover, 30% to 40% of patients with RA are negative for DR4, depending 
on the population studied, and in addition Jewish and Asian patients with RA 
show an association not with DRw4, but with DR1 (Grennan et al.. 1983). In 
the West of Scotland as much as 35% of the population are HLA-DR4 positive 
(Dick, personal communication).
1.1.4 Theories of aetiooathogenesis
Despite intensive clinical and experimental research, the aetiology of RA has 
eluded discovery and remains a challenging mystery. The literature on the 
subject is extensive and no attempt is made here to cover even the tip of this 
iceberg. Only a short review is given here; more detailed accounts can be found 
in a recent review (Phillips, 1986).
From experimental models in animals two main hypotheses have been proposed 
which may not necessarily be mutually exclusive. The first proposes that RA is
4
caused by infectious agents such as bacteria, mycoplasma or viruses. The second 
proposes that RA is an autoimmune disease.
The former theory has led to several studies which implicate various organisms 
in the pathogenesis of RA (Phillips, 1986). Unfortunately, attempts at isolating 
live bacteria have not yielded consistent or reproducible results. The emphasis 
then switched to an attempt to detect bacterial cell wall antigens. The idea that 
bacterial debris can be phagocytosed by macrophages but not degraded, thus 
allowing it to persist as a chronic irritant has been proposed by Bennett (1978). 
Ebringer and his associates in 1985, implicated Proteus mirabilis (P. mirabilisl 
as a causative agent after detecting antibodies (Abs) to these organisms in RA 
patient sera.
There has been a long-standing fascination with mycoplasmas as a cause of RA, 
since these organisms can also produce, in a range of animals, an experimental 
arthritis which bears a striking resemblance to RA in humans (Cole and Cassell,
1979). Infection with a mycoplasma might initiate an inflammatory response 
that is enhanced by the mitogenic activity of the organism. Cartilaginous and 
tissue damage ensues, leaving the joint more susceptible to host attack. The 
mycoplasma may then incorporate the host’s cellular antigens (Ags), thereby 
stimulating an autoimmune reaction that leads to chronic arthritis. Supporting 
the notion of their involvement in human arthritis, mycoplasmas have been 
isolated from human synovial fluid with increasing frequency (Taylor-Robinson 
et al.. 1978), primarily as a result of improved culture techniques. There is also 
the possibility that these could be contaminants.
The past decade has seen a heightened awareness of a possible viral aetiology 
because of the interesting association of RA nuclear antigen. This is an Ag
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induced in lymphoblastoid cell lines infected with Epstein-Barr virus. Serologic 
studies, confirmed that Ab to this Ag was found in 70% to 95% of RA patients 
compared with less than 20% of various control groups (Ferrell et al.. 1981). 
Rubella virus has been a perennial aetiologic candidate in RA, but recent, like 
earlier studies, have yielded conflicting results (Norval, Hart and Marmion, 
1979; Ford et al.. 1982). Outbreaks of epidemic polyarthritis following infection 
with the Ross River virus, an arbovirus, have been well documented (Bennett, 
1983). Hurst et al. (1983) described three patients who developed polyarthritis 
after an acute febrile illness with definite Coxsackie B virus infection. 
Cytomegalovirus has been detected in cells cultured from rheumatoid synovial 
membrane (Goodacre and Dick, 1984) and more recently parvovirus has 
attracted attention (White et al.. 1985).
To date, no virus has been proven to cause RA, but because of the capacity of 
viruses to alter immune responses, to produce experimental arthritis, and in 
certain known naturally occurring viral infections of man to mimic the clinical 
and pathologic features found in RA, they continue to be principal candidates 
for the initiation or propagation of the disease.
The second hypothesis proposes that the disease is the expression of disordered 
immunity leading to an autoimmune attack on the body’s own constituents. One 
possibility is autoimmunity to IgG, which would explain the production of RF. 
In 70% of patients RF can be demonstrated by serological means and IgM, IgA 
and more recently IgE (Zuraw et al.. 1981) have been detected in RA patient’s 
sera. Rheumatoid factor and the ICs generated from them, may explain the 
ongoing inflammatory and erosive disease, but not necessarily its onset; that is, 
these immune responses could be a secondary phenomenon, the result, rather 
than the cause, of RA.
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In normal individuals the synthesis of RF is tightly regulated. Removal of a 
stimulus results in decreased synthesis, whereas in RA RF is produced in 
excessive amounts, which appears to represent a fundamental breakdown in 
immunoregulation. It is also apparent that IgG can self-associate, forming 
complexes with other IgG molecules that may become large enough to be 
phagocytosed and to activate the classical complement pathway (Brown, 
Nardella and Mannik, 1982) (Fig II).
Polymorphonuclear neutrophils, although abundant in SF, are not found in the 
synovial membrane: characteristic inflammatory cells in the membrane are T 
and B lymphocytes, plasma cells and macrophages. Phagocytosis by PMNs 
generates many inflammatory mediators, such as hydrolytic enzymes (elastase 
and collagenase) which bind to proteinase inhibitors. Under certain 
circumstances these inhibitors are probably saturated or inactivated, and as a 
result the proteinases can act without inhibition on substrates within the joint 
cavity, including cartilage, bone, ligaments and tendons resulting in the 
characteristic joint deformities of RA.
Presently, there is much debate concerning an inherent defect of the 
lymphocyte in RA (Goodacre and Dick, 1984).
An attractive alternative hypothesis has recently come to light to explain the 
autoimmune features and hence the chronicity of RA -  the constant or 
recurring presence of many heterogeneous common agents as triggers, making 
the search for a single aetiologic agent unsuccessful.
Studies of various environmental factors as possible aetiologic agents include; 
nutrition (Ziff, 1983), silica (Klockars et al.. 1987), asbestos (Turner-Warwick
7
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and Parkes, 1970), smoking (Vessey, Villard-MacKintosh and Yeates, 1987), 
and climate (Hollander, 1961). There seems to be a high incidence of classic, 
seropositive erosive RA in male granite workers following silica or asbestos 
exposure, however the association of RA with nutrition is less definite. As 
recently as 1987, Vessey and his co-workers reported a strong association 
between referral to hospital for RA and cigarette smoking; the rate in women 
non-smokers was 0.27 per 1000 woman-years and in those smoking 15 or more 
cigarettes per day was 0.64 per 1000 woman-years. Interestingly, surveys have 
revealed that 2.5% of the adult population in temperate countries suffer from 
this disease, compared to 1% in the western world. Furthermore, Hollander 
(1961) observed that arthritis often worsened within a few hours of the onset of 
a combined rise in humidity and fall in barometric pressure. Such patients 
appear to be ’weather sensitive’. No pathogenetic mechanism has been proposed 
to explain this phenomenon.
It was once thought that the anxiety-ridden and depressed person who tends to 
suppress feelings of hostility and aggression seemed more prone to develop RA 
than the average, while the psychotic individual seemed less prone. However, 
the current consensus is that these psychological traits are an understandable 
reaction to the disease rather than a causative factor. Nevertheless in a given 
patient, emotional stress is often followed by an exacerbation of rheumatoid 
activity.
The final trimester of pregnancy is associated with disease remission, which 
frequently relapses after delivery (Persellin, 1977). This may be explained by 
the large rise in female sex hormone concentration and the subsequent fall 
postnatally. Wingrave and Kay (1978) hypothesize that exogenous sex hormones, 
specifically the oral contraceptive pill, protect against the development of RA.
The association with sex hormones is of interest given that one of the most 
consistent aspects of the epidemiology of RA is the 2 to 3-fold female 
predominance. Alternatively, the link between RA and pregnancy may be 
immunologically mediated by fetal stimulation of the maternal immune system, 
which might occur progressively with repeated pregnancies and thus result in 
the production of autoantibodies.
In summary, the causative agent of RA is unknown. However, in the 
genetically predisposed individual, multiple factors, host and environmental, 
may have a profound influence on the expression of the disease.
1.1.5 Diagnosis and treatment
There is, as yet, no single clinical or laboratory feature to identify RA; the 
diagnosis depends upon the presence of a composite of clinical articular and 
non-articular signs and symptoms, accompanied by radiological, histological and 
serological abnormalities. Some parameters commonly measured include the 
erythrocyte sedimentation rate (ESR), which is frequently elevated as are the 
acute phase reactants, fibronectin and C-reactive protein (CRP). Rheumatoid 
factor is measured by serological means, such as latex and sheep cell agglutinin 
test. The RF titre usually reflects the severity of the disease. Analysis of SF 
shows it to be turbid with excessive numbers of PMNs, low glucose 
concentration and less viscous than normal.
There is no specific cure for RA , however much can be achieved 
therapeutically for rheumatoid patients, provided the treatment is tailored to 
meet the specific needs of each individual. The aims of treatment (Table 1.1) as
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1. To help the patient understand the nature of the disease.
2. To provide psychological support.
3. To alleviate pain.
4. To suppress the inflammatory reaction.
5. To maintain joint function and prevent deformity.
6. To correct existing deformity.
7. To improve function.
8. To rehabilitate the individual patient.
Table 1.1 Aims of treatment of RA.
well as the available methods of treatment (Table 1.2) must be considered in 
planning a program. The goal of therapy in RA is to prevent disability.
Since the cause of the disease remains unknown, therapy has been directed at 
nonspecific suppression of the inflammatory process in the hope not only of 
alleviating symptoms, but also of preventing progressive damage to articular 
structures.
The non-steroidal anti-inflammatory drugs (NSAIDs) provide the ’first-line’ of 
treatment in RA. These give symptomatic relief only, and are thought to have 
no effect on the underlying disease process. They include the salicylates, for 
instance aspirin, which is not used very commonly in the United Kingdom 
because of its association with gastrointestinal irritation and bleeding. Adverse 
reactions are unfortunate consequences of therapy with most of the anti­
rheumatic drugs. One of the most useful and effective anti-inflammatory drugs 
available is indomethacin.
When the disease process progresses despite NSAID therapy, ’second-line’ or 
disease-modifying agents are implicated. These have minimal nonspecific anti­
inflammatory effects, but appear to have the potential to modify the course of 
the disease in some patients (Wright and Amos, 1980). Their use in RA is based 
almost entirely on clinical experience rather than knowledge of specific drug 
action. None of these agents was specifically developed to treat RA, except for 
sulphasalazine (SASP). The use of gold compounds, for instance, originated with 
the observation by Koch in 1890 that gold cyanide inhibited the growth of 
Mycobacterium tuberculosis. Because of the belief that gold compounds 
possessed nonspecific antiseptic properties, they were use to treat a variety of 
chronic conditions in which an infectious aetiology was suspected. It was not
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1. Psychological considerations.
Relationship between physician and 
patient developed by sympathetic 
understanding, free discussion of 
the nature of the disease, the 
prognosis and the proposed 
treatment. Also a need to have 
complete confidence in the 
physician.
2. Therapeutic agents.
Non-steroidal anti-inflammatory 
drugs (NSAIDs)
’First-line’ treatment eg.
Naproxen
Indomethacin
Disease-modifying drugs 
’Second-line’ eg.
D -penicillamine 
Sulphasalazine
Corticosteroids, ’third-line’ eg. 
Prednisolone
Immunoregulatory agents, eg. 
Azathioprine
3. Orthopaedic appliances.
Removable splints 
Remedial shoes 
Canes and crutches
4. Physical therapy.
5. Orthopaedic surgical 
operations.
eg. Synovectomy 
Prosthetic joint replacement
Table 1.2 Methods of treatment for RA
until 1944 that the results of a properly controlled clinical trial were first 
published by Fraser in Glasgow (Sneader, 1985) and thereafter the value of 
sodium aurothiomate (’Myocrisin’) in therapy was generally accepted.
A  characteristic feature of therapy with these drugs is a delayed onset of 
clinical effect. Gradual suppression of the signs and symptoms of inflammation 
may not be apparent until months after initiation of therapy and may persist 
for weeks after the drug has been discontinued. This is in contrast to clinical 
responses to NSAIDs which, when observed, are prompt and persist only as 
long as the drug is continued (Simon and Mills, 1980). Chloroquine and 
hydroxychloroquine have become the most frequently used antimalarials in RA 
but they have many minor side-effects such as nausea, headache, dizziness and 
diarrhoea.
A  newer compound, SASP, which consists of sulphapyridine (SP) and 5- 
aminosalicylic acid (5-ASA) is an antibacterial agent with ’second-line’ effects 
in RA. Svartz (1942) originally formulated SASP because SP alone had been 
unsatisfactory. It is now the first choice, of some clinicians, when initiating 
’second-line’ therapy for RA. Although the aforementioned ’second-line’ drugs 
are equally effective in the treatment of RA, this does not diminish the 
importance of the clinical observation that an individual patient may respond to 
one, but not another, and that such idiosyncratic responses are unpredictable. 
There is, however, some evidence that the incidence of toxic reactions differs; 
antimalarials having a much lower incidence of serious side effects, even after 
long-term administration (Richter et al.. 1980), than D-penicillamine and gold 
salts. In another study, Situnayake, Grindulis and McConkey (1987) found 
severe adverse effects were far more common with gold and D-penicillamine 
than with SASP.
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Severe unremitting polyarthritis may be an indication for ’third-line’ therapy 
(cytotoxic agents or corticosteroids), but only after second-line drugs have 
failed, either due to toxicity or lack of efficacy. This category is used sparingly 
in view of its greater toxicity, particularly of a cumulative or long-term nature. 
For patients over 60 years of age and those threatened with immediate 
disability, the guidelines for with-holding corticosteroid therapy are less 
stringent. A  special situation for systemic therapy is the patient with an active 
peptic ulcer or gastrointestinal haemorrhage who continues to have active and 
severe RA. Treatment of these patients always poses a major problem, since 
most of the medications used to treat RA have the potential for exacerbating 
the disease.
An additional class of therapeutic agents in RA is the immunoregulatory drugs 
such as Azathioprine, cyclophosphamide and methotrexate. Most physicians 
advocate their use late in the course of RA and, like disease-modifying drugs, 
they have a gradual onset of action. Although they clearly suppress active RA 
in 60% to 80% of patients in whom they are given, they rarely effect a true 
clinical remission. If these drugs are discontinued, the arthritis tends to flare 
again, usually within 1 to 2 months. Initiation of treatment with these agents 
implies there will be long-term therapy, long-term therapy implies a high risk 
of toxicity. The major immediate toxic side-effect is severe bone marrow 
suppression. Fortunately, this problem is not very common with the relatively 
low doses used in RA. The major long-term complications are carcinogenicity, 
irreversible sterility and a predisposition to serious infections. The fear of 
causing a potentially fatal malignancy in a patient whose disease is normally not 
fatal has severely curtailed the use of immunoregulatory drugs in RA except as 
a last resort in patients with extremely active, otherwise unresponsive disease. 
Combinations of immunoregulatory drugs might prove more effective and have
12
fewer side-effects if  lower doses of each could be used. A  preliminary study by 
McCarty and Carrera (1982) suggests that this may be the case.
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1.2 SEPTIC ARTHRITIS
The observation that patients with chronic RA who had bacteraemia were 
susceptible to spontaneous septic arthritis was first reported by Kellgren et al. 
(1958). Since then more than 100 cases have been reported in the English 
literature (Gristina, Rovere and Shoji, 1974). Table 1.3 reviews the most 
frequently encountered micro-organisms reported in the literature.
Although the incidence and causative organisms remain qualitatively 
unchanged, increasing numbers of cases are being seen among the elderly 
(Cooper and Cawley, 1986). Staphylococcus aureus is by far the most common 
causative agent in this country and other European studies (Russell and Ansell, 
1972; Lindgren and Lindberg, 1973; Newman, 1976). In a recent 30 year review 
by Newman (1976) Staphylococcal infections were found to have predominated 
throughout: but the percentage of penicillin-resistant organisms rose from 29% 
to 59% during the period reviewed. The American literature suggests a high 
prevalence of gonococcal and gram negative bacillary infections (Goldberg and 
Cohen, 1976; Manshady, Thomson and Weiss, 1980). Pneumococcal arthritis was 
a common complication of pneumonia in the preantibiotic area but it is now 
rare, representing less than 5% of septic arthritis (Morley, Hull and Hall, 1987).
Suppurative arthritis occurring in rheumatoid disease is relatively rare but 
dangerous; not only to limb but to life. At particular risk are the elderly with 
chronic advanced seropositive nodular disease, those on long-term systemic or 
intra-articular corticosteroid or other immunosuppressive therapy, and those 
with a primary or secondary infection. Furthermore, patients with RA may be 
more susceptible because of an inherent phagocytic defect (Mowat and Baum, 
1971; Turner, Schumacher and Myers, 1973). The skin and subcutaneous tissues
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Study Year Organising
Kellgren et al. 1958 S. aureus 
Escherichia coli
Rosin and Goldberg 1962 S. aureus
Rimoin and Wennberg 1966 S. aureus
Karten 1969 SLmreus 
Proteus mirabilis
Russell and Ansell 1972 S. aureus
Lindgren and Lindberg 1973 S. aureus
Haemonhilus influenzae
Gristina et al. 1974 S. aureus 
Escherichia coli
Goldenberg and Cohen 1976 S. aureus
Mitchell et al. 1976 S. aureus
Newan 1976 S. aureus
Cooper and Cawley 1986 S. aureus
Neisseria gonorrhoeae
Morley et al. 1987 Streutococcus
pneumoniae
Table 1.3 Micro-organisms associated with septic arthritis
are the most common sites frequently infected by staphylococci. Bacteria may 
also directly infect a joint from a deep penetrating wound, a concurrent urinary 
tract infection, a bronchopulmonary infection, prosthetic joint surgery or an 
intra-articular steroid injection (Rimoin and Wennberg, 1966). Intravenous drug 
users are prone to septic arthritis; it is often caused by bacteria that do not 
infect healthy persons, such as Pseudomonas aeruginosa (Roca and Yoshikawa, 
1979).
Sudden aggravation of the usual arthritic pain, abrupt onset of swelling, and 
increased joint temperature are the usual signs of sepsis (Gristina et al.. 1974). 
This often fatal complication may be easily overlooked as the clinical features 
simulate those of an acute, uncomplicated rheumatoid exacerbation. In some 
cases malaise and fever may occur. The presence of rigors may be an important 
differentiating point (Kellgren et al.. 1958). The most commonly affected joints 
are the knee and hip (Cooper and Cawley, 1986) with elbows, shoulders and 
wrists all being less frequently involved. Monoarticular and polyarticular 
involvement have been reported (Karten, 1969; Kellgren et al.. 1958; Rimoin 
and Wennberg, 1966). However, in general, the degree of joint involvement in 
RA patients seems to reflect the severity of the disease. The onset of infection 
may be acute or insidious.
Early treatment of a septic joint is vital to prevent destruction of cartilage and 
other joint structures, and therefore prompt diagnosis becomes essential. 
Diagnosis is suspected in patients showing a deterioration in general health, 
significant fever (>39°C) sometimes accompanied by rigors, and leucocytosis 
with more than 90% PMNs, but, as Rosin and Goldberg (1962) pointed out, 
marked leucocytosis characteristic of a profound bacterial infection may or may 
not occur in the presence of concurrent RA. Most patients have an elevated
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ESR, but this is not specific and therefore of no diagnostic value. Low SF 
glucose levels (Ward, Cohen and Bauer, 1960; Gristina et al.. 1974) and high SF 
lactate levels (King, 1985) have been suggested as reliable indicators of sepsis, 
however this remains controversial. Recently, Arthur et al. (1983) were unable 
to corroborate the findings of Brook et al. (1978) who reported that lactic acid 
elevations in SF were diagnostic of infectious arthritis. Arthur and coworkers 
(1983) found no significant difference between RA and septic arthritis. 
Kellgren et al. (1958) found the presence of chills helpful in diagnosis.
As soon as septic arthritis is suspected, prompt aspiration of the inflamed joint 
for microscopic examination and culture of SF is imperative. Blood cultures are 
also important. Aerobic and anaerobic cultures should be routinely grown. 
Antibiotic therapy should be initiated immediately and then modified when the 
culture and sensitivity results are available. Since the percentage of penicillin- 
resistant Staphylococci have significantly increased in the past decade, 
Penicillinase-resistant agents, such as methicillin, should be included in the 
initial therapeutic program. Intensive and long-term antibiotic therapy appear 
essential if  recurrence of infection is to be prevented. Before the advent of 
antibiotics, septic arthritis carried a substantial mortality. One would imagine 
that death from a pyogenic infection should now be preventable, however, 
from a review of fatalities in various studies (Table 1.4) this does not seem to 
be the case. The continuing mortality appears to relate to the rising age 
incidence and the vulnerability of the elderly, delayed diagnosis, and 
inadequate local treatment, despite the widespread systemic use of antibiotics. 
Hip infection, particularly in the elderly, has a poor prognosis.
The principles of management include specific antibiotic therapy and drainage, 
and joint immobilisation. There is unanimous agreement that systemic antibiotic
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Study Total no.
of cases
No. of 
deaths
Kelleren et al. 1958 13 6
Rosin and Goldberg 1962 5 2
Rimoin and Wennberg 1966 5 3
Karten 1969 5 2
Russell and Ansell 1972 28 2
Gristina et al. 1974 12 1
Mitchell et al. 1976 8 7
Newman 1976 134 1
Cooper and Cawley 1986 74 7
Table 1.4 A  review of fatalities from septic arthritis
therapy should be started as soon as a tentative diagnosis of septic arthritis is 
made, but the use of local antibiotics is still controversial. Mitchell and his 
associates (1976) showed no good reason for intra-articular injections, as these 
antibiotics, when administered systemically, pass freely into the joints from the 
blood stream, easily achieving therapeutic levels. This is the view held by 
others (Russell and Ansell, 1972; Cooper and Cawley, 1986). However, Kellgren 
et al. (1958) advised local instillations of antibiotic into infected joints.
Conflicting views also exist as to whether needle aspiration or surgical drainage 
is the best treatment. Most rheumatologists advocate an initial trial of closed 
needle aspiration of all joints except hips (Goldenberg and Cohen, 1976). Ward 
et al. (1960) and Goldenberg et al. (1975) indicate no obvious superiority of 
surgical drainage over needle aspiration. Gristina and co-workers (1974) showed 
that needle aspiration was the least effective therapy. They recommend as the 
treatment of choice: systemic antibiotic therapy and immediate arthrotomy 
followed by through-and-through irrigation with fluid containing the 
appropriate antibiotics. Almost all orthopaedic surgeons still advocate surgical 
drainage (Anon., 1976). Nevertheless, almost all clinicians, medical or surgical, 
would agree that early aspiration is essential not only for diagnosis but also for 
treatment. If antibiotic therapy and repeated aspirations prove inadequate 
surgical drainage is mandatory.
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1.3 NORMAL HOST DEFENCE MECHANISMS
Infections predictably occur when an unprotected individual encounters a 
virulent micro-organism. Normal protective mechanisms include the surface 
barriers - skin and mucus membranes of respiratory, gastrointestinal, and 
urinary tracts; leucocytes -  PMNs, monocytes, lymphocytes, eosinophils, and 
basophils; and humoral factors, predominantly Igs and complement (Fig. III). In 
normal individuals, serious infections occur only rarely because these protective 
mechanisms are intact. In many diseases, such as leukaemiaand hepatitis, and 
also as a side effect of many frequently used cytotoxic therapies, host defences 
are abnormal or depressed and infections occur with increased frequency and 
severity.
1.3.1 Skin
Normal skin is very resistant to infection by the micro-organisms to which it is 
constantly exposed. The dryness of the skin, the acid pH of its surface, and 
certain antibacterial properties of some long-chain fatty acids secreted by the 
sebaceous glands are thought to be important host defence factors. When the 
skin is excessively moist, superficial infections often occur. More frequently, 
infections occur because the homy cutaneous coat is compromised by abrasions, 
bums, implantation of foreign material, or insertion of needles.
1.3.2 Respiratory and gastrointestinal tracts
Although constantly bathed by micro-organisms, the mucosal surfaces form a 
very effective barrier against microbial invasion. On the other hand it is
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Fig. m  Three lines of defence against infection.
through defects in these barriers that systemic infections in compromised hosts 
most often occur. Non-steroidal anti-rheumatic drugs are associated with 
increased gastrointestinal permeability (Jenkins et al.. 1986) and consequently 
render it more susceptible to infection.
The two most important factors maintaining the sterility of the upper bowel are 
gastric acid and gastrointestinal motility. In addition, the host is protected from 
the bowel flora by the continuity of the epithelial cell layer, mucus, the 
digestive enzymes, Igs secreted from intestinal-associated lymphoid follicles and 
the constant exudation of blood PMNs into the intestinal lumen (McGuigan and 
Leibach, 1978).
The surface of the upper respiratory tract is covered by bacteria, but the lower 
respiratory tract is sterile. The airway is lined by mucus-covered ciliated 
epithelium. The mucus blanket is highly impermeable to water and serves to 
entrap particles reaching the lower levels.
The predominant Ig of the lower respiratory and gastrointestinal tracts is IgA. 
Its function is somewhat obscure because, in contrast to IgG, it does not 
opsonise bacteria or fix complement. Immunoglobulin A  is thought to facilitate 
aggregation of foreign particles on the mucosal surfaces and both to prevent 
their adherence to mucosal membranes and to aid their removal by this 
aggregation effect (Newhouse, Sanchis and Bienenstock, 1976). The cough 
reflex is stimulated by inhalation of foreign material and by inflammation in 
the lungs, trachea or larynx.
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1.3.3 Urinary tract
The bladder, ureters and kidneys are sterile in normal individuals. Bacterial 
colonization in the perineum extends a short distance into the urethra in both 
the male and female. The principal factor limiting the upward spread of 
bacteria is thought to be the repeated flushing of this mucosal surface by the 
downward stream of urine.
The upper urinary system is protected from infection by its anatomical 
remoteness from surface bacteria.
1.3.4 Polymorphonuclear leucocytes
Polymorphonuclear leucocytes are the first, cellular combatants in the battle 
that follows microbial invasion. However, these cells would be unable to 
effectively seek out, recognise, ingest and kill the invaders if  it were not for 
two additional lines of defence provided by specific Ab (section 1.3.6) and the 
complement system (section 1.3.7). There are approximately 5 x 1 0^  PMNs, 
produced and utilised daily under normal circumstances. It is estimated that 
production increases 10-fold in severe infection (Dale, 1981).
Polymorphonuclear leucocytes, their origin, functions and the process of 
phagocytosis are discussed in detail in chapter 2.
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1.3.5 Monocvtes
Monocytes are marrow derived phagocytic cells and share many of their 
properties with PMNs (Wilkinson, 1983). An important difference between 
PMNs and monocytes is that monocytes are not end-stage cells; they 
differentiate in the tissues into macrophages, which are motile and actively 
phagocytic cells.
Monocytes, like PMNs, have surface receptors for the Fc component of IgG. 
They also have receptors for IgM, complement and complement-derived 
chemotactic factors C3a, C5a and C5b67 (Cline, 1975). They contribute to the 
immune response, not only as phagocytes, but also as antigen-presenting cells 
and helper cells in T-cell dependent Ab production. Their capacity to augment 
their bactericidal mechanism by synthesis of new enzymes is a unique feature 
of these cells. Furthermore, monocytes can synthesize, upon stimulation, a 
number of soluble factors that contribute to host defence mechanisms (Dale, 
1981). These include IL-1, tumour necrosis factor (TNF), interferon and 
transferrin. The above features of monocyte function may be responsible for 
the containment of some organisms such as salmonella and Mycobacterium that 
can escape PMN bactericidal action.
Interleukin 1 is a cytokine that is produced by numerous mammalian cells in 
response to various stimuli, including bacteria, bacterial products, viruses, 
fungi, Ag-Ab complexes and lymphokines (Dinarello, 1984a). Monocytes and 
macrophages are unquestionably the major source of IL-1. It initiates or 
augments a number of pro-inflammatory biologic responses including the 
attraction of PMNs, mononuclear phagocytes and lymphocytes (Hunninghake et 
al., 1987). Interleukin 1 causes PMNs to degranulate their specific granules to
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the exterior and to increase their generation of superoxide. It is also capable of 
causing B-cells to multiply faster and it potentiates immunological responses 
which require a clonal expansion of T-cells (Murphy, 1985).
Concerning the therapeutic potential of IL-1, previous studies have shown that 
administration of recombinant IL-1 (rIL-1) substantially enhanced the 
antibacterial resistance of mice to Pseudomonas aeruginosa and Klebsiella 
pneumoniae (Ozaki et al.. 1987), and the facultative intracellular pathogen 
Listeria monocytogenes (Czuprynski et al.. 1988). The present consensus is that 
IL-1 acts indirectly to accelerate the protective response of the infected host. 
This hypothesis is supported by previous reports that IL-1 initiates or amplifies 
the in vivo and in vitro production of various biological mediators including 
interferon, colony stimulating factors, IL-2, TNF, and acute phase serum 
proteins (Czuprynski et al.. 1988). One or more of the above described factors 
might be required for the IL-1 mediated enhancement of antibacterial 
resistance.
1.3.6 Lymphocytes
Having evaded the non-specific defence mechanisms, the microbe will then 
encounter a specific line of defence, the T and B lymphocytes. Approximately 
80% of normal blood lymphocytes are T-cells. They emerge from a period of 
development and differentiation in the thymus as cells capable of a) undergoing 
blast transformation in response to certain mitogenic substances, b) producing 
many soluble mediators of immune reactivity, such as IL-2 (formerly T-cell 
growth factor), B-cell growth factor and IL-3, c) serving as memory cells (Tm) 
of previous antigenic exposures, d) being helper (Th) and suppressor (Ts) cells
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in many B-cell responses, and also e) having the special capacity to kill foreign 
cells through direct cytotoxic mechanisms (Tc) (David, 1973). Patients with 
deficient cell-mediated immunity have an increased susceptibility to infection 
with many viruses, fungi, yeasts, some intracellular bacteria and protozoa.
Controversy exists as to the possible association of a T-lymphocyte defect in 
RA (Goodacre and Carsondick, 1984).
B-lymphocytes are capable of differentiating into plasma cells and of producing 
Igs. Five classes of Igs are produced; IgG, IgA, IgM, IgD and IgE. Only IgG, 
IgM and IgA are known to have any specific role in protecting the host from 
micro-organisms. IgG is particularly important because it facilitates
phagocytosis through the process of opsonisation (Huber and Fudenberg, 1968) 
and fixes complement which would result in bacterial lysis by a direct action
on bacterial cell walls. Immunoglobulin M can also fix complement.
Immunoglobulin A  functions as previously discussed in section 1.3.2. These Abs 
also neutralize many viruses and prevent their entry into host cells.
A  proportion of the B-lymphocyte population differentiate into memory cells, 
capable of recognising organisms that have previously invaded the host and 
rapidly secreting specific IgG Abs. B-cell deficiency leads to severe infections 
by highly encapsulated micro-organisms such as Streptococcus pneumoniae and 
Haemophilus influenzae.
1.3.7 Complement
The complement system consists of several protein constituents that may be 
activated by two major pathways; the classical and the alternative. Detailed
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accounts of the chemistry of complement proteins and the role of complement 
in infectious diseases are available in two monographs, respectively (Frank, 
1975; Goldstein, 1980).
The complement proteins help protect the host against the overwhelming 
infections of certain pyrogenic bacteria and fungi. Some microorganisms, even 
in the absence of specific Ab, call initial attention to themselves by activating 
the alternative complement pathway. In the presence of Ab, activation of the 
classical pathway may also occur. Following either or both of these events, 
biologically active peptides are generated that increase the number of 
circulating leucocytes, promote adherence of leucocytes to vascular 
endothelium, and attract PMNs to the site of microbial invasion. Having arrived 
at the focus of the initial infection, these cells then recognise, ingest and kill 
the invaders. In some cases, killing may not even require phagocytes because 
certain microorganisms, especially Neisseria species (i.e. gonococci and 
meningococci), may be killed by the action of complement alone. These are 
susceptible to lysis by the terminal membrane attack sequence C5b-9 (Table 
1.5).
The specific serum requirements of any individual genus or species of 
microorganism that render it susceptible to phagocytosis and killing cannot be 
simply summarised. A  remarkable diversity exists that depends upon the 
chemical components of the cell surface of individual organisms. For instance, 
encapsulated staphylococci require specific IgG Ab as well as complement for 
optimal ingestion and killing, whereas most strains of S. eoidermidis can 
activate the alternative complement pathway and can be phagocytosed and 
killed by PMNs in the absence of specific Ab.
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INTERACTION WITH PHAGOCYTIC CELLS
Mobilization of leucocytes C3e
Adherence to vascular endothelium C5a
Chemotaxis C3a,C5a,C5b67,Ba
Opsonisation (phagocytosis) C3b
Stimulation of oxidative metabolism
(killing) C3b,C5a
Degranulation (killing and digestion) C3b,C5a
DIRECT ACTION OF SUSCEPTIBLE BACTERIA (lysis) C567$9
Table 1.5 Activities of complement that contribute to 
the maintenance of normal host defences
From the foregoing, one might predict that in certain clinical situations in 
which specific complement components are either depleted (as a consequence of 
in vivo complement activation), totally absent (as a consequence of a congenital 
defect), or depressed (as an effect of immunosuppressive drugs), host defences 
would be severely compromised. This is indeed the case. C3 and C6 deficiencies 
render the host susceptible to repeated bacterial infections. Persons lacking C6, 
C7 or C8 appear to be particularly susceptible to infections with Neisseria 
(Goldstein, 1980).
An involvement of the complement system in the pathogenesis of RA was 
suspected when it was observed that the total haemolytic complement activity 
and C2, C4 and C3 concentrations in joint fluids from RA patients, were 
depressed as compared to levels measured in SF from patients with degenerative 
joint disease (Hedberg, 1963). Furthermore, the simultaneous presence of C3 
and Ig deposits in synovium and in phagocytic cells of articular effusions was 
suggestive of the presence of ICs, which were subsequently directly 
demonstrated (Hannestad, 1968). Many researchers have reported high levels of 
RF and raised C3 split products, an indication of complement catabolism, in 
the plasma and SF of RA patients (Berkowicz et al.. 1983; Robbins, Feigal and 
Leek, 1986). These observations may indicate a continuous breakdown of C3 is 
taking place in the joints in active RA; it is not surprising then that an 
increased incidence of infection is a feature of this and other autoimmune 
diseases when compared to control populations.
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CHAPTER TWO - PHAGOCYTOSIS
2.1 INTRODUCTION
2.1.1 Polymorphonuclear leucocytes
(i) Origin and fate
It is over 200 years since an English surgeon, William Hewson (Gulliver, 1846) 
first described the white blood cells. In 1883, Eli Metchnikoff, the famous 
Russian zoologist, injected foreign particles (starfish larvae) into metazoans. He 
observed that these were taken up by a population of ’wandering mesodermal 
cells’ that resided in interstitial tissues. He named these wandering cells 
’phagocytes’. A  little more than 20 years were to pass before Metchnikoff 
observed and appreciated that the phagocytic white cell is capable of 
intracellular killing of bacteria (Metchnikoff, 1905). The predominant 
phagocytic white cells are the circulating PMNs.
Polymorphonuclear leucocytes are produced in the red bone marrow from a 
stem cell pool (Fig. IV). The stem cell is believed to be pluripotential, the 
common ancestor, also, of erythrocytes and platelets (Dunn, 1971). The 
granulocytic line begins as myeloblasts, which divide and differentiate into 
myelocytes over a 7-day period (Wade and Mandell, 1983). The transition from 
myelocyte to metamyelocyte marks the end of proliferation but the granulocyte 
continues to mature in the bone marrow, passing from metamyelocyte to band 
form to segmented PMN. This postmitotic period lasts approximately 6.5 days 
(Wade and Mandell, 1983). Thus the evolution from stem cell to mature blood 
PMN takes approximately 13-14 days.
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Each day 10 ^  mature PMNs enter the blood stream from the bone marrow. At 
any one time about half the intravascular population are not circulating but are 
adherent to the endothelium of small vessels, a process called margination. The 
number of PMNs circulating represent only 5% of the total body content. A 
large percentage of mature cells are stored in the bone marrow, ready to be 
called upon as needed to replenish cells in the circulation.
The half-life of PMNs in the blood stream is 6 hours; they are removed at 
senescence by splenic macrophages. From the bloodstream, PMNs enter the 
tissues, it is here that they are destined to fulfill their functional role, and it is 
here that the PMN ultimately dies after 2 to 3 days. Polymorphonuclear 
leucocytes are end cells; they have no regenerative capacity. Also, having 
migrated into the tissues, unlike mononuclear phagocytes, PMNs do not return 
to the circulation. Thus, from birth to senescence, the total life span of a PMN 
is of the order of 15 days.
(ii) Morphology
The PMN has a characteristic large multilobal (3-5) nucleus (Fig. V) and 
numerous cytoplasmic granules, which appear pale pink on Leishman stain. 
These granules are either primary (azurophil) or secondary (specific). The 
former appear early in development at the promyelocyte stage and are electron 
dense with a rich content of acid hydrolases (Table 2.1). The specific granules 
are formed during the maturation period and they are 3 times as numerous as 
the primary granules. They are called specific since they contain lactoferrin and 
cobalophilin (Table 2.1) which are regarded as specific cytochemical markers in 
PMNs. These are smaller, electron dense granules which lack digestive enzymes 
and peroxidase.
27
%
.«  •*»
t \  * %
>
* : >  *4
Fig. V The multilobed nucleus of the polymorphonuclear leucocyte.
(iii) Polymorphonuclear leucocyte functions
Adhesion
The PMN has a selective preference for adhering to endothelial cells (Hoover, 
Briggs and Kamovsky, 1978). The mechanism of adhesion is not known 
precisely. It involves both net surface negative charges (Hoover et al.. 1978) 
and physical contact, probably by microfilaments (Malech, Root and Gallin, 
1977), with the substrate. The cell surface charge may be important in allowing 
cells to approach one another sufficiently closely so that microfilament 
attachment can occur. Adherence to a surface is necessary for PMN locomotion. 
This is probably because micro filaments are involved in both processes.
Locomotion
Three types of locomotion are recognised: random migration, chemokinesis and 
chemotaxis. Random migration is multidirectional and occurs in the absence of 
any stimulus to motility. Chemokinesis is the stimulated random movement of 
PMNs by chemotactically active molecules present in uniform concentration 
without a gradient (Keller et al.. 1977). Chemotaxis is the directional movement 
of PMNs along a concentration gradient of chemotactic factors (McCutcheon, 
1946). The most important known source of chemotactic factors in vivo are 
generated by complement activation. Complement components C3a and C5a can 
be generated by activation of either the classical or the alternate pathway. A  
trimolecular complex of complement proteins acting later in the haemolytic 
sequence, C5b67, assembles and also has chemotactic effects (Goldstein, 1980). 
A  fourth fragment, Ba (a fragment of factor B resulting from the action of 
factor D in the alternate pathway) has chemotactic activity (Spragg and Austen,
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1977). Since both complement pathways act on C3 and C5, these proteins are 
absolutely required for the chemotactic activity of complement.
Phagocytosis
Phagocytosis is the act of internalisation and subsequent sequestration into 
phagosomes of extracellular particulate matter. The process is accompanied by 
profound metabolic changes in the cell designed to digest, or render inert, the 
ingested material. The subject of phagocytosis will be discussed in detail in 
section 2.1.2.
Secretory function
Over recent years it has been appreciated that exocytosis -  that is the fusion of 
specific granules or lysosomes with the cell membrane and subsequent release 
of their contents into the surrounding medium -  occurs in response to certain 
triggering factors, eg. bound ICs (Henson, 1971). It is an active process and is 
accompanied by metabolic sequelae associated with phagocytosis. The PMN may 
therefore legitimately be considered as a secretory cell. This release may be 
important for destruction of large pathogens which are not easily ingested.
This aspect of PMN function is of particular relevance from the standpoint of 
the mediation of tissue injury in the rheumatic diseases. Synovial fluid from 
patients with RA is characterised by the presence of PMNs, the major effector 
cells of acute inflammation. Also present, often in high concentration, are the 
constituents of azurophilic granules (Table 2.1) (Hensen, 1971) and products of 
oxygen metabolism in the form of cytotoxic free radicals and compounds (eg. 
superoxide anion (C>2- ), hydroxyl radical (OH- ) and hydrogen peroxide 
(H2O2)). Among the many lysosomal constituents released to the surrounding
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PRIMARY (AZUROPHIU SECONDARY (SPECIFIC)
Lysozyme 
Myeloperoxidase 
Cationic proteins 
Neutral proteases 
elastase 
collagenase
Acid hydrolases
B-glucuronidase
arylsulphatase
cathepsin
Lysozyme
Lactoferrin
Gelatinase
Collagenase
Cobalophilin (vitamin 
B-12 binding protein)
Table 2.1 The contents of polymorphonuclear leucocyte granules
tissues, particular attention has been devoted to the role of elastases and 
collagenases, as well as myeloperoxidase (MPO), which are associated with the 
breakdown of cartilage and connective tissues. The serine proteinase, elastase, is 
misnamed because elastin is not its only substrate. This proteinase can also 
degrade proteoglycan, type III collagen, and type IV collagen, found in 
basement membrane (Harris, 1984). It has been calculated that about 8mg of 
elastase is released into a typical rheumatoid knee each day. Unneutralised, this 
would be sufficient to release the total proteoglycan content of the joint 
together with 10-20% of the collagen content every 24 hours (Barrett, 1978).
Products of arachidonic acid metabolism may also generate and sustain 
inflammation. Leukotriene B4, produced by the action of lipoxygenase on 
arachidonic acid is one of the most potent chemotactic factors known. The 
resulting convergence of PMNs into the SF produces a surplus of extracellular 
enzymes, which bind to the synovial proteinase inhibitors alpha 2 
macroglobulin and alpha 1 macroglobulin. If these inactivators are saturated or 
inactivated, the proteinases act without inhibition on substances within the 
joint cavity, including cartilage, bone, ligaments and tendons (Harris, 1984) 
resulting in joint damage.
(iv) The role of polymorphonuclear leucocytes in immune response.
Metchnikoff, and his contemporaries, argued as to whether the PMN was a 
’brave soldier’, defending the organism from foreign intruders, or that it might 
be causing considerable harm, since it is found in the rheumatoid joints. It 
appears to be involved in both the aforementioned.
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The PMN is a specialised cell designed for adhesion, movement, ingestion and 
intracellular killing of microbes. It also behaves as a scavenger cell, removing 
products of tissue damage and breakdown, and dead or dying cells from the 
circulation.
The importance of PMNs to host resistance is illustrated by the consequence of 
their absence, agranulocytosis, or relative lack, neutropenia. Agranulocytosis is 
generally fatal. Infections with organisms such as S. aureus. Escherichia coli and 
Pseudomonas are not uncommon. The effects of the absence of PMNs on the 
overall response to infection shows that fever and malaise can still occur and be 
the only symptoms for 2 to 3 days, to be followed by necrotic ulcers at sites 
where a large micro flora exists; skin, nose, rectum and anus (Harkness, 1981). 
Neutropenia results in recurrent infections, especially in the mouth and skin.
The brief life of the PMN is devoted primarily to the task of migrating into 
the site of an inflammatory lesion. Having arrived, it responds with pronounced 
adhesion to the substratum, significant release of lysosomal constituents and 
production of oxygen radicals. Therefore, PMNs have the potential to be 
responsible for at least some of the joint destruction seen in RA.
2.1.2 Phagocytosis
Phagocytosis is the process whereby single cells internalise objects that they 
encounter (Fig. VI). The process is a matter of survival for primitive unicellular 
organisms, which use it to gain nourishment. In higher creatures it protects 
against assault by ubiquitous micro-organisms in the internal and external
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Fig. VI Polymorphonuclear leucocytes with internalised Staphylococcus aureus.
environment. Metchnikoff (1905) championed the cause of phagocytosis as the 
basis of survival against pyogenic infection.
Controversy arose from the proponents of humoral mechanisms of host 
protection, but from this dispute came about the realisation that humoral 
factors and phagocytes cooperate (Wright and Douglas, 1904), a concept 
popularised by George Bernard Shaw in The Doctor’s Dilemma:
The phagocytes won’t eat the microbes unless the microbes are 
nicely buttered for them. Well, the patient manufactures the butter 
for himself all light: but m y discovery is that the manufacture o f  
that butter, which I  call opsonin, goes on in the system by ups and
downs.  There is at the bottom only one genuinely scientific
treatment for all diseases, and that is to stimulate the phagocytes.
The subsequent passages include an introduction to phagocytosis by dividing it 
into convenient stages (Fig. VII). This sequence of activities occurs over 
approximately 6 hours. Death of the PMN in 1-2 days is believed to follow 
these events (Harkness, 1981).
(i) Production
As part of a response to infection there is an increase in PMN production, a 
leucocytosis. This is associated with acute inflammation and marked in 
infections with ’cocci’, especially if they are generalised (Harkness, 1981). 
Vigorous exercise and adrenalin are ’physiological’ factors causing leucocytosis 
by shifting the cells from marginal sites which may represent an adherent Tcell 
population. Such a leucocytosis is not accompanied by an increase in the total 
number of PMNs in the body.
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Fig. VII Schematic representation of the various stages of phagocytosis and 
intracellular killing of micro-organisms (van Furth, Zwet and Lcijh, 
1978).
(ii) Chemotaxis
A  variety of mechanisms for attracting phagocytes into inflammatory sites is 
presumably advantageous to the host, and the small molecular size of the 
attractants, namely C3a and C5a, may enhance their access by diffusion to 
phagocytes at distant locations.
A  fundamental observation relevant to the cellular aspect of chemotaxis is that 
PMNs rapidly enter inflammatory foci whereas monocytes arrive at a slower 
pace (Metchnikoff, 1905). Greater mobility underlies the prompt response of 
PMNs to chemotactic stimulation relative to monocytes. Although the early 
influx of PMNs could be explained by their speed, this hypothesis does not 
explain why PMNs stop appearing once the mononuclear cell infiltrate is 
established. Two speculative possibilities could explain this. Firstly, it could be 
due to the accumulation of inhibitors of PMN motility. Secondly, the PMNs 
may have a higher response threshold than that of monocytes, for reacting to 
chemotactic agents. As these chemotaxins are absorbed or inactivated by cells in 
the exudate, their concentration may fall below the response threshold of the 
PMNs.
(iii) Recognition and attachment
Having arrived at the invaded site, to attach to a bacterium, phagocytes must 
recognise it, i.e. phagocytes need specific receptors for something on the 
bacterial surface. Opsonins are humoral substances that can coat the bacterium 
to provide this recognition. Wright and Douglas (1903) originated the term 
opsonise from Greek, meaning ’to prepare for dining’. Immunoglobulin G and 
C3b are the primary opsonins which bind PMNs to bacteria and promote
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ingestion; PMN surfaces have receptors for C3b and the Fc portion of IgG 
(Horwitz, 1982). It was not until 1968 that Lay and Nussenzweig reported a 
complement receptor. Three types of C3 receptors have been described, one for 
C3b, one for C3bi (formed when C3b is cleaved by C3b inactivator and B1H 
globulin), and one for C3d (formed when C3bi is degraded further by 
proteases). C3bi or C3d receptors are, however, apparently lost by PMNs during 
maturation, C3b therefore being the predominant receptor. Of the IgG Abs, the 
subclasses IgG^ and IgG3 are the 'species' that participate in opsonisation. The 
presence of specific Ab as opsonin is termed immune opsonisation. The Fc 
portion of the Ab molecule, as well as the Fab segment that attaches to the 
particle, must be intact for expression of opsonic activity (Quie, 1972). Since 
the IgG immunoglobulins are resistant to heating, the heat-stable opsonic power 
of serum is due to the presence of Abs. Normal serum has little heat-stable 
opsonic activity. On the other hand, all normal sera have heat-labile opsonic 
activity, which can be entirely attributed to the complement protein C3b.
Certain organisms do not require Ab or complement for phagocytosis to take 
place. Examples of these are non-encapsulated pneumococci and many gram 
negative bacilli. Other bacteria, particularly encapsulated ones such as 
Klebsiella and virulent strains of S. aureus escape phagocytosis, unless Ab 
and/or complement is present, a characteristic that contributes to their 
pathogenicity.
(iv) Ingestion
Whereas attachment is independent of cell metabolism, ingestion requires the 
action of microfilament networks and active metabolism in the form of 
anaerobic glycolysis.
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Once particle attachment is complete the PMN puts out cup-like pseudopodia 
which surround the particle as a result of the sequential and circumferential 
interaction of receptors on the phagocyte surface with IgG or C3b ligands 
distributed diffusely over the particle surface. This has been termed the ’zipper 
mechanism’ (Griffin et al.. 1975).
The pseudopodia fuse at the distal side of the particle, which thereby becomes 
encased within a phagocytic vesicle, the phagosome, the lining of which being 
inverted plasma membrane. The phagosome gradually pinches off and moves 
centripetally away from the hyaline ectoplasm of the PMN.
(v) Fusion with cytoplasmic organelles
Membrane fusion between the phagosome and one of the specific granules 
ensues to produce a phagolysosome. This process is called degranulation, a 
mechanism whereby enzymes are delivered to their operational sites without 
subjecting the PMN cytoplasm to their potential injurious effects. Thus 
phagolysosomes contain a potent fungicidal, bactericidal and virucidal mixture 
of lysosomes, proteolytic enzymes, hydrolytic enzymes and lactoferrin. As a 
result of metabolic activity and the addition of specific granule contents, the 
pH inside the phagolysosome increases slightly and then falls (Segal et al.. 
1981). Subsequent to this, the primary granules fuse with the phagosome and 
release their contents within. Coincident with these events, a series of 
biochemical changes occur that result in the killing of ingested micro-organisms 
(Root and Cohen, 1981).
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(vi) Microbicidal activity
The microbicidal activities of PMNs can be divided into two major categories: 
1) oxygen-dependent and 2) oxygen-independent systems.
The oxygen-dependent process involves a co-ordinated series of metabolic 
events, dormant in resting cells, whose function is to produce a group of highly 
reactive microbicidal agents by the partial reduction of oxygen. During 
phagocytosis, an NADPH (reduced nicotinamide adenine dinucleotide 
phosphate) oxidase, located in the plasma membrane becomes activated (Babior, 
1978), allowing formation of superoxide (0 2 "). Collectively, the stimulation of 
these metabolic pathways is termed the ’respiratory burst’. This is characterised 
by 1) an increase in glycolysis, via the hexose monophosphate shunt, which 
provides the substrate NADPH as electron donor, 2) an elevation in oxygen 
consumption, 3) generation of 0 2 " anion and other oxy radicals and 4) the 
formation of lactic acid, which is in part responsible for the fall in pH and 
thus provides conditions favourable for the action of digestive enzymes (Babior,
1978). This respiratory burst is accompanied by the emission of light: 
chemiluminescence (Klebanoff and Clark, 1978). In addition to ingestion, 
binding to substances such as ICs, Igs, complement proteins and endotoxin, are 
capable of activating PMNs and triggering a respiratory burst (Wade and 
Mandell, 1983) (Fig. VIII).
The reduction of oxygen is a complex process, as outlined in Fig. IX. It results 
in the production of O2" anion, H2O2, OH", and singlet oxygen (IO2), a 
highly toxic bactericidal mixture (Babior, 1978). Almost all oxygen consumed 
by PMNs is reduced to 02" anion. Superoxide is short lived because it
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Fig. IX The products of oxygen reduction
undergoes rapid spontaneous or superoxide dismutase (SOD)-accelerated 
dismutation to H2O2.
Although H2O2 is bactericidal in its own right, its potency is greatly 
augmented (approx. 50-fold) in the presence of MPO and halide ions (I", Cl", 
Br") (Klebanoff, 1980). Myeloperoxidase, present within azurophilic granules is 
excreted into phagolysosomes. This excretion occurs concomitantly with 
activation of the respiratory burst. This process yields, for example, 
hypochlorite ion which allows destructive halogenation or oxidation of a wide 
variety of substances. In the presence of ammonia or amino acids, MPO and 
H2O2 can react to form N-chloroamines, which appear to act as long-lived 
microbicidal products (Weiss, Lampet and Test, 1983).
The H2 0 2 -MP0 -halide system is thought to be the major bactericidal 
peroxidative mechanism in PMNs. This system has an acidic pH optimum; a 
condition which is met in the phagocytic vacuole.
A  system of detoxifying substances within each cell serves to protect against its 
own oxidants. These include superoxide dismutase which converts 0 2 “ to 
oxygen and water; and catalase which converts H2O2 to oxygen and water. 
Staphylococcus aureus is a catalase-positive micro-organism. It contains high 
catalase activity, which destroys H2O2 and consequently reduces the killing 
efficiency of the PMN. In contrast, bacteria that are catalase-negative, for 
instance Escherichia coli. are effectively destroyed.
The oxygen-independent mechanisms are responsible for microbial killing in an 
anaerobic environment or in PMNs in which the oxidative capacity is deficient 
or absent (eg. chronic granulomatous disease). These factors are the acidic
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environment of the phagolysosome (pH 4.0 to 6.0), lactoferrin; an iron binding 
protein whose extracellular release can destroy microbes by starving them of 
iron (Root and Cohen, 1981), and the direct action of lysozyme, which attacks 
the peptidoglycan of some bacterial cell walls resulting in lysis of the micro­
organisms (Unanue, 1986). Primary granules are rich in arginine which rapidly 
affects the ability of bacteria to replicate without destroying their structural 
integrity. In addition, PMNs contain a variety of proteases and hydrolases 
which serve a digestive rather than a microbicidal function (Klebanoff and 
Clark, 1978).
Oxygen-dependent and oxygen-independent mechanisms tend to be studied 
separately, and little is known about their interactions. The two mechanisms 
may be synergistic, compatible, or unilaterally or mutually inhibitory. 
Interactions might include a cooperative attack of oxidants and hydrolytic 
enzymes. For example, exposing bacteria to a free radical-generating system 
increases their susceptibility to attack by lysozyme (Thomas, Lehrer and Rest, 
1988).
The foregoing stages are convenient for outlining the biology of phagocytosis 
but are not necessarily discrete in either space or time.
2.1.3 Measurement of phagocytic activity
The process of phagocytosis can be studied in vivo and in vitro. The latter 
offers several advantages: known homogeneous populations of phagocytic cells 
can be used, and the effects of serum and other factors on phagocytic function 
can be controlled. Many in vitro methods have been employed, and though they
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may be different in detail their general principles are similar. These are 
summarised in Table 2.2. The use of subjective techniques, such as microscopic 
examination of smear preparations and colony counting, have several 
disadvantages: they are tedious, time consuming, and subject to interobserver 
error. Also, results cannot be obtained before 24-48 hours. By contrast, the 
radiometric assay is an objective and sensitive method which eliminates the 
aforementioned drawbacks. Moreover, the test is easily quantitated so that 
results can be obtained within several hours. However, in all the above 
methods, there often lacks distinction between intracellular ingestion and 
extracellular attachment, therefore care must be taken when interpreting the 
results.
Polymorphonuclear leucocyte killing can be measured directly by the decrease 
in total number of live micro-organisms by radioactive probe or microbiological 
method. Recording the respiratory burst which accompanies PMN phagocytosis 
is an indirect measurement of the microbicidal activity of these cells. However, 
non-specific activation accompanied by a metabolic burst may not be 
accompanied by intracellular killing and therefore this type of measurement is 
unreliable.
Different methods have utilised bacteria, notably S. aureus (Bodel and 
Hollingsworth, 1966; Uden et al.. 1983), fungi such as baker’s yeast and 
Candida albicans (Brandt and Hedberg, 1969; Turner et al.. 1973; Corberand et 
al., 1977; Wilton, Gibson and Chuck, 1978; Sheehan, Brown and Durmonde, 
1984), and inert particles including polyvinyl toluene latex and colloidal carbon 
(Hallgren, Hakansson and Venge, 1978; Attia et al.. 1982a).
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PRINCIPLE
Phagocytosis
Determination of 
increase in number 
of intracellular 
particles
Determination of 
decrease in number 
of extracellular 
particles
Method
Microscopic
examination
Labelling of 
particles with 
radioactive 
probe
Direct
microbiological 
methods - colony 
counting
Electronic
particle
counter
Study
Bodel and 
Hollingsworth
Brandt and Hedberg
Turner et al.
Corberand et al.
Wilton et al.
Bultmann et al.
Attia et al.
Breedveld et al.
Foroonzanfar et al.
Verhoef et al. 
Sheehan et al.
Breedveld et al. 
Hallgren et al.
Year
1966
1969
1973
1977
1978 
1980 
1982a 
1985 
1976
1977a
1984
1985 
1978
Table 2.2 In vitro methods of phagocytosis
2.1.4 Phagocytosis of synovial fluid derived polymorphonuclear leucocytes
There is general agreement in the literature that SF-PMNs from patients with 
RA have a defective phagocytic capacity as measured by a number of different 
systems. Bodel and Hollingsworth (1966) using live S. aureus demonstrated that 
SF-PMNs from 18 patients had depressed phagocytosis and this could be 
improved, but not normalised, by RA serum. Phagocytosis of baker’s yeast 
particles and Candida albicans was also found to be defective (Brandt and 
Hedberg, 1969; Turner et al.. 1973; Wilton et al.. 1978).
The basis for the defect shown is unknown but it has been attributed to the 
presence of SF (Bodel and Hollingsworth, 1966); ingestion of IgG ICs in vivo 
(Turner et al.. 1973); hyaluronic acid (Brandt, 1974); a functional deficiency in 
C3b receptors on SF-PMNs (Wilton et al.. 1978); binding of soluble ICs and the 
consequent alteration of cell kinetics (Strakebaum, Jimenez and Arend, 1982); 
and the decreased expression of Fc receptors (Breedveld et al.. 1984).
2.1.5 Phagocytosis of peripheral blood derived polymorphonuclear leucocytes
The phagocytic capacity of PB-PMNs in patients with RA is more contentious 
than that of SF-PMNs. There are many conflicting reports, some of which are 
summarised in Table 2.3.
It is interesting that in the study by Wilton et al. (1978), they also noted a 
positive correlation between the phagocytic capacity of SF-PMNs and PB- 
PMNs which may suggest that the defective blood PMNs migrate into the SF.
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Study Organism/Particles used Observation
Bodel and Hollingsworth, 
1966
Brandt and Hedberg, 1969 
Turner et al.. 1973 
Goetzl, 1976 
Hallgren et al.. 1978 
Biiltmann et al.. 1980 
Sheehan et al.. 1984 
Breedveld et al.. 1985 
King, 1985
Corberand et al.. 1977 
Wilton et al.. 1978 
Attia et al.. 1982a
Staphylococcus aureus no defect
Baker’s yeast no defect
Baker’s yeast no defect
Erythrocytes no defect
Latex particles no defect
Candida albicans no defect
Candida albicans no defect
Stanhvlococcus aureus no defect
Staphylococcus aureus and P. mirabilis no defect
Baker’s yeast decreased
phagocytosis
Candida albicans decreased
phagocytosis
Latex particles decreased
phagocytosis
Table 2.3 Phagocytic capacity of blood polymorphonuclear leucocytes from patients 
with rheumatoid arthritis
In the SF, a further inhibition takes place since the defect of SF-PMNs was 
significantly greater than that shown by blood PMNs.
These contradictory reports may have arisen through the use of various 
subjective techniques.
2.1.6 The effect of rheumatoid arthritis serum on phagocytosis
Serum from RA patients has been shown to inhibit phagocytic uptake by 
normal PMNs (Attia et al.. 1982b). It may then be proposed that the defective 
phagocytosis seen in RA PMNs, tested in a serum-free environment in vitro, is 
the consequence of these cells not having recovered from the extrinsic 
inhibitory effect of sera in vivo. Corberand et al. (1977) showed that RA PB- 
PMNs bathed in autologous sera had defective phagocytosis; this is possibly due 
to an extrinsic defect arising from the inhibitory action of RA serum.
Others reported that RA serum did not affect the phagocytosis of S. aureus 
(Breedveld et al.. 1985), baker’s yeast (Turner et al.. 1973), or Candida albicans 
(Sheehan et al.. 1984) by normal PMNs.
There is evidence that ICs and aggregated IgG will inhibit phagocytosis (Turner 
et al.. 1973; Breedveld et al.. 1985). Furthermore, the study by Starkebaum et 
al. (1982) confirms that insoluble ICs are ingested more readily by normal 
PMNs than are soluble complexes. Also, preincubation of either soluble ICs or 
soluble aggregates of IgG with PMNs, inhibits subsequent phagocytosis of 
insoluble ICs in a process that appears to involve metabolic activation of the 
PMN and may be accompanied by the loss of cell surface Fc receptors. Changes
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in the expression of Fc and C3 receptors on PMNs may influence cell functions 
(Breedveld et al.. 1985).
Hallgren et al. (1978) showed impaired PB-PMN phagocytic ability in 5 of his 
patients, which he correlated with high RF titres in their sera. Interestingly, 
Turner et al. (1973) also found a significant negative correlation between the 
RF titre and phagocytic uptake by normal PMNs suspended in RA serum. Attia 
et al. (1982b) found no correlation between titres of RF, or circulating ICs with 
the inhibition of PMN phagocytosis by RA serum. This is in agreement with 
Corberand et al. (1977).
2:1.7 The effect of svnovial fluid from patients with rheumatoid arthritis on 
phagocytosis
The RA joint is the site of an active inflammatory response, resulting in joint 
destruction. Tissue deposition of circulating ICs, with subsequent complement 
fixation and release of lysosomal enzymes, highly reactive oxygen radicals and 
their derivatives from activated SF-PMNs, is thought to be important in the 
pathogenesis of immune complex diseases (Panayi and Chapel, 1987). Previous 
exposure of normal PMNs to ICs or IgG aggregates produces a burst of 
chemiluminescence (Starkebaum et al.. 1981). As ICs are present in the SF and 
SF-PMNs of RA patients, and can be detected in normal PMNs preincubated 
with SF (Cats, Lafeber and Klein, 1975) it has been proposed that they activate 
PMNs.
It has been illustrated that SF from RA patients was inhibitory to phagocytosis 
by normal blood PMNs (Turner et al.. 1973; Wilton et al.. 1978). Turner et al. 
(1973) noted that this inhibitory activity was not specific to SF from RA
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patients. He compared SF from RA, osteoarthritis and a miscellaneous arthritis 
group. His results showed phagocytosis to be decreased equally and significantly 
in all SF. However, RA SF-PMNs showed significantly less phagocytosis than 
miscellaneous arthritis SF-PMNs, or PB-PMNs from all three groups. This 
might suggest an additional intrinsic defect in RA SF-PMNs.
This depressed phagocytic activity of SF-PMNs from RA patients has been 
ascribed to the ingestion of ICs in vivo (Turner et al.. 1978). Binding of ICs, in 
the SF, to normal PMNs, may block surface Fc and C3b receptors; induce 
interiorisation of unoccupied Fc receptors; or damage Fc receptors (Starkebaum 
et al.. 1982), and thereby render them unrecognizable to opsonised particles, 
which consequently escape phagocytosis. Breedveld et al. (1984) have shown 
that PB-PMNs from RA patients also show decreased expression of Fc 
receptors and increased expression of C3b receptors after ingestion of ICs. In a 
more recent study (Breedveld et al.. 1986), he indicated that phagocytosis of SL 
aureus was as effective in SF-PMNs with SF as in PB-PMNs with serum, and 
that the presence of intracellular ICs in SF-PMNs did not influence the 
phagocytic activity of these cells.
Synovial fluid also contains hyaluronic acid and free iron (Gutteridge, Rowley 
and Halliwell, 1982). It has been shown that hyaluronate molecules depress the 
ability of PMNs to dispose of particulate material. Ingestion being inversely 
related to both the concentration and molecular weight of the synovial 
hyaluronate (Brandt, 1974). There is evidence that Fe(III) can induce a defect 
in phagocytosis, however this is dependent on the nature and concentration of 
the ligand attached to the iron ion. It has been suggested that the noxious effect 
of iron on PMN function is a result of its ability to catalyse the generation of 
toxic oxygen species by these cells (Sweder van Asbeck et al.. 1984).
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Such a defect of phagocytosis, combined with the chemotactic defect described 
by Mowat and Baum (1971) could jeopardize the inflammatory response and 
allow infection to become easily established.
2.1.8 Opsonic activity of serum and synovial fluid from patients with rheumatoid 
arthritis
A  lack of opsonins, C3b or IgG, or the presence of inhibitors of opsonisation 
will impair phagocytosis. Although the level of serum complement in RA is 
usually normal or slightly elevated, 4% of RA patients are 
hypocomplementaemic (Hunder and McDuffie, 1973) and, as one might expect, 
these patients have an abnormally high incidence of bacterial infection. 
Measurement of C3d, a breakdown product of C3b, provides a useful means of 
detecting in vivo complement activation. Nydegger et al. (1977) and Mallya et 
al- (1982) found elevated plasma C3d concentrations in RA patients. This 
suggests significant breakdown of C3b and consequently fewer opsonically 
active complement fragments. The low levels of haemolytic complement and the 
presence of complement fixing materials in hypocomplementaemic serum 
suggests that activation and utilisation of complement by ICs is responsible 
(Hunder and McDuffie, 1973). In support of this theory, Mallya et al. (1982) 
found a significant correlation between C3d concentration and circulating ICs 
in their patients.
Fluid C3b, a by-product of the activation of large amounts of C3, has been 
shown to inhibit phagocytosis, possibly by competing with C3 for the C3 
convertase on the bacterial cell surface or by blocking the sites where nascent 
C3b would bind covalently to manifest its opsonic function (Ogle, Ogle and 
Alexander, 1983).
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Several authors have shown titres of whole complement and individual 
complement proteins to be lower in SF from RA patients than levels present in 
RA serum, normal serum or serum from patients with other arthritic diseases 
(Hedberg, 1963; Ruddy and Austen, 1970). A  few years later, Pruzanski, Leers 
and Wardlaw (1974) reported that the bacteriolytic and bactericidal activity of 
RA SF was less than that of autologous serum, or SF and serum from 
osteoarthritic patients.
The presence of elevated levels of C3 breakdown products in serum or SF 
indicates that the lack of complement components is due to the continuous 
activation of the complement pathway by both the classical and alternate routes 
(Hunder, McDuffie and Clark, 1979).
2.1.9 The effect of drugs on polymorphonuclear phagocytosis
It seems reasonable to suggest that the aforementioned discrepancies of PMN 
phagocytosis, may be due to differences in drug regimens. Drugs used in the 
treatment of RA are discussed in chapter 1. The NSAIDs have been shown to 
depress phagocytosis and intracellular killing in vitro (Whittaker, Hughes and 
Khurshid, 1975; Robinson, 1978) and in vivo (Whittaker et al.. 1975) though 
high concentrations of drug are frequently required. Inhibition may also occur 
with therapeutic concentrations of corticosteroids (Jones, Morris and Jayson, 
1983). There is a widespread clinical experience that corticosteroid treatment 
increases the incidence of bacterial infection. There are several reports that 
phagocytosis is increased following treatment with penicillamine (Hallgren et 
al., 1978). The use of D-penicillamine, a reducing and chelating agent, in the 
treatment of RA is based upon the observation that this drug acts by
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dissociating the disulphide bonds of RF (Jaffe, 1962). This may lead to 
decreased IC formation and consequently reduced blocking of C3b and Fc 
receptors on the PMN cell surface. These receptors are then free to attach and 
ingest opsonised particles. Some antirheumatic drugs have been reported to 
decrease PMN adherence (MacGregor, Spagnudo and Lentnek, 1974). However, 
the significance of this to phagocytic function is unclear since Youinou and Le 
G off (1987) showed that inhibition of bactericidal ability of the PMN is not the 
consequence of weakened adherence or impaired bacterial engulfment, but an 
induced defect in the respiratory burst. Impairment of lysosomal enzyme release 
by PMNs treated with indomethacin, as demonstrated by Northover (1977), is 
another possibility for the depressed killing ability of PMNs. Despite these 
theories, Wilton et al. (1978) found no correlation between drug therapy and 
defective phagocytosis by either SF-PMNs or PB-PMNs. It may be necessary to 
differentiate between the effects of drugs on RA and normal PMNs, since 
Spisani and colleagues (1982) reported that rifamycin sv inhibited phagocytosis 
by RA but not normal PMNs.
2.1.10 Aims of the study
In the light of conflicting reports of PMN phagocytic function, this study set 
out to investigate 1) a possible intrinsic cellular defect in RA PMNs compared 
to PMNs from healthy controls, 2) possible extrinsic inhibitory activity inherent 
to RA serum or SF and 3) if present, could this inhibitory activity be 
transferred in vitro to normal PMNs? Furthermore, the opsonic activity of 
serum and SF from normals and patients with RA was investigated, to 
determine whether the phagocytic dysfunction could be the consequence of an 
opsonic defect rather than a PMN abnormality.
46
The fact that patients with RA are susceptible to infection, together with the 
high incidence of isolation of S. aureus as the causative agent, suggests a 
possible defect in PMN phagocytosis.
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2.2 MATERIALS AND METHODS
2.2.1 Patients
All RA patients studied in this and subsequent chapters had clinical or definite 
RA according to the American Rheumatism Association (Appendix A). They 
were either in-patients or attending clinics at the Centre for Rheumatic 
Diseases, Glasgow Royal Infirmary. Controls free from any clinically detectable 
disease and non-users of drugs, were similarly tested in parallel for each test. 
Some patients and controls were tested on more than one occasion.
2.2.2 Collection of samnles
All centrifugation througout this study was performed at 37°C unless otherwise 
specified.
To aid puncture of an antecubital vein, and consequent blood flow, a rubber 
tourniquet applied gentle pressure. Using either a 19 or 21 gauge, sterile, 
disposable butterfly needle (Abbot Irland Ltd. U.K.), blood was slowly 
withdrawn into a sterile plastic syringe (Becton, Dickinson & Co. Ltd., U.K.). 
The whole blood samples were collected into sterile universal containers 
(Laboratory Sales Ltd., U.K.) containing preservative free sodium heparin to a 
final concentration of 10 Units/ml of blood (1000 Units/ml, Leo Laboratories, 
U.K.), as anticoagulant. The universals were securely sealed and the contents 
gently mixed.
48
For separation of serum, blood was collected into glass tubes containing no 
anticoagulant (Labco, U.K.). These were clotted at ambient temperature for 80 
minutes. The tubes were then centrifuged (Mistral 4L, MSE, U.K.) at 2000g for 
10 minutes, the serum removed and stored at -70°C in 1ml aliquots.
All blood samples were collected between 9.00 and 10.00 am to minimise the 
effect of diurnal variation. Samples were processed as soon as possible after 
collection.
Synovial fluid was aspirated from the joints of RA and non-RA patients, and 
collected into universals containing no anticoagulant. Synovial fluid was 
centrifuged at 2000g for 10 minutes to pellet all the cells present and the 
supernatant removed and stored at -70°C in 1ml aliquots.
Serum and SF samples, separated for the measurement of complement 
components, were centrifuged at 2000g for 10 minutes, within 30 minutes of 
collection.
2.2.3 General media
(i) Dextran 150
A  5% (w/v) dextran 150 (Fisons, U.K.) solution was prepared in saline (0.9% 
(w/v) sodium chloride (NaCl); BDH Chemicals Ltd., U.K.). Once totally 
dissolved, it was filtered through a 0.2p sterile, disposable, filter assembly 
(Gelman Sciences, U.S.A.) into a sterile glass bottle and stored at 4°C.
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(ii) Lymphoprep
Lymphoprep (Nyegaard, U.K.) is a commercially available sterile solution of 
sodium metrizoate and Ficoll in concentrations of 9.6% (w/v) and 5.6% (w/v) 
respectively. It has a density of 1.077 g/ml and an osmolarity of 300 mOsm/kg. 
This solution is stored at or below 20°C protected from light for optimum 
stability.
(iii) Ammonium chloride
Ammonium chloride (NH4CI: Sigma, U.K.) was prepared as a 0.87% (w/v) 
solution in distilled water and stored at 4°C.
(iv) Gel-Hanks
Gel-Hanks (GH) was prepared by adding 10ml of Hanks’ Balanced Salt Solution 
(HBSS: lOx, Gibco Ltd., U.K.), without calcium and magnesium, to 80ml of 
sterile distilled water. Gelatin (1% (w/v), BDH Chemicals Ltd., U.K.) (10ml), 
20mM N-2-hydroxyethylpiperazine-N2-ethansulphonic acid (HEPES buffer) 
(1M solution, Northumbria Biologicals Ltd., U.K.) and sodium bicarbonate 
solution (7.5% (w/v); Northumbria Biologicals Ltd., U.K.) (1.1ml) were added 
to stabilize the solution. The pH was adjusted to 7.2 with 1M sodium hydroxide 
(BDH Chemicals Ltd., U.K.) and 1M Hydrochloric acid (HQ). Gel-Hanks was 
used as a washing medium and stored at 4°C.
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(v) Tris (hydroxymethyl)aminomethane (Tris) buffer
Stock solutions
A: 0.2M solution of Tris (Sigma, U.K.).
B: 0.2M HC1 (specific gravity 1.18; BDH Chemicals Ltd., U.K.).
50ml o f A  + xml of B diluted to a total of 200ml with distilled water.
X pH
5.0 9.0
8.1 8.8
12.3 8.6
16.5 8.4
21.9 8.2
26.8 8.0
32.6 7.8
38.1 7.6
41.4 7.4
41.2 7.2
2.2.4 Isolation of polymorphonuclear leucocytes from whole blood
Polymorphonuclear leucocytes were prepared from heparinised peripheral blood 
using a modification of the method described by Boyum (1968). Approximately 
7ml of blood was mixed with a 5% (w/v) solution of dextran 150 (3ml) in 15ml 
plastic conical centrifuge tubes (diameter 12mm: Elkay products Inc., U.S.A.),
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and allowed to gravity-sediment for 30 minutes at ambient temperature. 
Erythrocytes settle at the bottom of the tube (Fig. X). The PMN-rich plasma 
was layered onto lymphoprep (4ml) and centrifuged at 290g for 25 minutes. 
Polymorphonuclear leucocytes pellet while the monocytes settled at the 
interphase (Fig. XI). The supernatant was decanted and the pellet resuspended 
in cold 0.87% NH4CI (10ml), to lyse any contaminating erythrocytes. After 20 
minutes the PMNs were centrifuged at 290g for 5 minutes, resuspended and 
washed once in GH for 5 minutes. The PMNs were finally resuspended in GH 
(1 ml). A  small volume of PMN suspension was diluted 10-fold in white cell 
diluting fluid (2% glacial acetic acid (May and Baker, U.K.), and a few grains 
of crystal violet (BDH Chemicals Ltd., U.K.) in distilled water), to immobilize 
the cells, and 10|il was added to an improved Neubauer haemocytometer 
(Gallenkamp, U.K.). The cells were counted under a light microscope using xlO 
magnification. (Watson microsystem 70, U.K.). The white cell count was 
determined by taking the mean number of cells (Y) in the four outermost 
comers (each of 16 squares) of the grid within the chamber. Total white cell 
count = Y  x dilution (i.e 1/10) x 10  ^ giving number of cell per ml, i.e. Y x 10^  
cells per ml. The PMNs were adjusted to a concentration of 1 x 10  ^ colony 
forming units (c.f.u.)/ml for the phagocytic assays.
Use of this method for counting cells had the advantage that purity of 
individual fractions could be assessed along with cell counts, as the staining 
allowed differentiation between the nuclei of mononuclear leucocytes and 
PMNs.
The viability of the PMNs was determined at the beginning and end of the 
phagocytosis experiments, by trypan blue exclusion (0.5% solution in 0.85% 
saline: Flow laboratories, U.K.). Equal volumes (lOgl) of PMN preparation and
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RA Controls
Number 38 38
Mean age (years) 53 29
(range) (28-76) (23-43)
Sex* M=14 M=17
F=24 F=21
Mean duration of
disease (years) 10 NA
(range) (1-27) NA
Drug therapy NSAID only =15 NA
2nd line only =13  
3rd line only = 5 
2nd line + NSAID = 5
* M: male; F: female
RA: rheumatoid arthritis
NSAID: Nonsteroidal anti-inflammatory drug
2nd line: gold, penicillamine, auranofin or sulphasalazine
3rd line: cyclophosphamide, methotrexate or azathioprine
NA: not applicable
Table 2.4 Clinical data of rheumatoid arthritis and controls
trypan blue were mixed together and the cells examined within 2 minutes. 
Non-viable cells stained deep blue whereas viable cells remained unstained. 
Viability of more than 95% was found in all samples examined, with greater 
than 94% purity.
2.2.5 Radiometric phagocytic assays
A  modification of the method of Verhoef, Peterson and Quie (1977a) was used, 
and is described in the following text.
(i) Patients and controls
For the study of phagocytic uptake of S. aureus and P. mirabilis. PB-PMNs 
from 38 patients with RA were compared to PB-PMNs from 38 sex-matched, 
healthy laboratory staff. The clinical data of patients and controls are shown in 
Table 2.4.
(ii) Bacterial strains and radioactive labelling.
Mueller-Hinton broth (10ml) (Oxoid Ltd., U.K.) containing [^Hj-adenine 
(0.1ml) (TRK.343, specific activity 851 Gigabequerels/mmol; Amersham 
International, U.K.) was inoculated with one colony of S. aureus cowan 1 or P. 
mirabilis (laboratory strain). The broths were incubated overnight at 37°C, in 
which time the growing bacteria incorporated the [^H]-adenine into their own 
DNA sequence. The bacteria were washed thrice in sterile phosphate-buffered 
saline (PBS: Oxoid Ltd., U.K.), pH 7.4, at 2000g for 10 minutes (MSE, Super 
Minor, U.K.). The concentration of the bacterial suspension was adjusted to 1 x 
107 cfu/m l using a Cecil spectrophotometer (Unicam, S.P. 1700, U.K.), set at a
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wavelength of 620nm and slit width of 0.1mm. An optical density (O.D.) of 
0.025 corresponded to 1 x 10  ^ cfu/ml in the case of both organisms. This was 
confirmed by the Miles and Misera technique (1938). For standardisation of 
bacterial concentrations see Appendix B.
(iii) Bacterial opsonisation
Bacteria were opsonised with an equal volume of pooled human serum diluted 
in GH. Opsonisation of S. aureus and P. mirabilis with 10% and 50% serum 
respectively, was found to give optimum phagocytosis (Appendix B). The 
bacteria and serum mixtures were incubated at 37°C on an orbital shaker 
(150rpm). After 15 minutes, they were removed and centrifuged at 2000g for a 
further 15 minutes. The supernatant was discarded and the bacteria resuspended 
in the original volume of GH.
(iv) Uptake of bacteria
To measure phagocytic uptake (Fig. XII), duplicate polypropylene scintillation 
vials (Pony vials: Canberra Packard, U.K.) containing PMNs (0.1ml) and 
opsonised bacteria (0.1ml) were incubated at 37°C, on a shaking incubator 
(150rpm). A  1:1 ratio of PMN:bacteria was found to give the optimum 
phagocytosis (Appendix B). After 15 minutes the vials were removed and 
phagocytosis was terminated in one of the duplicate vial sets (Fig. XII) by the 
addition of scintillation fluid (3ml) (299: Canberra Packard, U.K.). Ice cold PBS 
(3ml) was added to the other set of vials, which were washed thrice with PBS 
at 160g for 5 minutes. After the final wash, the pellet was resuspended in 
scintillation fluid (3ml). The purpose of the PBS washes was to remove any 
extracellular, non-phagocytosed bacteria which were not pelleted during the 
differential centrifugation. Thus, only those organisms which were leucocyte-
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Stages V1AL1 VIAL 2 VIAL 3 VIAL 4
©  100 ul PMN 100 ul PMN 100ulGH 100ulGH
at 1x10 7/ml at 1x10 7/ml
© Incorporate tritiated adenine 100 ul S. aureus (1x107 /ml) added to all vials
Incubate at 37°C for 15 minutes©
©  Add Wash x3 Add Wash x3
scintillation with phosphate scintillation with phosphate
fluid buffered saline fluid buffered saline
© Add
scintillation
fluid
Add
scintillation
fluid
©  Amount of radioactivity was determined using a 
liquid scintillation counter
®  Results expressed as phagocytic uptake
% Uptake .  ( g -m v'.al 2 x 100) _  ( cpmviaU x 1Qo)
cpm vial 3cpm viall
Fig. xn Outline of the phagocytic assay.
associated would remain. The amount of radioactivity was determined using a 
liquid scintillation B counter (1216 Rackbeta II, LKB, U.K.). Each sample was 
counted for 60 seconds. All experiments contained duplicate control vials in 
which PMNs were replaced by GH. These were treated as described above. 
They were included to control for non-specific bacterial aggregation and 
adherence to the vials. Phagocytic uptake was calculated as the percentage of 
radioactivity associated with the PMN (Fig. XII).
(v) The effect of drugs on phagocytic uptake of S. aureus by normal 
polymorphonuclear leucocytes.
The drugs studied were Tenidap (CP-66,248; Pfizer, U.K.), SASP (Pharmacia 
Ltd., U.K.), Hydrocortisone sodium phosphate (Efcortesol, 100 mg/ml solution, 
Glaxo, U.K.), and Indomethacin (Sigma, U.K.). Sulphapyridine and 5-ASA, the 
two components that constitute SASP, were also studied individually. Tenidap, 
SASP, SP and 5-ASA were dissolved in Tris buffer pH 9.0, neutralised with 
0.2M HC1, as far as possible without precipitation, at concentrations of 
lOmg/ml for all except Tenidap which was at lmg/ml. Indomethacin was 
dissolved in 95% ethanol (James Burroughs (F.A.D.) Ltd., U.K.) at lOmg/ml 
and was diluted just before use to lgg/m l, the final concentration of ethanol 
being approximately 0.01%. All drugs were filter sterilised (0.2p) before use. 
Tenidap, SASP, SP and 5-ASA were stored at -70°C in 0.5ml and 0.1ml 
aliquots. Indomethacin and Hydrocortisone were stored at 4°C. The drugs were 
diluted with GH to the appropriate working concentrations (Table 2.5), prior to 
use in the assay. The final concentrations of drugs used in in vitro experiments 
are as detailed in Table 2.5.
Polymorphonuclear leucocytes (0.1ml, 1 x 107/ml) were incubated with each 
drug (0.1ml) at 37°C. As a control, PMNs were incubated with GH alone. After
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Drugs
Tenidap
Sulphasalazine
Sulphapyridine
5-Aminosalicylic acid
Hydrocortisone 
sodium phosphate
Indomethacin
Working
concentrations
(pg/ml)
2 4 10 20
20 40 200 1000 
20 40 200 1000 
20 40 200 1000
20 40 60 
2
Final
concentrations
(pg/ml)
1 2 5 10
10 20 100 500 
10 20 100 500 
10 20 100 500
10 20 30 
1
Table 2.5 Drugs and concentrations studied
60 minutes, samples were removed and washed with GH (2ml) at 160g for 5 
minutes. The cells were resuspended in GH (0.1ml) to restore them to their 
original concentration. The ability of PMNs to phagocytose S. aureus was 
measured as described in section 2.2.5(iv). The effect of drugs on the 
phagocytic uptake of S. aureus by PMNs was calculated from the phagocytic 
differential (PD).
PD (uptake) = % uptake (PMN-drug) - % uptake (PMN-GH) 
where % uptake is calculated as described in Fig. XII.
(vi) The effect of rheumatoid factor on phagocytosis of S. aureus by normal 
polymorphonuclear leucocytes.
Commercially available RF (American Hospital Supply company, U.S.A.) at a 
concentration of 250 International Units (IU)/ml was purchased. Rheumatoid 
factor (0.1ml) was added to PMNs (0.1ml) at 37°C in an orbital shaking 
incubator (150rpm). The concentration of PMNs was 1 x 10  ^ cfu/ml and final 
assay concentrations of RF were 125, 100, 75, 50, 25, and 0.5 IU/ml in GH 
(PMN-RF). As a control, PMNs were incubated with GH alone (PMN-GH). 
After 30 and 60 minutes, samples were removed and washed with GH (2ml) at 
160g for 5 minutes. Cells were resuspended in GH at 1 xlO^ cfu/ml. The 
ability of normal PMNs to phagocytose S. aureus was measured using the 
radiometric assay described in section 2.2.5(iv). The effect of RF on 
phagocytosis by normal PMN was calculated from the phagocytic differential 
(PD).
56
PD (uptake) = % uptake (PMN-RF) - % uptake (PMN-GH)
where % uptake is calculated as described in Fig. XII.
(vii) The effect of serum on phagocytosis of S. aureus by polymorphonuclear 
leucocytes
In this study serum was obtained from 33 RA patients and 16 healthy controls. 
The clinical data are shown in Table 2.6.
Polymorphonuclear leucocytes (0.1ml) were incubated at 37°C, with sera (0.1ml) 
from RA patients (Groups I, II and III) or controls (PMN - serum). Serum was 
present at a final concentration of 50% and PMNs at 1 x 10  ^ cfu/m l in GH. As 
a control, PMNs were incubated with GH alone (PMN-GH). After 60 minutes, 
samples were removed and washed with GH (2ml) at 160g for 5 minutes. Cells 
were resuspended in GH (0.1ml) to restore them to their original concentration. 
The ability o f PMNs to phagocytose S. aureus was measured as described 
previously.
Group I : serum from RA patients with high RF titre (>1/1024) (n= ll).
Group II : serum from RA patients with low RF titer (< 1/64) (n=12).
Group III : serum from RA patients with no detectable RF (seronegative) 
(n=10).
Group IV : serum from healthy controls (n=16).
The effect of serum on the phagocytic uptake of S. aureus by PMNs was 
calculated from the phagocytic differential (PD).
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RA Controls
Number 33 16
Mean age (years) 54 26
(range) (28-78) (23-32)
Sex* M = ll M=9
F=22 F=7
Mean duration of
disease (years) 7 NA
(range) (1-20) NA
Drug therapy NSAID only = 1 5  NA
2nd line only = 17 
2nd line + NSAID = 3
* M: male; F: female
RA: rheumatoid arthritis
NSAID: Nonsteroidal anti-inflammatory drug
2nd line: gold, penicillamine, auranofin or sulphasalazine
N A  not applicable
Table 2.6 Clinical data of patients and controls, from whom serum was collected
PD(uptake) = %uptake (PMN-serum) -  %uptake (PMN-GH)
Where % uptake is calculated as described in Fig. XII.
(viii) The effect o f synovial fluid on the phagocytosis o f S. aureus by 
polymorphonuclear leucocytes.
In this study, the effect of SF from 30 RA patients, on PB-PMN phagocytosis 
was compared with SF from 15 non-RA patients. This group consisted o f 1 
adult Still’s disease, 1 systemic lupus erythematosus, 2 psoriatic arthritis, 3 
juvenile RA, 3 reactive arthritis and 5 ankylosing spondylitis patients. The 
clinical data of RA and non-RA patients is presented in Table 2.7.
Polymorphonuclear leucocytes (0.1ml) at a final concentration of 1 x  10  ^
cfu/m l were incubated at 37°C with SF (0.1ml) from RA and non-RA patients 
(PMN-SF). Synovial fluid was present in the assay at final concentrations of 
25%, 50% and 75%. As a control, PMNs were incubated with GH alone (PMN- 
GH). After 60 minutes, the samples were removed and washed with GH (2ml) 
at 160g for 5 minutes. Cells were resuspended in GH (0.1ml). The phagocytic 
uptake assay was measured as previously described.
The effect o f SF on phagocytosis was calculated by the phagocytic index (PI).
% uptake (PMN-SF)
PI (uptake) = ---------------------------------------------  x  100
% uptake (PMN-GH)
Where % uptake is calculated as described in Fig XII.
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RA Non-R A
Number 30 15
Mean age (years) 57 29
(range) (36-77) (16-46)
Sex* M=20 M = ll
F=10 F=4
Mean duration of
disease (years) 9 4
(range) (2- 20) (1- 10)
Drug therapy NSAID only = 9 
2nd line only = 1 4  
3rd line only = 1 
2nd line + NSAID = 6
NA
* M: male; F: female 
RA: rheumatoid arthritis 
NSAID: Nonsteroidal anti-inflammatory drug 
2nd line: gold, penicillamine or sulphasalazine 
3rd line: azathioprine
Table 2.7 Clinical data o f patients with and without rheumatoid arthritis
(ix) Opsonic activity of serum and synovial fluid
Serum and SF were collected as detailed in section 2.2.2. Opsonic activity was 
examined in the serum samples described in 2.2.5(vii), and the SF samples 
described in section 2.2.5(viii).
Several dilutions (10%, 20%, 25%, 50% and 75%) of SF in GH were tested for 
optimal opsonic activity. No significant differences were found between any 
two dilutions. However, 50% SF gave the lowest percentage precision value 
(Appendix B). As a consequence of these preliminary experiments, 50% SF was 
used as opsonin in subsequent opsonisation experiments. Serum, as an opsonin, 
was used at a concentration of 10% in GH. Radioactively labelled ([^H]- 
adenine) S. aureus was opsonised as previously specified. Serum or SF, both 
inactivated and untreated were used as opsonins. Inactivation was performed by 
incubating the serum or SF for 30 minutes at 56°C, before use.
Phagocytic uptake was measured as described in section 2.2.5(iv).
2.2.6 Immune complex assay
A  commercially available kit (M201 CIC screening kit: Mercia diagnostics, 
U.K.) was used to measure circulating ICs (IgG and IgM) in serum and SF. The 
assay procedure was based on precipitation of ICs by polyethylene glycol 
(PEG). It was a two stage procedure; an initial precipitation by PEG followed 
by the subsequent quantitation and characterisation of the complexes by single 
radial immunodiffusion. The assay was performed according to the instructions 
supplied with the kit.
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Immune complex study groups.
The same groups of sera and SF were used in this study as in section 2.2.5(vii) 
and (viii) respectively. Sera or SF that were known to be positive and negative 
for ICs were included as quality control samples in each assay. This enabled the 
precipitation to be qualitatively validated. In addition to this the kit included 
plate controls, which allowed both quantitative and qualitative validation.
2.2.7 Evaluation of immunological parameters in serum and svnovial fluid
Complement and RF titre were quantitated by the Department of Clinical 
Immunology, Glasgow Royal Infirmary. Complement components, C3 and C4, 
were quantitated using commercially available immunodiffusion plates. 
Rheumatoid factor titre was determined by the Rose-Waaler agglutination 
technique (Rose et al.. 1948).
Immunoglobulin and CRP were evaluated by the Department o f Clinical 
Biochemistry, Glasgow Royal Infirmary. Immunoglobulin (IgG, IgM and IgA) 
levels were obtained by immunoturbidimetry using an ’Encore’ centrifugal 
analyser (Baker Instruments, U.K.). C-reactive protein was estimated by 
fluorescence polarization immunoassay technology using an Abbott TDx system 
(Abbott laboratories, U.K.).
2 .2.8 Statistical analysis
Statistical analyses of all results were performed by computer analysis using the 
Statgraphics software package (version 2.6) (STSC Inc., U.S.A.). All correlations
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were performed using Spearman’s rank correlation procedure. Statistical 
significance was sought using the non-parametric Mann Whitney U  test for 
unpaired data, or the Wilcoxon rank test for paired data. All significance was 
assessed at the 5% probability level. Methods are detailed in Appendix C.
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2.3 RESULTS
2.3.1 Effect of drugs on phagocytic uptake bv normal polymorphonuclear leucocytes
As shown in Fig. XIII phagocytic capacity was depressed in a dose dependent 
fashion, in normal PMNs treated, in vitro, with Tenidap. The concentrations, 
10, 5, and 2pg/ml significantly inhibited PMN uptake compared to lpg/m l 
(p=0.014, p=0.002, p=0.005 respectively), but not when compared with 
untreated PMNs (p>0.05). Interestingly, the lowest concentration of lgg/m l 
significantly increased phagocytic uptake when compared with untreated PMNs
(p<0.001).
Sulphasalazine weakly depressed phagocytic uptake (Fig. XIV), as did the two 
individual components that constitute SASP; SP (Fig. XV (A)) and 5-ASA (Fig. 
XV (B)), however, this difference was not significant. A  fall in uptake was 
observed when the concentration of SP was increased from 10|ig/ml to 20|ig/ml. 
However, at higher concentrations, uptake remained relatively constant, at a 
level comparable to that at 20gg/ml. A  similar response was found with 5- 
ASA, but not with SASP. No dose dependent response was observed in PMNs 
pretreated with SASP. Also, SASP did not induce significantly greater 
inhibition than either SP or 5-ASA alone (p>0.05).
No significant impairment of uptake could be detected with hydrocortisone 
sodium phosphate although PMN uptake showed a definite downward trend 
with increasing drug concentration from lOpg/ml to 20gg/ml to 30|ig/ml (Fig. 
XVI).
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Fig. XIII Effect o f lenidap on polymorphonuclear phagocytosis.
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tenidap concentration(pg/ml)
•j* median plus interquartile range (8 experiments)
PD : phagocytic differential
PD (uptake) = % uptake (PMN - tenidap) -  % uptake (PMN-GH)
PMN : polymorphonuclear leucocyte 
GI I : gel-hanks
Significant difference between concentrations Igg/ml and 2gg/ml: p=0.005, 
l[ig/ml and 5 fig/ml: p=0.002, and lgg/m l and lOgg/ml: p=0.014 
Wilcoxon rank test.
XIV Effect o f sulphasalazinc on polymorphonuclear phagocytosis.
____________ i_______i____ i___ i— i  t i n ____________ i i i  i i i  i  11____________ i______ i____ i___ i__ i i 1 1 1
1 to 100 1000
SASP concentration (pg/ml)
- | -  median plus interquartile range (8 experiments)
PD : phagocytic differential
PD (uptake) = % uptake (PMN-SASP) -  % uptake (PMN-GH)
PMN : polymorphonuclear leucocyte 
SASP : sulphasalazinc 
GH : gel-hanks
No significant difference between concentrations. Wilcoxon rank test.
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Pig. XV Effect o f A) sulphapyridinc and B) 5-aminosalicylic acid on
polymorphonuclear phagocytosis.
A)
5.0
- 5.0
- 10.0
i i i  i  i  i  i  i  i i » i i » I i i » i  » i i i i  i  1 1
10 100 
SP concentration (pg/ml)
1000
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10 100 
5 -A S A  c o n c e n t r a t i o n  (p g /m l)
1000
median plus interquartile range (8 experiments)
PD : phagocytic differential
PD (uptake) = % uptake (PMN-drug) - % uptake (PMN-GH)
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GH 
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sulphapyridinc 
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No significant difference between concentrations. Wilcoxon rank test.
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Pig. XVI liffccl of hydrocortisone on polymorphonuclear phagocytosis.
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h y d r o c o r t i s o n e  c o n c e n t r a t i o n  (u g /m l)
- |— median plus interquartile range (8 experiments)
PD : phagocytic differential
PD (uptake) = % uptake (PMN-drug) - % uptake (PMN-GH)
PMN : polymorphonuclear leucocyte 
GI I : gcl-hanks
No significant difference between concentrations. Wilcoxon rank test.
Indomethacin, at a concentration of lpg/m l, had no effect on normal PMN 
phagocytosis.
2.3.2 Comparison of the phagocytic function of peripheral blood polymorphonuclear
cells from rheumatoid arthritis patients and controls
As shown in Fig. XVII, the phagocytic capacity of PB-PMNs from RA patients 
was significantly impaired, in the case of S. aureus (p=0.011) and P. mirabilis 
(p=0.005). No significant correlation could be found between the duration of 
disease, age, or drug therapy of the patients, and defective phagocytosis by 
their PB-PMNs.
A  similar study using PMNs from controls showed a poor correlation between 
age and PMN uptake (Fig. XVIII) (rs=0.416). However, this study showed an 
upward trend in uptake up to approximately 50 years o f age, thereafter uptake 
dropped slightly and remained relatively constant. Phagocytosis by PMNs from 
other age groups was by no means impaired when compared with PMNs from 
the younger age groups.
2.3.3 Effect of rheumatoid factor on phagocytosis bv normal polymorphonuclear
leucocytes
There was no significant difference in the phagocytic uptake o f S. aureus by 
normal PMNs pretreated with various concentrations o f RF for 30 minutes or 
60 minutes (Table 2.8: p>0.05). No dose-dependent response was detected.
63
ph
ag
oc
yt
ic
 
up
ta
ke
 
(%
)
Fig. XVII Phagocytic uptake of S. aureus and P. mirabilis by polymorphonuclear 
leucocytes from normals and patients with rheumatoid arthritis.
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RF
(IU/ml)
Incubation time (minutes) 
30 60
PD uptake (%)
25 * -2.4 4.3
** (-6.5,8.9) (-4.11,11.0)
50 -3.8
(-6.2,13.8)
1.7
(-1.7,8.2)
75 4.1
(-2.3,15.2)
2.9
(-4.1,8.8)
100 1.0
(-2.1,11.9)
1.1
(-6.3,6.5)
125 - 1.1
(-3.7,12.4)
2.7
(-2.0,6.3)
* Median.
* *  Range.
RF: rheumatoid factor.
PD: phagocytic differential.
PD (uptake) = % uptake(pjy[]sj_Rp) -  % uptake(pMN-GH)
PMN: polymorphonuclear leucocytes.
GH: gel-hanks.
IU: international units.
No significant difference between 30 and 60 minute incubations, p>0.05. 
No significant difference between any two concentrations, p>0.05.
Mann Whitney U  test.
Table 2.8 Effect of rheumatoid factor on phagocytic uptake of 
Stanhvlocuccus. aureus by normal polymorphonuclear 
leucocytes
2.3.4 Effect of serum on phagocytosis bv polymorphonuclear cells from rheumatoid 
arthritis patients and normals
As shown in Fig. XIX, the phagocytic capacity of normal PB-PMNs, pre­
incubated for 60 minutes in 50% serum from 36 RA patients, did not differ 
significantly from PMNs pretreated with 50% normal serum (p>0.05). 
However, both groups showed significantly depressed phagocytosis o f S. aureus 
when compared to PMNs incubated with GH alone (patient serum, p=0.001; 
normal serum, p=0.003).
No significant difference of normal PMN or RA PMN function was observed 
between RF positive, RF negative or normal serum (Fig. XX: p>0.05; Fig. XXI: 
p>0.05).
Significantly higher IC levels were detected in the RA serum (IgG: median 
34.5pg/ml, range 0-357pg/ml, p<0.001; IgM: median 69gg/ml, range 0- 
221pg/ml, p<0.001) than in normal serum (IgG: median Opg/ml, range 0- 
58pg/ml; IgM: median Opg/ml, range 0-41pg/ml). In an extended study, 20 out 
of 48 (IgG: 42%) and 15 out of 48 (IgM: 31%) were outwith the normal range. 
No significant correlation was found between RF titre and either IgG (rs=0.192, 
p>0.05) or IgM (rs=0.311, p>0.05) IC concentrations. Comparison of uptake of 
bacteria by normal PMN or RA-PMN with serum IC levels revealed no 
significant correlation.
The results of quantitative Ig, complement and CRP determination in RA  
serum revealed a wide range of values (Fig. XXH). Immunoglobulin A, C3c, 
C4 and CRP concentrations were significantly higher than normal serum values 
(IgA  0.01<p<0.05; C3c: 0.001<p<0.01; C4: 0.001<p<0.01; CRP: p<0.001). Serum
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Fig. XIX Effect of scrum on phagocytic uptake of S. aureus by normal
polymorphonuclear leucocytes.
8 0  h
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 1------
RA-serum N-serum
-* median plus interquartile range
RA : rheumatoid arthritis
N : normal
GH : gcl-hanks
S. aureus : Staphvlococcus aureus
Significant difference between RA-serum and GH: p=0.001, and N-serum and 
GH: p=0.003, but no significant difference between RA-scrum and N-serum: 
p=0.05. Mann Whitney U test.
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Fig. XX Effect of seropositive and seronegative serum on phagocytic uptake of
S. aureus by normal pholymorphonuclcar leucocytes.
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-60
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(1/1024)
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(1/64)
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se ro
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 1-----
N-serum
- -  median plus interquartile range
RF : rheumatoid factor
Sero neg : scrum with no detectable rheumatoid factor
N : normal
PD : phagocytic differential
PD (uptake) : % uptake (PMN-scrum) - % uptake (PMN-GH)
PMN : polymorphonuclear leucocytes
GH : gcl-hanks
No significant difference between groups: p>0.05. 
Mann Whitney U test.
Effect of seropositive and seronegative scrum on phagocytic uptake of 
S. aureus by polymorphonuclear leucocytes from patients with 
rheumatoid arthritis.
-10
- 2 0 -
- 3 0 -
-40
low RFhigh RF sero N-serum
(1/1024) (1/64) neg
median plus interquartile range
RF : rheumatoid factor
Sero ncg : serum with no detectable rheumatoid factor
N : normal
PD : phagocytic differential
PD (uptake) : % uptake (PMN-scrum) -  % uptake (PMN-GH) 
PMN : polymorphonuclear leucocytes
GH : gcl-hanks
No significant difference between groups: p>0.05. 
Mann Whitney U test.
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IgG and IgM from patients with RA, were comparable to levels detected in 
normal serum. Overall, no parameter was found to be significantly lower in 
the RA group compared to the normal group studied, although 4, 5 and 10 
individual patients showed reduced IgA, IgG and IgM respectively.
Comparison of the serum mediated effect on phagocytosis by normal or RA  
PMNs with immunological parameters measured in the serum revealed no 
correlation.
2.3.5 Effect of svnovial fluid on the phagocytosis of Staphylococcus aureus
Synovial fluid from 30 RA patients inhibited the uptake of S. aureus by normal 
PB-PMNs in a dose-dependent fashion (Fig. X X m ). It was observed that this 
inhibitory activity was not specific to RA SF. A  similar but less striking 
inhibition was recorded with SF from 15 patients with other arthritic diseases 
(Table 2.9). However, there was significantly greater inhibition of uptake 
induced by 75% SF from RA patients compared with 75% SF from other 
arthritides (Fig. XXIV, p=0.0001). Synovial fluid from patients with RA had a 
similar dose-dependent inhibitory effect on RA PB-PMNs as on normal PB- 
PMNs. The inhibition induced by 75% SF was significantly greater in normal 
PMNs compared to RA-PMNs (Fig. XXV, p<0.001).
Immunological parameters measured in RA SF revealed a wide range of values 
(Fig. XXVI). As illustrated, IgG and IgM were found to be significantly lower 
in SF compared to normal serum concentrations (IgG, p=0.027; IgM, p=0.003), 
whereas IgA did not differ significantly from the normal range (p>0.05). The 
values o f CRP were significantly higher in 30 out o f 37 (81%) SF tested
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Tig. XXIII Effect of synovial fluid from patients with rheumatoid arthritis on
phagocytic uptake of S. aureus by normal polymorphonuclear
leucocytes.
120
100
80
60
4 0  -
20  -
• • • • • •
50% 75%
synovial fluid dilutions
median plus interquartile range
S. aureus : Staphylococcus aureus 
PI : phagocytic index
PI (uptake) = % uptake (PMN-SF) x q^q 
% uptake (PMN-GH)
PMN : polymorphonuclear leucocyte
SF : synovial fluid
GH : gcl-hanks
Significant difference between 25% and 50% SF: p=0.002, 25% and 75% SF 
p<0.001, and 50% and 75% SF: p=0.014.
Wilcoxon rank test.
SF concentration PI (Uptake)
25%
50%
75%
*
**
56.65
(9.45 -  97.66) 
57.76
(13.30 -  79.43) 
47.43
(21.36 -  93.00)
* median 
** range
SF: Synovial fluid, 
PI: phagocytic index
% uptake (PMN-SF)
PI (uptake) =   x  100
% uptake (PMN-GH)
PMN: polymorphonuclear leucocyte 
GH: gel-hanks
No significant difference between 25% and 50% SF (p>0.05), 50% and 75% SF (p>0.05) 
or 25% and 75% SF (p>0.05).
Mann Whitney U  test.
Table 2.9 Effect of synovial fluid from patients with other arthritic diseases 
on phagocytic uptake by normal polymorphonuclear leucocytes.
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X X I V  Synovial fluid induced inhibition of phagocytic uptake of S. aureus
normal polymorphonuclear leucocytes.
P=0.0001
100
80
40
20  -
RASF NON-RASF
median plus interquartile range
S. aureus : Staphylococcus aureus 
R A  : 75% rheumatoid arthritis synovial fluid
N O N -R A  : 75% synovial fluid from patients with other arthritic diseases
PI : phagocytic index
PI (uptake) = % uptake (PM N-SF) x 100 
% uptake (PM N-GI I)
PMN : polymorphonuclear leucocyte
SF : synovial fluid
GII : gcl-hanks
P : significance level determined by Mann Whitney U  test
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Fig. XXV Synovial fluid induced inhibition o f  phagocytic uptake o f  S. aureus: 
normal PMNs versus rheumatoid arthritis PMNs.
P<0.001
1 0 0  -i
80 -
60  -
40  -
20  -
RA-PMNN-PMN
median plus interquartile range
S. aureus : Staphylococcus aureus
N : normal
PM N : polymorphonuclear leucocyte
R A  : rheumatoid arthritis
PI : phagocytic index
PI (uptake) = % uptake (PMN-SFI x ioo
% uptake (PM N -G H )
SF : 75% synovial fluid from patients with RA
GH : gcl-hanks
P : significance level determined by Mann Whitney U  test
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(pcO.OOOl). C3c was found to be significantly lower than the normal range in 
all of the samples tested (p<0.0001). Although 25 out of 43 (58%) of C4 results 
were lower than the normal range, this did not reach significance (p>0.05).
No correlation was found between inhibition o f uptake by normal or RA PMNs 
and the pH of SF, titres o f RF, IgG or IgM ICs, C3c, C4, IgG, IgA, IgM or 
CRP in the SF.
2.3.6 Opsonic activity o f serum
The concentration of C3c and C4 was not significantly different in serum from 
RA patients compared to control serum (Fig. XXII, p>0.05). Also, there was 
no significant difference between the uptake of S. aureus opsonised with 
patient serum or normal serum (Table 2.10: p>0.05). Bacteria opsonised with 
heat-inactivated normal or RA serum were significantly less phagocytosed than 
those opsonised with the corresponding untreated sera (normal serum: p< 0.001; 
RA serum: p<0.001). There was no significant difference between phagocytic 
uptake o f St aureus opsonised with heat-inactivated normal or RA serum 
(p>0.05).
2.3.7 Opsonic activity of svnovial fluid
The C3c and C4 concentrations were below the normal serum range in the 
majority o f SF tested (Fig. XXVI). The concentration of C3c in SF from RA  
and non-RA patients was significantly lower than normal serum values (p< 0.001 
and p=0.001 respectively). The median value o f complement levels in fluids 
from patients with RA was lower than that in a control group of patients with
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OPSONIC ACTIVITY
Uptake o f Staphylococcus aureus (%)
Untreated Inactivated
RA serum
Normal
serum
RA SF
Non-R A SF
*
* *
29.51
(23.23 -  35.22) 
24.44
(20.46 -  29.96) 
12.80
(5.64 -  32.06) 
18.84
(13.40 -  32.28)
5.03
(3.48 -  8.85) 
3.34
(0.61 -  8.04) 
10.30
(4.87 -  15.99) 
8.68
(3.65 -  20.36)
<0.001
<0.001
<0.001
>0.05
* median
** interquartile range 
RA: rheumatoid arthritis 
SF: synovial fluid
p: significance value determined by Mann Whitney U  test for unpaired and Wilcoxon test
for paired data
RA SF: RA serum; p = 0.003
Non-R A SF: RA serum: p = 0.002
Inactivated RA SF: Inactivated normal serum; p = 0.004
Inactivated Non-RA SF: Inactivated normal serum; p = 0.007
Inactivated RA SF: Inactivated RA serum; p = 0.03
Inactivated Non-R A SF: Inactivated RA serum; p = 0.04
Table 2.10 Opsonic activity of serum and SF from patients 
with and without RA and controls
other forms of arthritis, although this difference did not reach significance 
(Table 2.11: C3c, p>0.05; C4, p>0.05). There was no significant difference 
between the opsonic activity of untreated or heat-inactivated synovial fluids 
from patients with and without RA (Table 2.10: p>0.05). Also, there was no 
significant difference in opsonic activity of RA SF or non-RA SF when 
compared to normal serum (p>0.05). However, this opsonic activity was 
significantly less than that of RA serum (RA SF: p=0.003; non-RA SF:
p=0.002). There was a significant increase in the phagocytic uptake of
aureus opsonised with inactivated SF compared with inactivated normal serum 
(Table 2.10: RA SF, p=0.004; non-RA SF, p=0.007) and inactivated patient 
serum (RA SF, p=0.03; non-RA SF, p=0.04).
Opsonic differentials (OpD) were calculated for RA  and non-RA fluids and 
compared with those for normal serum.
OpD (uptake) = % uptake o f S. aureus - % uptake o f S. aureus
opsonised opsonised
with untreated with inactivated
serum or SF serum or SF
The OpD calculated for RA SF were significantly lower than those calculated
for normal serum (Table 2.12; p=0.03), but not those calculated for non-RA SF
(p>0.05). There was no significant difference between OpD calculated for non-
RA SF and normal serum (p>0.05).
Synovial fluid
RA
Non-R A
C4
(mg/dl) 
22.0 -  55.0
** 7.5
*** (6.0 -  30.0)
11.0
(7.0 -  37.0)
C3c
(mg/dl)
55.0 -  120.0
19.0
(12.5 -  35.0)
34.5
(33.0 -  43.0)
* normal serum range 
** median 
*** range
R A  rheumatoid arthritis
N on -R A  patients suffering from other arthritic diseases.
SF: synovial fluid
RA SF and normal serum: p< 0.001; Non-RA SF and normal serum: p=0.001
No significant difference between the concentrations o f C4 (p>0.05) or C3c (p>0.05) in 
synovial fluids from RA and non-RA patients. Mann Whitney U  test.
Table 2.11 Concentration of complement components in 
synovial fluid
ppsonrn OpD (uptake) %
RA SF
**
10.99
(4.75 -  25.03)
N on-R A  SF 17.62
(14.23 -  29.06)
normal serum 18.87
(16.17 -  26.34)
* median
** interquartile range 
OpD: opsonic differentials
OpD(uptake) = % uptake o f S. aureus -  % uptake o f S. aureus
opsonised with untreated opsonised with inactivated
serum or SF serum or SF
SF: synovial fluid 
RA: rheumatoid arthritis
Significant difference between RA SF and normal serum (p=0.03) 
No significant difference between RA SF and Non-RA SF (p>0.05) 
or Non-RA SF and normal serum (p>0.05). Mann Whitney U  test.
Table 2.12 Opsonic differentials o f rheumatoid arthritis and non- 
rheumatoid arthritis synovial fluid and normal serum
2.4 CONCLUSIONS
In vitro cell assay systems were utilised throughout, as these have several 
advantages over in vivo methods: some of the clinical and immunochemical
variables inherent in patient-orientated studies can be eliminated, known 
homogenous granulocyte cell populations can be used, the effect o f serum and 
SF on PMN phagocytosis can be controlled, and the process o f phagocytosis and 
intracellular killing can be assessed independently of each other, if  desired.
2.4.1 Effect o f drugs on PMN phagocytosis
This study was performed to assess whether any relationship exists between the 
reactivity o f PMNs and drug therapy. Since RA is characterised by chronic 
inflammation with a vast accumulation of PMNs at sites of joint inflammation 
it is possible that, by changing PMN function with drugs know to inhibit or 
stimulate PMNs, the activity of the disease may be modified. However, 
clinicians must be careful not to prescribe such high doses which would 
suppress PMN phagocytic function to such an extent that would render the 
patient more susceptible to bacterial infection.
Tenidap [(z)-5-chloro-3, 2-dihydro-3-(hydroxy-2-thienyl m ethylene)-2-oxo- 
lH -indole-1 -carboxamide], a novel NSAID, possesses good anti-inflammatory -  
analgesic activity in laboratory models, possibly by impairing chemotaxis of 
PMNs into the inflammatory site and it has been found to inhibit arachidonic 
acid-induced PMN degranulation (Otterman, Personal communication). In the 
present study, a dose-dependent inhibition of uptake of S. aureus was observed, 
compared to untreated PMNs. Although this impairment did not reach
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significance, it is possible that higher concentrations o f tenidap will be 
detrimental to PMN phagocytosis. To the best of my knowledge, no other 
studies concerning this aspect of tenidap activity have been published.
In in vitro studies of PMNs from healthy subjects, SASP inhibited random and 
chemotactic migration but had no effect on phagocytosis (Molin and Stendahl,
1979). Furthermore, long term treatment with SASP has shown depressed PMN 
chemotaxis but no consistent change in PMN phagocytic function 
(Hermanowicz et al.. 1985). The present study confirms that over a wide 
concentration range (10gg/m l-500gg/ml), SASP, SP or 5-ASA had no significant 
inhibitory effect on normal PMN phagocytic activity. The impaired 
chemotactic response of PMNs pre-incubated with SASP, will attribute to the 
anti-inflammatory property of this drug. The efficacy of the antibacterial 
component of SASP permits speculation about the role of a bacterial pathogen 
in the aetiopathogenesis of rheumatoid disease.
Indomethacin has proved, at least, in vitro to be a very potent anti­
inflammatory drug. The present in vitro study used indomethacin at a 
concentration of lgg/m l, such as that which occurs in the blood plasma during 
normal drug therapy, and no impairment of PMN phagocytosis was observed. 
This is in agreement with the findings of Youinou and Le G off (1987). In 
contrast, Hannelore, Stelzner and Kunze (1984), found that indomethacin 
dissolved in ethanol clearly inhibited the phagocytosis of both S. aureus and 
Escherichia coli. This inhibition was significant at concentrations o f 1x10"^ 
and 2xlO"^M/l (equivalent to 35.78 and 71.56pg/ml respectively). In clinical 
practice indomethacin is often given in multiple divided doses at 6 or 12 hour 
intervals (50-200mg maximum). Emori et al.(19731 found a mean peak serum 
level of 2.88gg/ml, for SF it was lower, 0.69gg/ml (1 and 2 hours respectively
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following a single 50mg dose). In a later study, Emori et al. (1976) showed that 
with multiple dose schedules plateau levels were reached with maximum peak 
levels not exceeding 2(ig/ml. Therefore, it is unlikely that a patient on the 
maximum dose of 200mg (4x50mg) is going to develop serum or SF 
concentration of 35(ig/ml due to the short half-life o f indomethacin (approx. 5 
hours). The results of Hannelore et al. (1984) are therefore not surprising; 
indomethacin at such high concentrations are perchance toxic to the PMN, 
resulting in cell death. The use o f indomethacin in children was curtailed in 
1967 on the basis of a report that high doses might impair responses to 
infection, with serious consequences (Jacobs, 1967). Such findings have not 
been reported since.
Non-steroidal anti-inflammatory drugs certainly influence the behaviour of 
PMN cells. The impairment of lysosomal enzyme release, demonstrated by 
Northover (1977) in the case of indomethacin, and the inhibition o f neutral 
proteases (Kruze et al.. 1976) are no doubt important anti-inflammatory 
mechanisms. The general consensus however, is that indomethacin does not 
impair PMN phagocytosis.
It is possible that the vast majority of drugs that interfere with host defence 
mechanisms do so not by influencing phagocytosis or bacterial killing but by 
injuring haematopoietic stem cells in the bone marrow or adversely affecting 
the function of differentiated lymphoid cells. Since phagocytosis is augmented 
by bacterial opsonisation, interference by drugs with Ab production is 
ultimately reflected in diminished phagocytic function.
It must be emphasised that results obtained in vitro do not always reflect what 
happens in vivo. This reinforces the need to study the effect o f drugs in vivo
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and thus to focus attention on patient’s PMNs, taking into account their current 
drug treatment. Patients with chronic RA are often treated with multiple-drug 
regimens which complicates the interpretation of in vivo studies. Other factors 
must also be taken into consideration; such as frequency of administration, 
dosage and food intake which may have important modifying effects on serum 
drug concentrations and consequently PMN function. It is probable that some 
of the conflicting results in the literature, may be explained by varying drug 
regimens.
The majority o f patients in the following studies were either treated with 
NSAIDs or ’2nd line’ drugs. Since SASP and indomethacin did not significantly 
impair PMN phagocytosis, drug interference by some o f the commonly used 
anti-rheumatic drugs does not seem to be responsible for the impaired 
phagocytosis observed with PMNs from patients with RA, in this study.
2.4.2 Peripheral blood polymorphonuclear phagocytosis
It has previously been suggested that the defective capacity o f PMNs in RA is 
due to intrinsic cellular defects (Attia et al.. 1982a). Using a radiometric assay, 
the present study provides presumptive support for the theory of an intrinsic 
defect in PMN phagocytosis. This study further demonstrates that the defect is 
not specific for gram positive organisms but also encompasses gram negative 
bacteria.
This PMN phagocytic impairment is in agreement with the findings of 
Corberand et al. (1977) and Wilton et al. (1978). However, other investigators 
found no anomaly of PB-PMN phagocytosis (Brandt and Hedberg, 1969;
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Sheehan et al.. 1984; Breedveld et al.. 1985). Previous contradictory reports can 
be ascribed to differences in techniques employed and also to the use of 
different micro-organisms (baker’s yeast, Candida albicans’), since all micro­
organisms have specific opsonic requirements, (van Furth, Leijh, and Klein,
1984). It has been suggested that the failure to remove autologous sera in some 
studies (Brandt and Hedberg, 1969; Corberand et al.. 1977; Bultmann et al..
1980) makes interpretation of their results difficult and thus, the intrinsic 
phagocytic ability o f PMNs cannot be distinguished from the effect of serum 
upon the PMNs. Furthermore, some researchers failed to separate the processes 
of opsonisation and phagocytosis (Brandt and Hedberg, 1969; Turner et al.. 
1973; Sheehan et al.. 1984). In this study S. aureus and P. mirabilis were pre- 
opsonised, PMNs were suspended in GH, and the assay performed in a serum 
free milieu. The results therefore suggest an intrinsic PMN defect. Another 
possible explanation could be that the PB-PMNs from RA patients have 
migrated from the SF and have not had sufficient time to fully recover from 
the inhibitory activity of the SF (section 2.4.4). Alternatively, the reduced 
uptake may indicate either a reduced flow of young PMNs from the bone 
marrow into the circulation, a rapid elimination of recently formed PMNs or a 
high proportion of older PMNs at the time of bleeding. The impaired 
phagocytosis in RA-PMNs is unlikely to be attributed to the treatment per se. 
in light of the results of the previous study. Of all patients studied only 5 were 
receiving third line therapy, none were receiving salicylates, hydrocortisone or 
tenidap, however, they were on NSAIDs. One other possible explanation 
could be the advancing age of the patients in the study, compared to the 
control group. Although there was no significant correlation between impaired 
uptake and drug therapy, disease duration or age, a slightly downward trend in 
uptake with increasing age was observed. This was not confirmed in a larger
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study, which revealed that PMNs from older normal subjects were no less 
efficient phagocytes than PMNs from young normal subjects.
Vaughan and others (1968) whilst examining blood leucocytes o f patients with 
RA, found Ig inclusions, and a considerable number of them. This would 
result in interiorisation of Fc receptors, leaving fewer membrane receptors for 
subsequent attachment of opsonised bacteria. This could be partly responsible 
for the reduced PMN uptake observed.
The majority of investigators used subjective techniques for measuring 
phagocytosis (Bodel and Hollingsworth, 1966; Brandt and Hedberg, 1969; 
Turner et al.. 1973; Biiltmann et al.. 1980; Breedveld et al.. 1985), such as 
microscopic assays which have several limitations: the small number of PMNs 
examined may be unrepresentative of the behaviour of the PMN population as 
a whole, it is impossible to determine whether organisms or particles associated 
with PMNs have been ingested or are merely adherent to the cell membrane, 
and microscopic determination is open to interobserver error. By contrast, the 
radiometric assay described herein is both objective and sensitive. 
Furthermore, it has been shown, by means of Giemsa-stained preparations and 
electron-microscopic observations that after being washed twice, PMNs no 
longer carry any bacteria on their surface (van Furth et al.. 1984). In this 
investigation the PMNs were washed thrice. It is therefore highly likely that 
the assay system is measuring ingestion and not merely bacterial attachment.
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2.4.3 Effect of serum on phagocytosis bv polymorphonuclear leucocytes
Results of the present study revealed significant impairment of phagocytosis in 
normal PMNs pre-incubated in serum from normals and patients with RA, 
compared to untreated PMNs. However, there was no significant difference in 
PMN uptake whether in the presence of patient serum or normal serum. This 
is in agreement with the recent observation made by Breedveld et al. (1985). 
Nor was there any increase of phagocytic activity of patient PMNs when 
suspended in normal serum compared to patient serum. Furthermore, no 
significant difference was observed between the effect o f seropositive or 
seronegative serum on phagocytosis.
Disparate results have been reported concerning the effect of serum on 
phagocytosis (Turner et al.. 1973; Attia et al.. 1982b; Breedveld et al.. 1985) 
which may be the consequence of different test procedures. In these previous 
studies PMNs were not pre-incubated with serum, and organisms were 
opsonised in test serum, before or during the measurement o f phagocytosis. By 
separating opsonisation, pre-treatment of PMNs with test serum and 
phagocytosis, and washing PMNs and bacteria after each process, as was done 
in this study, the phagocytic uptake can be attributed to the effect o f the serum 
on the PMNs, and not differences in the opsonic activities of the serum.
It has been suggested that the presence of RF can activate the complement 
pathway, producing ICs, which can bind to, or be phagocytosed by PMNs, via 
their C3b receptor. This may interfere with subsequent phagocytosis of 
complement-coated bacteria. Turner et al. (1973), discovered a significant 
relationship between the increase in RF titre and the phagocytic capacity 
decrease of normal PMNs, as was also observed by Hallgren (1978), but not
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other investigators (Corberand et al.. 1977; Attia et al.. 1982b). The findings of 
the present investigation do not support the theory that RF interferes with 
phagocytic uptake as no correlation between the two could be detected. Also, 
normal sera was described as seronegative and the majority contained no 
detectable ICs of either the IgG or IgM class, yet both normal sera and patient 
sera inhibited phagocytosis to the same extent. No correlation was found 
between RF and ICs illustrating that there was no equilibrium between 
complexed and free RF in the sera tested, nor was there any relationship found 
between ICs and phagocytic uptake. Furthermore, PMNs in this study were 
washed after treatment with serum. This process is likely to dislodge any 
surface bound complexes and consequently reveal free C3b receptors.
The concentration of serum complement in RA has been reported as normal or 
elevated (Brandt, 1967; Mallya et al.. 1982). Measurement o f C3c or C3d is a 
useful means of detecting in vivo complement activation. Increased levels are 
in agreement with Nydegger et al. (1977) who showed that complement 
activation is detectable in the circulation of the majority of patients with RA  
and is not confined to the joint space as previously reported (Versey, Hobbs 
and Holt, 1973). Others found lower complement values (Hunder and 
M cDuffie, 1973) which accompanied the high incidence of recurrent bacterial 
infections. Comparable levels of C3c and C4 were detected in serum from RA  
patients and normals, but like previous studies, no relationship was found 
between phagocytosis and the complement level, if  the latter was normal or 
increased (Brandt, 1967). Mallya et al. (1982) found a significant correlation 
between C3d concentration and circulating ICs in their patients, supporting the 
hypothesis that activation of the complement system may be due to the 
presence o f ICs. This study failed to confirm this.
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As non-immune serum was used as opsonin in this study, the majority of 
bacteria will be coated with C3b, however, approximately 5% of normal uptake 
occurs when opsonisation is performed using heat-inactivated serum (section 
2.4.5). This may represent Fc-mediated phagocytosis arising from the presence 
of non-specific Abs. Loss of Fc-mediated phagocytosis by PMNs which have 
fewer/no Fc receptors as a consequence of ingestion of ICs cannot explain such 
a large decrease in phagocytic uptake as detected in the present study. 
Depressed phagocytosis observed in this system is most possibly due to masking 
of C3b receptors by RA or normal serum C3.
2.4.4 Effect of svnovial fluid on phagocytosis bv polymorphonuclear leucocytes
The S. aureus-PMN system employed here also detected a humoral defect in the 
SF of patients with RA, significantly greater than in SF of patients with other 
arthritides. This does not agree with Turner et al. (1973) who reported that 
phagocytosis of yeast by normal PMNs was depressed equally and significantly 
in SF from patients with RA, osteoarthritis and miscellaneous arthritides. 
However, they used the test synovial fluid for opsonisation and failed to 
separate the processes of opsonisation and phagocytosis. In RA, elevated serum 
complement levels and depressed joint fluid complement levels, have been 
reported (Pekin and Zvaifler, 1964), and are in agreement with the results of 
this study. Since complement enhances phagocytosis, through opsonisation, this 
difference in complement activity may be responsible for the decreased uptake 
of Baker’s yeast seen in Turner’s study, rather than the direct action of SF on 
the PMNs. Bodel and Hollingsworth (1966) also reported that plasma- 
containing medium permitted more phagocytosis by both PB-PMNs and SF- 
PMNs than did the SF-containing medium. Wilton et al. (1978) reported
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similar phagocytic inhibition by normal PMNs in SF from RA patients. In the 
present study, trypan blue staining demonstrated no increased incidence of cell 
death in the test PMNs as a result of incubation with SF.
Several factors may be implicated to explain this finding. Immune complexes 
and fluid C3b may be responsible for the inhibitory effect o f SF, in a similar 
fashion, to that described for RA serum. Like RA serum, it is unlikely that 
the inhibitors responsible in RA SF act by blocking surface receptors as PMNs 
were washed after incubation with SF. Turner et al. (1973) showed that 
ingestion of ICs would inhibit subsequent phagocytosis. This would imply that 
the C3b, or Fc receptors are absent due to internalisation of the PMN 
membrane, rather than blocked. This is highly feasible since both IgM and IgG 
ICs were detected in SF from all patients, however no correlation between these 
and the phagocytic index was detected in this study.
Synovial fluid from patients with RA contains free iron (Gutteridge et al..
1982). Both free iron and ICs stimulate the production of oxygen radicals by 
PMNs, which prevent phagocytosis, possibly by damaging surface receptors 
(Starkebaum et al.. 1982). Furthermore, joint fluid components such as 
hyaluronic acid, might impede phagocytosis by interfering with cell-particle 
association, possibly due to the increased viscosity of the fluid surrounding the 
PMNs (Brandt, 1984).
The present studies demonstrate that cellular dysfunctions are in part 
transferable by SF to PMNs of healthy controls, explaining a SF-dependent 
granulocyte function disturbance in patients with RA, although the inhibitory 
factor(s) as yet, remain unidentified.
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2.4.5 Opsonic activity of serum
Opsonisation of S. aureus was equally effective with patient or donor serum. 
The concentration of complement and Ig opsonins in the majority o f patient 
sera was within the normal range and the absence o f inhibitors o f opsonisation 
was evident by the tantamount ability o f RA and normal serum to support 
bacterial phagocytosis.
2.4.6 Opsonic activity of svnovial fluid
This study illustrated significantly less C3c in RA SF than in normal serum. 
Berkowicz et al. (1983) disagree with this observation; they reported that C3c 
levels were higher in SF from patients with RA. However, Molenaar et al. 
(1974) have shown that antisera raised against C3c also binds to antigenic 
determinants on native C3, thus the C3c levels reported in this study represent 
the overall concentration of C3, which other investigators have found to be 
depressed in RA SF (Ruddy and Austen, 1970). Indigenous C3 was removed 
from the SF by Berkowicz and his colleagues (1983), and therefore they only 
recorded the concentration of breakdown products of C3. Thus, it appears that 
SF from patients with RA contain lower total levels o f C3, which consist o f a 
higher proportion of C3c than other breakdown products, compared with SF 
from other forms of arthritis.
The heat-labile opsonic activity of RA SF as measured by the OpD (uptake) 
was significantly lower than that of normal serum. However, the overall 
opsonisation of S. aureus was equally effective with normal serum and SF from 
patients with and without RA. This is in agreement with the findings of
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Breedveld et al. (1986). In the present study this was the consequence of an 
increase in the opsonic activity of inactivated SF compared with inactivated 
serum, that is, Fc-mediated opsonisation. These Ab opsonins are unlikely to be 
specific Abs, as no patients had had a recent bacterial infection and no anti- 
staphylococcal Abs were found in the SF.
Verhoef, Peterson and Quie (1977b) presented evidence that suggested that 
bacteria opsonised in the presence of complement and Igs are primarily 
phagocytosed via the complement receptor. The receptor for bacteria opsonised 
with heat-inactivated serum is specific for the Fc fragment of Ig and appears 
to play a minor role in the phagocytosis o f bacteria opsonised in normal serum. 
The SF used in this study had a very low concentration of complement and 
therefore Fc-mediated phagocytosis seems to predominate in this situation.
The in vivo significance of these findings is unclear, the greater uptake of S,. 
aureus opsonised with inactivated SF compared to inactivated serum, suggests a 
higher IgG content in the SF. It is conceivable that in the rheumatoid joint the 
Igs could bind to and block the Fc receptors on the PMN membrane, thereby 
preventing subsequent Fc-mediated phagocytosis. This phenomenon is unlikely 
to be wholly responsible for the susceptibility to infection seen in RA patients. 
Nevertheless, in conjunction with a depressed C3b opsonic activity of SF and a 
possible intrinsic PMN defect, this could result in a detrimental impairment of 
phagocytosis. Furthermore, the SF tested were observed to be of high viscosity, 
which may also be detrimental in vivo, causing clumping of PMNs, and 
preventing sufficient contact between PMNs and bacteria.
In this assay system, opsonisation with SF may have caused aggregation of Si 
aureus. By clumping together, more bacteria can be phagocytosed via a single
79
receptor, which could compensate for the decrease in C3b production. 
Therefore, the fact that there was no significant difference between the opsonic 
activity o f normal serum and SF from RA and non-RA patients may be due to 
the increased viscosity of SF compared to serum.
In summary, the results of this study suggest, 1) the possibility o f an intrinsic 
cellular phagocytic defect, 2) SF has an inhibitory activity on PMN 
phagocytosis in the rheumatoid joint and 3) a significantly lower concentration 
of C3c detected in SF as compared to serum may consequently result in less 
C3b-mediated phagocytosis in the joint. Some S. aureus strains (eg. Cowan) 
possess an outer layer called protein A, which renders the bacteria more 
resistant to phagocytosis unless adequately opsonised. The foregoing may 
explain, at least in part, the susceptibility of patients with RA to intraarticular 
infections (most commonly S. aureus) as first described by Kellgren et al. 
(1958).
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CHAPTER THREE -  STANDARDISATION OF A N  INTERLEUKIN 1
BIOASSAY
3.1 INTRODUCTION
Mononuclear phagocytes are important contributors to the immune response as 
previously discussed in Chapter 1. A  variety o f stimulants including bacteria, 
viruses, immune complexes, and lymphokines can induce monocytes to
synthesise a number of soluble factors that contribute to host defence 
mechanisms (Dinarello, 1984a) including TNF, colony stimulating factor, 
interferon and IL-1 (Dale, 1981). The most potent stimulator for IL-1 
production is bacterial endotoxin, which has been shown to be active down to a 
concentration of 50pg/ml (Duff and Atkins, 1982). Whole bacteria such as 
Staphylococcus albus (now designated S. epidermidisl also have been shown to 
stimulate in low numbers; as few as 10 bacteria per monocyte will stimulate IL- 
1 production (Gearing, Johnstone and Thorpe, 1985).
Interleukin 1, which is thought to be identical to endogenous pyrogen (EP), is a 
cytokine produced predominantly by mononuclear phagocytes (Gearing et al..
1985) although it is produced by several mammalian cell types. Two forms of 
human IL-1 (alpha and beta) are encoded by separate genes with inducible 
expression in many cell types. The initial product of each is a propeptide of 31 
kilodaltons from which a mature peptide of 17 kilodaltons is excised
(Dinarello, 1986). Interleukin 1 alpha and beta have only 26% amino acid
homology but have similar biological activities (Dinarello, 1986). In resting 
blood monocytes IL-1 messenger RNA is undetectable but after cellular
activation it accumulates rapidly and IL-1 beta is usually the predominant form
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(Dinarello, 1986). It is a moderately stable polypeptide surviving temperatures 
from -70°C to +56°C and pHs ranging from 3 to 11.
Interleukin 1 has a wide range of biological activities (Fig. XXVII) both in vivo 
and in vitro, many of which are considered essential for the induction of 
immune responses against infection and perhaps against malignancies (for 
review, see Dinarello, 1984a). Probably the most significant of these is the 
capacity to stimulate the production of EL-2 by T-cells (Smith et al.. 1980) but 
it also causes an increase in body temperature in vivo (Rosenwasser and 
Dinarello, 1981) which may augment the immune response to bacteria and 
viruses by enhancing the effects of IL-1 on T-cell proliferation (Hanson et al.. 
1983) and potentiating production and secretion of Ab by B-cells (Lipsky et al..
1983).
There is also evidence that injected IL-1 rapidly induces neutrophilia due to 
increased release of PMNs from the bone marrow (Oppenheim, 1986). 
Moreover, in vitro studies indicating that IL-1 is a chemotaxin for PMNs and 
monocytes (Luger et al.. 1983), and lymphocytes (Hunninghake et al.. 1987). 
Virtually all chemotaxins also activate the cells they mobilize. Likewise IL-1 
induces PMNs to increase glucose metabolism through the hexose 
monophosphate shunt and to generate superoxide and intralysosomal enzymes as 
measured by the capacity to reduce intracellular nitroblue tetrazolium salt 
(NBT) (Hunninghake et al.. 1987). Interleukin 1 also induces PMNs to release 
specific granules and to selectively release lysozyme and lactoferrin, which in 
turn sequester iron. In vivo. IL-1 also causes elevation of acute phase proteins 
(APPs) (Dinarello, 1984a) and some of these can act as opsonins to promote 
ingestion of invading organisms by phagocytes (Pepys and Baltz, 1983). 
Furthermore, a combination of IL-1 and LPS or serum factors can increase the
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natural killer activity of large granular lymphocytes. Because these cells have 
natural killer activity and play a significant role in eliminating blood-borne 
metastasising tumour cells, IL-1 may amplify nonspecific host defence 
mechanisms against tumours and virus-infected cells.
Together these findings suggest that IL-1 is indeed produced to facilitate the 
eradication of invading organisms as soon as possible. However, IL-1 does 
have a number of deleterious effects, such as cartilage destruction, muscle 
wasting, high fever, anorexia and inflammation. Indeed IL-1 activity has been 
detected in the SF of patients with RA (Wood et al.. 1983); a disease that is 
characterised by chronic inflammation and cartilage destruction.
The majority o f IL-1 assays utilise in vitro cell or tissue culture techniques. 
Originally, IL-1 was described by Gery and Waksman (1972) in a mouse 
thymocyte co-mitogenesis assay in which IL-1 augmented the proliferation of 
thymocytes and production of IL-2 in response to suboptimal concentrations of 
T-cell mitogens such as phytohaemagglutinin (PHA). Although this assay was 
easy to perform and relatively sensitive, it required primary cultures of thymus 
which were non-specific, for instance they responded to IL-2 (Gearing et al..
1985). Therefore, the assay lacked specificity. Furthermore, it required 72 
hours for maximum proliferation which is a potential disadvantage.
Because o f these problems, several alternative IL-1 assays have been developed. 
These use T-cell lines such as LBRM 33 or EL-4 which produce IL-2 in 
response to IL-1 when co-stimulated with lectin or ionophore (Gillis and Mizel, 
1981; Simon, Laydon and Lee, 1985). The IL-2 is measured by its effects on 
IL-2 dependent cell lines eg. continuous T-lymphocyte line. Such two stage 
assays have the disadvantages that they take 72 hours for completion and that
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background IL-2 production is high. Conlon (1983) has improved this system 
by incorporating the IL-2 dependent continuous T-lymphocyte line in the same 
assay wells as mitomycin C-inactivated LBRM 33 cells co-stimulated with 
PHA. In this one stage assay, IL-1 caused increases in IL-2 production, and 
hence T-cell line proliferation within 24 hours.
The murine T-cell line DIO proliferates in response to IL-1 and has been used 
to measure IL-1 concentrations (Kaye et al.. 1984). However, the DIO cell line 
is difficult to maintain, very time consuming and relatively expensive. Also, 
the assay takes 72 hours to complete.
Additional assays, employing non-lymphoid cells, are available. However, 
many of these are also stimulated by TNF which is probably present in a large 
number of crude IL-1 containing supernatants Therefore the specificity of 
these assays is poor unless advantage is taken of neutralising Abs specific for 
individual cytokines, which are increasingly becoming available.
In the present study, a 24 hour, highly sensitive bioassay for the detection of 
IL-1 was chosen, which was first described by Larrick, Brindley and Doyle 
(1985). A  6-thioguanine-resistant mutant of the murine lymphoma cell line 
LBRM 33 was selected (LBRM TG-6). When this cell line was incubated with 
a suboptimal concentration of PHA and IL-1 it produced IL-2. Interleukin 2 
dependent HT2 cells were co-cultured with the LBRM TG-6 cells to measure 
the release of IL-2. The principle of the assay relies on the fact that LBRM 
TG-6 cells do not incorporate thymidine when cultured in the presence of 
hypoxanthine/azaserine supplemented medium, which metabolically blocks 
DNA synthesis by LBRM TG-6 cells but not by HT2 cells. This selection 
medium replaces the conventional hypoxanthine, aminopterin, thymidine
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medium. This resulted in an assay with a minimal amount of technical 
modifications.
These bioassay systems are, however, vulnerable to interference by IL-2 that 
directly stimulates T-cell proliferation (Lisi et al.. 1987).
The measurement o f IL-1 present in the supemates from cultured cells in vitro 
can be affected by the transfer of substances used either to stimulate or 
suppress IL-1 production. For example, endotoxins and other bacterial 
products often mimic IL-1 activities in vivo. Several pharmacological agents 
which inhibit IL-1 production also interfere with biological assays for IL-1, 
while PHA can affect T-cell assays by the induction of IL-2 production (Lisi et 
M-, 1987) which consequently results in falsely high levels o f IL-1 as measured 
in the bioassay. Furthermore, we cannot rule out the possibility that bacterial 
stimulants affect the release o f both IL-1 and IL-1 inhibitors, which might 
cause variability in assaying the level o f IL-1 activity. Consequently, the 
determination of IL-1 activity by bioassay is not a straightforward process and 
great caution must be taken when interpreting the results.
3.1.1 Aims of the study
The present study seeks to define the optimal conditions for in vitro IL-1 
synthesis by human monocytes, to be used routinely in the laboratory. In 
addition the relative amount o f biologically active IL-1 produced by monocytes 
in response to different stimuli (Lipopolysaccharide (LPS) and S. aureusl is 
compared.
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3.2 MATERIAL AND METHODS
3.2.1 Collection o f peripheral blood
Peripheral blood was withdrawn from normal healthy volunteers as previously 
described in 2.2.2. It was collected into sterile universal containers containing 
ethylenediaminetetra-acetic acid di-potassium salt (K/EDTA:2mg/ml. BDH 
Chemicals Ltd., U.K.).
Normal blood donors were free from any clinically detectable disease and were 
non-users o f drugs.
3.2.2 Separation media
(i) Dextran 500
A  6% (w /v) dextran 500 (Fisons, U.K.) solution was prepared in saline (0.9% 
(w /v) NaCl). Once totally dissolved, it was filtered through a 0.2g sterile 
disposable filter assembly into a sterile glass bottle and stored at 4°C.
(ii) Nycodenz Monocytes
Nycodenz Monocytes (Nyegaard, U.K.) is a commercially available, slightly 
hypertonic, sterile solution for the isolation of monocytes from leucocyte-rich 
plasma. The solution contains Nycodenz, a non-ionic derivative o f tri- 
iodobenzoic acid with a molecular weight of 821, dissolved in: KCL
(1.2mmol/l), CaNa2EDTA (0.1mmol/l), NaCl (0.1mol/l) and Tris buffer (pH 
7.5; 0.2mmol/l). It has a density o f 1.068g/ml and an osmolarity of 337
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mOsm/kg. It is stored at or below 20°C protected from light for optimum 
stability.
(iii) Washing fluid
After separation of the leucocyte-rich plasma on Nycodenz Monocytes, the 
plasma was retained and made up to a 5% solution in saline (0.9% (w /v) NaCl). 
This constituted the ’washing fluid’ and was prepared fresh for each monocyte 
population.
(iv) RPMI 1640
RPMI 1640 (Gibco, UK) was used with the following supplements: lOmM
HEPES buffer, 2mM L-glutamine (200mM; Gibco, U.K.), 50 IU/ml
penicillin/50 IU/m l streptomycin (5000IU/5000IU; Gibco, U.K.), and 2xlO“^M 
2B-mercaptoethanol (20mM; Sigma, U.K.). This complete medium will be 
referred to as RPMI 1640 through this text, unless otherwise specified.
This medium was prepared under sterile conditions and stored at 4°C for not
more than 3-4 days prior to use. Heat-inactivated fetal calf serum (FCS; 
Gibco, U.K.) was added to a final concentration of 10%. Heat-inactivation 
was performed by heating at 56°C for 30 minutes. All FCS used was heat- 
inactivated unless otherwise stated.
All separation media were checked for contamination with endotoxin by Dr. C. 
McCartney, Department of Bacteriology, Glasgow Royal Infirmary, using a 
sensitive chromogenic Limulus Amoebocyte Lysate Micro-assay (Piotrowicz, 
Edlin and McCartney, 1985).
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Nycodenz Monocytes, physiological saline and RPMI 1640 culture medium were 
found to be free of endotoxin. However, heat-inactivated FCS and 6% Dextran 
solution were found to contain approximately 0.04ng/ml and 0.08ng/ml 
respectively, of endotoxin. Consequently, adequate controls were included in 
the assay system to eliminate any endotoxin effect on monocytes.
3.2.3 Separation of monocvtes from whole blood
All centrifugation was performed using a Mistral 4L centrifuge (MSE, U.K.) at 
4°C unless otherwise specified.
Monocytes were separated from K /EDTA blood using a modification of the
method described by Boyum (1968). Peripheral blood (10 parts) was mixed
with 6% (w/v) Dextran 500 (1 part), in a 15ml sterile conical centrifuge tube 
(12x17mm diameter, Sarstedt, UK). The plasma layer, containing the 
leucocytes was removed when the erythrocytes had sedimented (30-60 minutes 
at ambient temperature). The leucocyte-rich plasma (5-6ml) was layered over 
Nycodenz Monocytes solution (3ml) and centrifuged at 600g for 15 minutes.
The recommended method suggests centrifugation at ambient temperature. 
However, I found that this caused considerable irreversible clumping of 
monocytes. For this reason all centrifugation was performed at 4°C which 
eliminated the problem.
Immediately after spinning, clear plasma was removed down to 3-4mm above 
the interphase and retained. Thereafter, the remaining plasma together with 
the interphase and slightly more than half the volume of the separation fluid
was collected into a centrifuge tube. The cells from one tube were diluted to 
6-7ml with physiological saline and centrifuged at 600g for 10 minutes. The 
supernatant fraction was discarded and the cell pellet resuspended in calcium- 
free and magnesium-free HBSS (1 ml) and layered over platelet-free autologous 
K /EDTA plasma (3ml). The tube was centrifuged at 50g for 10 minutes and 
the supernatant carefully removed by pipetting. The monocytes were 
resuspended in ’washing fluid’ (7-8ml) and washed twice at 600g for 10 
minutes. The monocytes were suspended in RPMI 1640 supplemented with 
10% FCS (1ml). A  1/10 dilution of the monocyte suspension was prepared in 
white cell diluting fluid and the cells counted in an improved Neubauer 
counting chamber as before (2.2.4). Cells were adjusted in RPMI 1640 
containing 10% FCS to give the desired concentration.
To determine purity, cells were stained for esterase activity, an enzyme specific 
to monocytes (alpha-Naphthyl Acetate Esterase Kit, Sigma, U.K.). Monocytes 
separated with Nycodenz Monocytes solution were o f high purity (>90%) and 
greater than 99% viability.
3.2.4 Preparation of standard IL-1
An internal laboratory IL-1 standard was prepared from cultures of human 
monocytes obtained from one donor, as described in 3.2.3. Cells were adjusted 
to lxlO^/ml. Sufficient autologous plasma and LPS from Escherichia coli 
055:B5 (Sigma, U.K.) was added to give final concentrations of 5% and 
lOOng/ml respectively and incubated in 7 5 cm2 tissue culture flasks (Bibby 
Scientific Products Ltd., U.K.) for 18 hours at 37°C, in a humidified 
atmosphere of 5% carbon dioxide (C02)/95% air. The solution was pipetted 
into sterile universals, centrifuged at 600g for 10 minutes to remove cells and
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the supernatant filtered through a 0.2 \l  sterile, disposable filter assembly, diluted 
to 1/100 concentration and stored at -20°C in 1ml aliquots. The standard was 
used at a 1/100 concentration with 6 serial dilutions.
3.2.5 Preparation of IL-1 supernatant
Culture conditions, for the generation of IL-1 from monocytes, were optimised 
in these preliminary experiments comparing:
a) monocytes at final concentrations o f 1.25x10^, 2.5x10^, 5x10^ and 1.0x10^ 
cells/ml; and
b) LPS stimuli at 0.1, 1.0 and lOpg/ml final concentrations or S. aureus 
(Pansorbin Brand preparation, Behring Diagnostics, U.K.) at final 
concentrations o f 1x10^, 5x10^ and 1x10^ c.f.u./ml. All dilutions were made in 
RPMI 1640 supplemented with 10% FCS. Monocytes and stimuli were cultured 
in triplicate, in a final volume of 200|il, in flat bottomed 96-well microtitre 
plates (Northumbria Biologicals Ltd., U.K.) for 18 hours at 37°C in a 
humidified atmosphere of 5% CC>2/95% air.
To assay for spontaneous production of IL-1, cell suspensions were incubated 
without LPS or S. aureus for the same period of time. In addition, control 
medium was prepared by incubating RPMI 1640 plus 10% FCS with LPS or 
aureus (without monocytes). To determine whether FCS was capable of 
activating the cells, a control well containing monocytes in RPMI only without 
FCS was set-up.
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After 18 hours, cell-free IL -1-containing supernatants were harvested by 
centrifugation at 600g for 15 minutes at ambient temperature, triplicate cultures 
pooled, filter sterilized (0.2^i), and frozen at -2CPC until assayed for IL-1 
content. Interleukin 2 was not detected in any crude IL-1 supernatants 
prepared in this manner when they were assayed using the HT2 cell line (Cetus 
Corporation, U.S.A.) in a microtitre assay as described by Watson (1979).
3.2.6 IL-1 assay
The 24 hour IL-1 assay, described by Larrick et al. (1985) was performed using 
a slightly modified protocol. The assay makes use o f two cell lines, LBRM 
TG -6 (Cetus Corporation, U.S.A.) and HT2. The LBRM TG -6 cells were 
subcultured at lxlO^/ml in Iscove’s modified Dulbecco’s medium (Gibco, U.K.) 
supplemented with 50IU penicillin/50IU streptomycin and 10% FCS, every 3-4  
days. The HT2 cells were subcultured to a concentration of 4xl0^/m l in RPMI 
1640 containing 10% FCS and fed with 200 units/ml human recombinant IL-2 
(BCL., U.K.) every 48 hours.
The cells were counted and the viability assessed using trypan blue exclusion. 
Sufficient cells were pelleted, at 600g for 10 minutes, such that in the final 
suspension there were 1.5xl0^/ml HT2 cells and lxlO^/ml LBRM TG-6 cells. 
The cells were washed twice in RPMI 1640 supplemented with 10% FCS 
(10ml), before being made up to the final volume to give the required 
concentrations of cells. The standard used in the assay was obtained as 
previously described in 3.2.4. Standard IL-1 was diluted in RPMI 1640 plus 
10% FCS to give working concentrations o f 1/100, 1/1000, 1/2000, 1/5000, 
1/10000, 1/25000 and 1/50000. Interleukin 1-containing supernatants to be
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assayed also required to be diluted to give working concentrations of 1/100, 
1/1000, 1/5000 and 1/10000 for LPS stimulated cultures, and 1/100, 1/500, 
1/1000 and 1/2500 for S. aureus stimulated cultures. The LBRM TG-6  
(lx l05 /w ell) and HT2 (1.5x104/well) cells were distributed into 96-well (u- 
shaped) microtitre plates (lOOul) in RPMI 1640 plus 10% FCS, further 
supplemented with PHA (Wellcome, U.K.) to give a final concentration of 
l|ig/m l. An equal volume (lOOul) of IL-1 standard dilutions and experimental 
sample dilutions was added, in triplicate, to the plates.
A  control was required where no lectin was added, to measure spontaneous IL- 
1 production. Therefore, unstimulated LBRM TG -6/H T2 cells (lOOul) were 
added to triplicate wells containing culture medium only (lOOul). An 
additional control was included which consisted of culture medium and PHA- 
stimulated cells only, no IL-1-containing supernatant.
The cultures were incubated for 18 hours at 37°C in a humidified atmosphere 
of 5% CC>2/95% air. After the incubation period, hypoxanthine (10“^M; final 
concentration: Sigma, U.K.) and azaserine (lOpg/ml; final concentration: Sigma, 
U.K.) were added to the cultures and incubated in the same conditions as 
before. After 4 hours, each well was pulsed with 37 Megabequerels of [^H] 
thymidine (TRK 418, specific activity 1.67x10^ Gigabequerels/mmol; 
Amersham International, U.K.) and incubated for a further 4 hours at 37°C in 
a 5% CC>2 humidified incubator. The cultures were then harvested onto glass 
fibre filter discs (Skatron, U.K.) using a Titertek Cell Harvester (Skatron, 
U.K.). The discs were left overnight to dry and then transferred to 
polypropylene scintillation vials, to which was added scintillant (PPO/toluene 
(4g/l); Canberra Packard, U .K ./ May and Baker, U.K.) (3ml). The
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incorporated radioactivity was assessed by liquid scintillation using a LKB 1216 
Rackbeta II counter.
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3.3 RESULTS
3.3.1 Standard preparation of IL-1
The standard IL-1 preparation was diluted and assayed using the bioassay 
system. As shown in Figure XXVTR, the preparation contains IL-1 activity. 
The X-axis dilutions are on a logarithmic scale which illustrates the results as a 
sinusoidal curve. The Y-axis shows the percentage o f maximum activity. The 
assay system is unable to distinguish between the activity due to the alpha and 
beta form of IL-1. However, in this study such a distinction is not required.
3.3.2 In vitro production of IL-1 bv human monocvtes
The response to supernatants from 1.25xl0^/ml monocytes incubated with 
increasing concentrations of LPS are shown in Figure XXIX. The supernatants 
from these incubations were diluted 4-fold and assayed for IL-1. The 
supernatants from cultures of monocytes at 1.25xl0^/ml and different 
concentrations of heat-killed S. aureus (Cowan 1 strain) were similarly assayed. 
The results are shown in Figure XXX. The concentration of LPS and & 
aureus which illustrated the greatest range of activity was l|ig /m l and 1x1$ /ml 
respectively.
3.3.3 IL-1 production bv varying numbers of monocvtes
The minimum number of monocytes which produced detectable IL-1 activity 
when incubated with lgg/m l LPS or 1 x 1 $ /m l S. aureus was 1.25x1$ /m l (Fig.
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XXXI and XXXII). When the number of monocytes per incubation was 
increased but the same concentration of LPS or S. aureus, progressively more 
IL-1 was produced but the drop o ff from the lowest dilution to the highest 
dilution was diminished.
All other possible combinations of monocytes and LPS or S. aureus 
concentrations were tested. The figures shown represent the optimum 
monocyte and stimulant concentrations for the purposes o f this study.
As a control, monocytes were incubated with RPMI supplemented with 10% 
FCS. Background levels of IL-1 were produced but this was negligible when 
compared to test conditions. As an additional control, monocytes were diluted 
and incubated with RPMI only, in the absence of FCS. From all figures in 
this chapter it can be observed that the FCS used in these assays did not 
significantly activate the monocytes in vitro.
As a consequence of these preliminary studies, monocytes at 1.25xl0^/ml, LPS 
at lpg/m l and S. aureus at lxlCPVml were chosen as the optimum conditions for 
future assays.
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3.4 CONCLUSIONS
The main goal of the present study was to define the experimental conditions 
for routine in vitro IL-1 production. A  prerequisite for defined stimulation of 
monocytes is endotoxin-free culture conditions. The difficulty was knowing 
whether cells that release IL-1 in vitro without deliberate stimulation had, in 
fact, been activated in vivo or inadvertently stimulated during handling. 
Particular care must be taken to exclude accidental contamination with 
endotoxin during cell separation or from the culture media. Commercially 
prepared density gradient media are not necessarily endotoxin free. For this 
reason all media were tested before use and adequate controls incorporated into 
the assays. It is also possible that FCS contains factors other than endotoxin 
which may promote IL-1 release by monocytes (Shore et al.. 1986). Therefore, 
I used filtered, heat-inactivated FCS and included an appropriate control 
comprising monocytes with RPMI alone (no FCS present), which showed that 
FCS was not significantly activating the cells. It is relevant that the same 
batch, not only of FCS, but of all media was used throughout individual 
studies. These measures enabled me to culture monocytes without significant 
activation of the cells.
Polymyxin B is a very effective inhibitor of endotoxin activity in vitro (Duff 
and Atkins, 1982) but the amount o f polymyxin B which can be safely added to 
cell cultures may limit its use in the face of heavy endotoxin contamination. 
We were measuring the effect of LPS and for this reason could not add 
polymyxin B to our cultures, which would eliminate the desired response.
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While we observed little spontaneous in vitro IL-1 production by monocytes 
from healthy individuals we were able to induce high levels o f IL-1 by lpg/m l 
LPS and S. aureus at a concentration of 1x10^ /ml.
Most protocols for IL-1 production suggest that cells should be cultured at 1- 
2x 106/m l, and that their supernatant should be harvested after 18-48 hours of 
culture to give optimal IL-1 titres. It has been suggested that conditions 
outside these limits may result in low yields of IL-1 (Gearing et al.. 1985). 
From the preliminary studies herein, a monocyte concentration o f 1.25xl0Vm l 
was chosen as the standard concentration to be used in subsequent experiments. 
This allows a large number of samples to be separated daily due to the smaller 
volume of blood needed to yield the desired monocyte concentration. We also 
chose 18 hours for culture, since supernatants tested showed demonstrable IL-1 
but no IL-2 production within this time period (Smith, Personal 
communication). It is also important to use fresh monocytes, as cultured 
monocytes differentiate to macrophages which produce little IL-1 (Gearing et 
al., 1985).
Interleukin 1 activity in tissue fluids and also from culture supernatants can be 
obscured by inhibitory material. In culture the most common inhibitor is 
prostaglandin E2 , release of which can be inhibited by indomethacin (Gearing 
et al.. 1985).
The LBRM TG-6/HT2 bioassay was the assay of choice because it was quick 
(24 hours), relatively easy to perform and one of the most sensitive available at 
the initiation o f these studies. Furthermore, the cell lines were readily 
available within the laboratory.
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Other potential problems which accompany all systems that utilise cell lines 
maintained for continuous culture, include possible phenotypic and genotypic 
changes in the cell, as well as contamination of the cell line with mycoplasma. 
Larrick et al. (1985) have found the LBRM TG-6 cell line to show no evidence 
of reversion in over 8 months of continuous culture. Both problems, however, 
are easily controlled by returning to a frozen stock of cells.
More recently radioimmunoassays (RIA) have become commercially available 
from Cistron Biotechnology. Radioimmunoassays have several advantages over 
bioassays: 1) it is possible to measure concentrations in samples containing
interfering factors that would otherwise mask IL-1 bio-activities; 2) it is 
possible to measure one form of IL-1 (ie. either alpha or beta gene product) a 
specificity that is, at present, not possible with any bioassay. Nevertheless, 
they are not without disadvantages: 1) the sensitivity o f RIA are significantly 
reduced (250pg/ml) in comparison with bioassay systems (50pg/ml), however, 
Endres et al. (1988) recently reported IL-1 beta levels as low as 115pg/ml in 
an RIA system; 2) possibly the Ab may recognise epitopes of the molecule that 
are not necessarily relevant to biological activity (Symons et al.. 1987). This 
problem may be overcome in the future by the use of monoclonal Abs directed 
at the active site of IL-1. Another potential disadvantage is the high cost 
which reduces the feasibility of RIA, especially when measuring large numbers 
of samples and working within financial constraints.
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CHAPTER FOUR - INTERLEUKIN 1 PRODUCTION IN RHEUMATOID 
ARTHRITIS
4.1 Introduction
Historically, IL-1 was first used to describe macrophage-derived lymphocyte 
activation factor (LAF) (Gery and Waksman, 1972). However, long before the 
discovery o f LAF, phagocytic cell products had been described and 
characterised as endogenous pyrogen (EP), which caused fever (Atkins, 1960) 
and leucocytic endogenous mediator, which induced neutrophilia, 
hypoferraemia, hypozincaemia and increased the hepatic synthesis of (APPs 
(Kampschmidt, 1981), which contribute to an elevated ESR. This constellation 
of responses are collectively referred to as the acute phase response (APR). 
Since upon purification these biological activities were inseparable from LAF 
activity, it became clear that IL-1 had other activities in addition to its ability 
to augment lymphocyte proliferation (for review see Dinarello, 1984a) (Fig. 
XXVH).
It appears possible that IL-1 fulfills ongoing roles in normal physiology. Such 
a ’non-inflammatory’ role has become plausible with the detection of IL-1 
activity in normal serum (Gahring, Sholly and Daynes, 1984) and urine 
(Kimball et al.. 1984). However, others may disagree, for instance Dinarello 
(1984b) detected very little or no IL-1 in human plasma or serum obtained 
from healthy resting subjects. This could be explained by simultaneous 
production of inhibitors and masking the in vitro detection of serum or urinary 
IL-1. The normal serum levels observed by some (Gahring et al.. 1984) are 
observed to vary, with increases occuring during exercise or even diurnal 
period of waking (Durum, Schmidt and Oppenheim, 1985). This therefore
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raises the questions, do these basal IL-1 levels serve the organism in some 
beneficial way and will deficiencies lead to pathology, as with other hormones?
Interleukin 1 has attracted considerable interest in the past decade primarily as 
a mediator o f host defence (Dinarello, 1984a) and in its pathogenic potential in 
inflammation and immune diseases (Duff, 1985).
Some of the effects of IL-1 on the host have an important and vital role in 
defence against infection and malignant transformation. These basal levels 
could well be essential in maintaining this aspect o f host defence. For example, 
the increase in temperature, mediated by an abrupt increase in the synthesis of 
prostaglandins (PG), most notably PGE2, in the hypothalmic thermoregulatory 
centre, has a direct effect on immunologic responses. Temperatures of 38 and 
39°C dramatically augment the action of IL-1 on T-cell proliferative responses 
(Hanson et al.. 1983), the generation of cytotoxic T-cells, B-cell activity, and Ig 
synthesis (Lipsky et al.. 1983). In addition these febrile temperatures adversely 
affect the replication of several bacteria and viruses. The requirement for iron 
as a growth factor for micro-organisms increases at elevated temperatures 
(Bullen, 1981).
There is further evidence which suggests that IL-1 or its agonists could be 
beneficial in patients with deficient IL-1 production. Highly purified 
recombinant human IL-1 alpha, when administered intramuscularly, has been 
shown to enhance resistance, in a dose-dependent manner, of both normal and 
neutrophilic mice to infection with Pseudomonas aeruginosa and Klebsiella 
pneumoniae (Ozaki et al.. 1987). Czuprynski et al. (1988) illustrated that 
administration of exogenous rIL-1 alpha accelerated the protective response of 
mice to infection by the facultative intracellular pathogen Listeria
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monocytogenes. In a further study, Minami et al. (1988) have shown IL-1 to 
enhance resistance in mice to a wide variety of organisms, including S. aureus. 
Furthermore, IL-1 has been observed to protect rats from a fatal dose of 
Salmonella tvnhimurium (Dinarello, 1984a). Collectively these observations 
suggest a possible use for this cytokine in treatment o f opportunistic infections 
in immunosuppressed patients. Therefore, any disturbance o f the monocyte 
population or deficiencies in the production of IL-1 may render the host less 
resistant to infection.
Conversely, excessive IL-1 production may be detrimental to the host. For 
example, much evidence has implicated IL-1 in the pathogenesis o f RA: high 
levels are found in RA joint effusions (Fontana et al.. 1982; Wood et al.. 1983; 
Nouri et al.. 1984); RA synovial cells spontaneously produce biologically active 
IL-1 in vitro (Nouri et al.. 1985); blood monocytes from patients with RA  
spontaneously secrete elevated levels of IL-1 in vitro (Nouri et al.. 1985; Shore, 
Jaglal and Keystone, 1986); and in-situ hybridisation of messenger RNA shows 
that DL-1 gene expression is activated in vivo in RA synovial cells (Duff et al.. 
1988). Interleukin 1 was initially reported in joint fluids in 1968 by Bodel and 
Hollingsworth, who described a pyrogen, resembling EP, found not only in 
joint fluid o f patients with RA but also in patients with rheumatic fever and 
pseudogout, as well as other disease states. Since EP or leucocytic pyrogen has 
now been shown to be indistinguishable from IL-1 (Rosenwasser and Dinarello, 
1981), these results are quite consistent with those of subsequent researchers. 
In 1984, Tan et al. reported that patients with RA exhibit an enhancement of 
in vitro cytokine release. However they were unable to differentiate IL-1 from 
IL-2 since unseparated peripheral blood mononuclear cells (containing both 
monocytes and T-cells) were used to generate cytokines. More recently, the 
same group extended the study and showed enhanced spontaneous generation of
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IL-1 by monocytes from recently active RA patients but normal IL-2 
generation by their T-lymphocytes (Shore et al. 1986).
Additional evidence that overproduction of IL-1 is associated with pathological 
states, is that many activities of IL-1 are relevant to RA (Dinarello, 1984a). 
Interleukin 1 increases the release from synovial cells o f vasoactive agents and 
mediators of tissue damage (eg. PGE2, collagenase, reactive oxygen molecules 
and proteinolytic enzymes) (Dinarello, 1984a), and is a powerful stimulus of 
bone and cartilage resorption (Dinarello, 1986). It induces an increase in APPs 
(eg. CRP) (Dinarello, 1984b), neutrophilia and fever (Dinarello, 1986), the 
measurement o f which are well-established procedures for monitoring many 
disease states, including RA. Also IL-1 may potentiate chronic inflammation 
by induction of lymphocyte growth factors such as IL-2 and its receptor 
(Durum et al.. 1985). In addition, it is chemotactic for PMNs (Luger et al.. 
1983) and induces lactoferrin release from PMN specific granules, which in 
turn sequester iron, which consequently contributes to the anaemia often seen 
in patients with RA.
There is ample evidence that products formed from arachidonic acid by the 
fatty acid cyclooxygenase pathway (eg. PGs) are mediators of inflammation 
(Vane, 1971). Firstly, these compounds provoke many of the cardinal signs of 
inflammation (eg. erythema, fever, pain, oedema). Secondly, PGs are 
synthesised by phagocytic cells; macrophages are believed to be the major 
source of local PG formation in RA (Sturge et al.. 1978) and finally, synthesis 
of stable PGs (eg. PGE2) is inhibited by many anti-inflammatory drugs.
Indeed elevated PGs have been reported in synovial effusions from patients 
with RA (Sturge et al.. 1978). In addition human rheumatoid synovial tissues
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have been shown to produce approximately 10 times more PGE2, during in 
vitro culture, than does normal synovial tissue (Robinson, Dayer and Krane, 
1979).
The data suggests that these factors could contribute to the pathogenesis of RA, 
therefore the challenge is to identify and develop specific IL-1 antagonists that 
will provide potential therapeutic means o f alleviating symptoms of RA, while 
allowing the many potentially beneficial actions o f IL-1 to continue at a 
functional level.
There are 3 possible types of therapy that therefore might affect the 
pathogenesis of R A  1) drugs that directly affect IL-1 production, 2) drugs 
that interfere with manifestations of the APR for instance, by inhibiting the 
cyclooxygenase system and thereby indirectly interfering with IL-1 production, 
and 3) drugs that modify the effect of IL-1 on target cells, ie. specificity may 
be a key issue. It may be possible to inhibit specific target sites of IL-1 
stimulation and avoid inhibiting other vital target tissues. Qearly, it could be 
argued that to interfere with IL-1 at all could have profound deleterious 
effects, for example, in the amplification of the immune response.
At pharmacological concentrations, only a few agents have been shown to 
inhibit IL-1 production. Hydrocortisone at 10“  ^ to 10“^M inhibits both the 
production and co-mitogenic effects of IL-1. This inhibitory effect may 
account in part for the anti-inflammatory effects of steroids (Oppenheim,
1986). Bondy and Bodel (1971) have also shown that corticosteroids are highly 
effective in reducing IL-1 production in vitro and in vivo. However, their 
side-effects are associated with recurrent infections, in support o f the argument 
that interference with IL-1 production may be detrimental to the host.
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On the other hand, therapeutic concentrations of NSAIDs such as indomethacin, 
do not reduce the production of IL-1 directly (Dinarello, 1984a). They fall 
into the second category of drugs. Indomethacin inhibits the conversion of 
arachidonic acid to biologically active PGs, which indirectly interferes with IL- 
1 production. This suggests that such inhibition may well explain the anti­
inflammatory action of NSAIDS in vivo (Vane, 1971), but unlike the steroids, 
these are not associated with recurrent infections.
4.1.1 Aims of the study
The aim of the present investigation was to test rheumatoid and healthy blood 
monocytes for spontaneous and stimulated IL-1 release, to determine if  patients 
with RA were perhaps susceptible to sepsis as a result o f a deficiency in this 
particular host defence response. Also, to determine if  rheumatoid joints were 
less protected from infection due to their monocytes showing a reduced IL-1 
response either spontaneously or by stimulation, with LPS or S. aureus. 
Furthermore, the study was designed to investigate the effect o f anti­
rheumatic drugs on IL-1 production by monocytes from normals and patients 
with RA and normals.
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4.2 MATERIALS AND METHODS
As the result of preliminary experiments (Chapter 3), IL-1-containing 
supernatants are generated under optimal conditions as follows: monocytes at a
final concentration of 1.25xl0^/ml are stimulated with LPS or S. aureus at final 
concentrations o f lpg/m l and l x l (7 /m l respectively. A ll concentrations are 
made up in RPMI 1640 supplemented with 10% heat-inactivated FCS.
4.2.1 Induction of IL-1 production: rheumatoid arthritis versus normal monocvtes
(i) Subjects
Peripheral blood was aspirated from 9 patients with definite or classical RA  
(Appendix A) (M:F = 4:5), with an average age o f 52 years (range: 38-62 
years), and collected into K /EDTA as previously described in Chapter 3 (3.2.1). 
Peripheral blood was also collected from 10 healthy volunteers (M:F = 5:5), 
with an average age o f 28 years (range: 23-32 years). All patients received 
NSAIDs, and some received ’2nd line’ medication. None were prescribed 
steroids. Controls were free from any clinically detectable disease and were 
non-users of drugs.
(ii) Cell preparation
Peripheral blood monocytes were isolated, as described in Chapter 3 (3.2.3) and 
diluted to a working concentrations of 2.5x10^/ml.
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(iii) IL -1 generation
To obtain monocyte supernatants for IL-1 determination, monocytes were 
stimulated with lpg/m l LPS and S. aureus at a concentration o f lx lti7 /ml, as 
detailed in Chapter 3 (3.2.5).
(iv) Assay for IL-1 activity
The monocyte supernatants were assayed for IL-1 activity using the LBRM 
TG -6/H T2 bioassay system as detailed in Chapter 3 (3.2.6).
4.2.2 Induction of IL-1 production: PB monocvtes versus SF monocvtes
(i) Subjects
Seven patients with definite or classical RA (Appendix A), attending a 
rheumatology outpatient department were recruited.
(ii) Cell preparation
Peripheral blood monocytes were isolated, as previously described (3.2.3) and 
diluted to a working concentration of 2.5xl0^/ml.
Matched SF was aspirated from an inflamed joint and collected into sterile 
universals containing K /EDTA (2mg/ml). Monocytes were separated from SF 
as described for peripheral blood with the exception of the 6% dextran 
sedimentation stage. The SF (5-6ml) was initially layered over Nycodenz 
Monocytes (3ml). If the SF was particularly viscous, it was diluted with an 
equal volume of RPMI 1640 (without FCS) prior to being layered onto the
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Nycodenz Monocyte preparation. Monocytes were adjusted to a working 
concentration of 2.5x10^/ml.
(iii) IL-1 generation
Monocytes were stimulated with 1 |ig/m l LPS and S. aureus at a concentration of 
lx l0 7/m l., as previously described in Chapter 3 (3.2.5).
(iv) Assay for IL-1 activity
Paired PB monocyte and SF monocyte supernatants were assayed for IL-1 
activity using the LBRM TG-6/HT2 bioassay, described previously (3.2.6).
4.2.3 Interleukin 1 production bv monocvtes from patients with RA: before and after 
the in vivo administration of sulnhasalazine
(i) Subjects
Eight patients with definite or classical RA (Appendix A), were recruited into 
this study. The group consisted of 6 females and 2 males with an average age 
of 50 years (range: 34-68 years). These patients had all previously received 
NSAIDs and a variety of ’2nd line’ drugs but had never been prescribed SASP. 
Each patient was prescribed a target dose o f SASP between 2-5mg to be taken 
once daily for the treatment of their RA.
(ii) Cell preparation
Peripheral blood (10ml) was aspirated prior to SASP treatment and monocytes 
separated as previously discussed in Chapter 3 (3.2.3), and diluted to a working 
concentration of 2.5xl0^/ml.
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After 12 weeks of SASP treatment, the same patients were recalled to the clinic 
and were retested as above.
(iii) IL-1 generation
Monocytes were stimulated with lpg/m l LPS and S. aureus at a concentration of 
lx l0 7/m l, as previously detailed in Chapter 3 (3.2.5).
(iv) Assay for IL-1 activity
Monocyte supernatants were assayed for IL-1 activity using the LBRM TG- 
6/HT2 bioassay, described in detail in Chapter 3 (3.2.6).
4.2.4 Effect o f drugs on Interleukin 1 production
(i) Drugs
The drugs studied were the same as those described in Chapter 2 (2.2.5 (v)); 
Tenidap, SASP, SP, 5-ASA, Hydrocortisone sodium phosphate and 
Indomethacin. They were prepared and stored as previously described. Assay 
concentrations o f each drug were as shown in Table 2.5. The drugs were 
diluted to the appropriate working concentrations with RPMI 1640 (without 
FCS) culture medium just prior to use in the assay.
(ii) Subjects
Peripheral blood was aspirated from 7 patients with definite or classical RA  
(Appendix A) (M:F = 2:5), with an average age o f 47 years (range: 35-62 
years), and 7 healthy controls (M:F = 3:4) with an average age o f 32 years
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(range: 25-42 years). All patients were attending the rheumatology outpatient 
clinic at Glasgow Royal Infirmary and were receiving either NSAIDs or ’2nd 
line’ therapy at the time of bleeding. Controls were free from any clinically 
detectable disease and under no medication at time of testing.
(iii) Cell preparation
Blood monocytes were separated as previously described in Chapter 3 (3.2.3), 
and diluted to a working concentration of 5xl0^/m l in RPMI 1640 
supplemented with 20% FCS.
(iv) IL-1 generation
To induce IL-1 release, monocytes at 5xl0^/m l (50ul) were stimulated with 
either LPS at 4|ig/ml (50ul) or S. aureus at a concentration of 4x1(7 /m l (50p.l), 
made up in RPMI 1640 plus 20% FCS. The drugs (at working concentrations) 
were added (lOOpl) to the cell cultures to give a final volume of 200ul and final 
assay concentrations of : monocytes 1.25xl0^/ml; LPS lpg/ml; S. aureus 
lxlO^/ml; and drugs (as shown in Table 2.5). The cultures were incubated at 
37°C in a 5% CO2 humidified incubator for 18 hours as described previously in 
Chapter 3 (3.2.5). Control cultures were prepared excluding the drugs but 
including the solvent used to dissolve the drug. Another set of control cultures 
were prepared excluding the LPS or S. aureus stimulants but including the 
various drug concentrations to examine if  drug alone could stimulate IL-1 
activity.
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(v) Assay for IL-1 activity
The monocyte supernatants were assayed for IL-1 activity using the LBRM 
TG -6/H T2 bioassay as detailed in Chapter 3 (3.2.6).
4.2.5 Expression of results
A  standard IL-1 preparation, as described in Chapter 3 (3.2.4) was included in 
each experiment to ensure the efficiency o f the bioassay. The results o f all 
studies in this chapter are expressed as a percentage o f the maximum activity 
of the standard IL-1 preparation.
4.2.6 Statistical analysis
The data are expressed as the median plus upper and lower quartile values and 
were analysed using non-parametric tests; either the Mann Whitney U  test, for 
unpaired data or the Wilcoxon rank test, for paired data. All significance was 
assessed at the 5% probability level.
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4.3 RESULTS
The monocyte supernatants were found to have maximal IL-1 activity at a 
1/200 dilution. Therefore, the data shown throughout this chapter are 
representative o f this dilution.
4.3.1 Interleukin 1 production bv monocvtes from patients with RA and controls
The results o f IL-1 production by PB monocytes, spontaneously and after 
stimulation with lpg/m l LPS or 1x1(7 /m l S. aureus, from 9 patients with RA  
and 10 control subjects are shown in Fig. XXXIIL Unstimulated RA cells 
produce significantly more IL-1 than normal monocytes (p<0.001) and this 
difference was maintained after LPS and S. aureus stimulation (LPS: p<0.001; 
aureus: p< 0.001). In the case of both RA and control monocytes, LPS or ^  
aureus stimulation resulted in increased IL-1 production over the unstimulated 
cells (LPS: p<0.01, S. aureus: p<0.01 for RA; LPS: p<0.01, S. aureus: p<0.01 for 
normals).
It is interesting to note that in the case o f RA monocytes, LPS appears to be 
the more potent stimulant over S. aureus (p<0.01), whereas for normal 
monocytes, S. aureus stimulates more IL-1 production (p<0.01).
4.3.2 Interleukin 1 production bv paired PB and SF monocvtes from patients with
rheumatoid arthritis
When 8 paired PB and SF monocytes were compared, it was found that PB cells 
spontaneously produced significantly more IL-1 than corresponding SF
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Fig. XXXIII Interleukin 1 production by monocytes from patients with rheumatoid
arthritis and normals.
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S. aureus : Staphylococcus aureus - stimulated IL-1 production
IL-1 : interleukin 1
P : significance level. Mann Whitney U  test
monocytes, as shown in Fig. XXXIV (p=0.01). However, when spontaneous 
IL-1 production by SF monocytes was compared to spontaneous IL-1 
production by control PB monocytes, the former was significantly higher
(p<0.001).
After LPS or S. aureus stimulation, both PB and SF monocytes produced 
significantly more IL-1 over spontaneous production (LPS: p=0.01; S. aureus: 
p=0.01 for both PB and SF monocytes). However, the PB monocytes 
produced significantly more stimulated IL-1 than corresponding SF monocytes 
in the case o f both stimulants (Fig. XXXTV) (p=0.01).
It is interesting to point out that IL-1 production by RA SF and normal PB 
monocytes was also significantly different after stimulation with either LPS or 
S. aureus, a much greater response to both stimulants being shown by SF 
monocytes (LPS: p< 0.001; S. aureus: p< 0.001).
4.3.3 Effect o f sulnhasalazine in vivo on in vitro monocvte IL-1 production
As seen in Fig. XXXV, monocytes from 8 patients with RA released IL-1 
spontaneously. The median value for spontaneous IL-1 release before SASP 
treatment was 20.2%, and this rose significantly to 29.9% in monocytes from 
these same patients, 12 weeks after commencing SASP treatment (p=0.01). This 
increased production was consistent in all 8 patients studied. 
Lipopolysaccharide stimulated IL-1 release in all patients as did S. aureus. The 
median value for LPS and S. aureus-stimulated IL-1 release prior to SASP 
treatment was 31.1% and 34.3% respectively. After 12 weeks of SASP 
treatment these rose to 36.2% and 37.8% respectively, however, this difference
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Fig. XXXIV Interleukin 1 production by paired PB and SF monocytes from patients
with rheumatoid arthritis.
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Pig. XXXV Interleukin I production by PB monocytes from patients with
rheumatoid arthritis: before and after sulphasalazinc treatment
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was not significant (Fig. XXXV). While taking SASP, LPS-stimulated IL-1 
release rose in 62.5% (5/8) and fell in 37.5% (3/8) of patients, and S. aureus -  
stimulated IL-1 release increased in 50% (4/8), decreased in 25% (2/8) and 
remained unchanged in 25% (2/8) of patients (Fig. XXXV).
4.3.4 Effect o f drugs in vitro on monocvte IL-1 production
Monocytes obtained from 7 healthy volunteers and incubated directly with 
tenidap, SASP, SP, 5-ASA and indomethacin, at the concentrations shown in 
Table 2.5, did not release significantly more or less IL-1 than cells not exposed 
to these drugs (Table 4.1). The effect was variable and it did not follow a clear 
dose-response relationship. Upon stimulation with LPS or S. aureus. IL-1 
release was significantly increased (LPS: p=0.04; S. aureus: p=0.04). None of the 
5 drugs mentioned above exhibited an inhibitory action on monocytes, in 
respect to their ability to spontaneously release IL-1 (Table 4.1). However, 
monocytes incubated directly with hydrocortisone sodium phosphate, at 
concentrations of 20 and 30gg/ml, released significantly less IL-1 than 
untreated monocytes (Table 4.1) (p=0.04). Furthermore, in LPS and S. aureus- 
stimulated cultures, hydrocortisone sodium phosphate at all concentrations 
inhibited IL-1 release from monocytes. This effect was consistent in the 7 
control subjects and followed a clear dose-response relationship.
Monocytes obtained from 7 patients with RA and subjected to these same 6 
pharmacological agents demonstrated similar results (Table 4.2). Hydrocortisone 
sodium phosphate was the only agent to effectively reduce IL-1 .release, in a 
dose-dependent manner, both spontaneously (p=0.02) and in stimulated 
monocyte cultures (p=0.02). Upon stimulation with LPS or S. aureus. IL-1
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RPMI LPS stimulated S. aureus
(spontaneous) stimulated
Monocytes 19.4 (11.6-27.8) 56.2 (46.7-58.8) 69.1 (51.8-78.3)
(control)
Drug pg/ml 
TENIDAP
1 15.9 (10.5-17.9) 46.4 (42.6-55.0) 65.7 (56.9-74.1)
2 16.6 (11.9-22.6) 48.2 (40.1-57.4) 64.7 (47.9-74.6)
5 23.4 (11.2-25.8) 48.1 (44.4-55.6) 61.7 (51.7-77.9)
10 13.3 (10.5-19.3) 50.2 (38.4-52.9) 68.6 (59.2-79.1)
SASP
10 20.0 (16.5-21.6) 54.4 (44.5-55.5) 62.4 (56.0-80.1)
20 16.6 (8.5-21.6) 57.2 (51.6-61.5) 65.7 (57.1-68.4)
100 18.8 (9.4-22.0) 49.2 (47.4-62.6) 64.2 (58.2-68.3)
500 16.2 (15.5-22.6) 58.8 (50.9-60.9) 63.8 (50.9-72.3)
SP
10 26.6 (21.0-30.0) 46.1 (37.9-57.5) 63.6 (49.7-82.9)
20 30.2 (17.4-34.8) 45.4 (42.0-64.1) 65.7 (44.9-79.1)
100 27.9 (10.4-30.9) 49.8 (44.6-50.6) 60.6 (50.6-81.0)
500 25.6 (18.2-27.6) 47.8 (42.3-58.0) 64.4 (51.0-81.1)
5-ASA
10 19.4 (17.9-24.8) 46.8 (40.1-52.9) 66.8 (53.1-81.6)
20 18.8 (11.6-22.1) 48.6 (45.6-50.7) 64.1 (56.2-73.1)
100 22.6 (15.3-28.0) 47.4 (40.6-58.6) 67.8 (55.8-81.4)
500 20.8 (10.6-25.4) 51.9 (44.1-60.2) 59.6 (49.1-76.5)
HC
10 11.4 (10.5-20.4) *37.8 (29.7-47.1) *50.9 (41.6-61.8)
20 *13.6 (9.7-16.8) *29.4 (22.2-32.6) *39.4 (31.6-47.1)
30 * 9.9 (8.9-14.2) *19.8 (17.5-22.5) *22.8 (19.6-30.6)
Indo
1 16.4 (9.2-19.9) 58.9 (50.9-60.6) 65.5 (48.9-83.0)
All results are shown as median (range). * = 0.05>p>0.01.
LPS: lipopolysaccharide, S. aureus: Staphylococcus aureus.
SASP: Sulphasalazine, SP: Sulphapyridine, 5-ASA: 5-Aminosalicylic acid, 
HC: Hydrocortisone sodium phosphate, Indo: Indomethacin.
Table 4.1 In vitro drug effect on interleukin 1 production by monocytes from 
normal subjects
RPMI LPS stimulated S. aureus
(spontaneous) stimulated
Monocytes 33.7 (32.4-49.0) 73.2 (69.4-75.7) 58.2 (54.5-64.3)
(control)
Drug jig/ml 
TENIDAP
1 27.6 (22.4-40.1) 67.6 (62.9-88.8) 57.2 (52.6-60.6)
2 33.5 (31.6-52.5) 63.3 (61.2-87.2) 55.1 (48.2-63.6)
5 35.4 (32.8-48.5) 71.7 (68.9-84.2) 56.9 (55.2-59.6)
10 36.2 (31.8-44.9) 76.6 (62.4-81.7) 59.4 (51.6-60.0)
SASP
10 41.6 (34.7-45.5) 69.8 (68.5-79.7) 60.0 (55.0-66.6)
20 42.9 (34.4-48.9) 72.2 (68.6-75.4) 56.9 (53.1-65.1)
100 39.6 (35.6-48.8) 72.6 (70.3-73.5) 57.7 (51.2-67.2)
500 35.7 (26.7-39.6) 72.9 (62.0-76.7) 57.3 (45.4-63.6)
SP
10 38.0 (29.6-47.5) 67.8 (46.9-80.6) 54.3 (49.7-67.2)
20 39.8 (38.1-48.8) 73.2 (65.4-79.9) 56.3 (51.2-65.2)
100 41.9 (33.2-50.2) 72.0 (69.2-76.5) 54.4 (48.6-61.5)
500 40.3 (39.4-46.9) 70.0 (68.0-80.0) 57.3 (54.1-60.5)
5-ASA
10 44.7 (32.4-50.6) 73.1 (62.1-77.0) 60.1 (51.6-63.3)
20 47.6 (34.2-48.5) 71.4 (63.5-80.9) 57.0 (51.5-71.6)
100 45.6 (41.4-50.4) 68.4 (62.5-74.9) 53.8 (45.2-66.7)
500 42.6 (40.4-49.0) 67.2 (60.0-73.0) 56.4 (46.7-67.6)
HC
10 26.2 (23.0-37.7) *45.9 (30.6-52.6) *32.4 (26.2-35.5)
20 *21.6 (17.9-32.5) *39.6 (29.1-54.2) *26.5 (25.0-29.6)
30 *18.2 (14.6-29.5) *30.2 (27.7-49.6) *24.1 (17.6-26.0)
Indo
1 33.5 (26.1-42.8) 62.5 (54.9-69.7) 54.9 (46.4-59.8)
All results are shown as median (range). * = 0.05>p>0.01.
LPS: lipopolysaccharide, S. aureus: Staphylococcus aureus.
SASP: Sulphasalazine, SP: Sulphapyridine, 5-ASA: 5-Aminosalicylic acid, 
HC: Hydrocortisone sodium phosphate, Indo: Indomethacin.
Table 4.2 In vitro drug effect on interleukin 1 production by monocytes from 
rheumatoid arthritis subjects
release from RA monocytes, was significantly increased (LPS: p=0.02; S. aureus:
p=0.02).
A  significantly higher degree o f spontaneous and LPS-stimulated, but not 
aureus -stimulated. IL-1 production was evident in monocytes from RA patients 
compared to the control group (p<0.01).
4.4 CONCLUSIONS
The results o f this study have shown that:
1) PB monocytes of patients with RA produce significantly more IL-1 than 
normal controls both spontaneously and after LPS or S. aureus stimulation.
2) Synovial fluid monocytes spontaneously produce less IL-1 than paired PB 
monocytes, and such a difference was maintained after LPS or S. aureus 
stimulation.
The findings o f the first study confirm those of Nouri et al. (1985) and Shore 
et al. (1986). However, the observations made in the latter study are in 
disagreement with Nouri et al. (1985). He observed higher spontaneous IL-1 
production from SF mononuclear cells than from corresponding PB cells, 
however this was not observed after stimulation. In the present study, the 
possibility remains that the apparent lower level of IL-1 production by 
monocytes from SF, may have been due to the presence o f IL-1 inhibitors.
Spontaneous IL-1 production by monocytes has been previously described 
(Shore et al.. 1986) and in all cases may be due to trauma during isolation
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procedures. This could explain enhanced spontaneous IL-1 production by SF 
mononuclear cells in the study by Nouri et al. (1985). He included a 
centrifugation and resuspension step to remove the cells from the SF. This step 
was omitted during the separation of mononuclear cells from peripheral blood. 
Possibly, this additional treatment has overstimulated the SF mononuclear cells. 
In the present study, SF was diluted 1:1 with culture medium before being 
layered directly onto Nycodenz Monocytes. Other than this it was treated in 
exactly the same way as the PB samples. Furthermore, there was no mention of 
any attempts to limit endotoxin contamination in Nouri’s studies. Endotoxin 
could have been a significant contributing factor to the amount of IL-1 
produced.
Another explanation for the controversial results may have been due to the use 
of LPS or S. aureus as stimulants rather than PHA, as used by Nouri and his 
colleagues (1985). Mononuclear cells contain T-cells, B-cells and monocytes. 
Relevant to this Shore et al. (1986) have found that IL-2 generation by PB 
mononuclear cells in response to PHA is highly variable. This may explain why 
Nouri and his colleagues (1985) did not observe any difference in the mouse 
thymocyte assay between SF and PB mononuclear cells after stimulation, since 
the mouse thymocyte assay is sensitive to IL-2 contaminating IL-1 supernatants.
Enhanced spontaneous generation of IL-1 in the RA patient group suggests in 
vivo activation of their monocytes. Monocytes from patients with RA are 
known to have increased numbers of Fc receptors and elevated activity of their 
hexose monophosphate shunt (Shore et al.. 1986), both features indicative of 
activation. Furthermore, Eastgate et al. (1988) have found messenger RNA for 
IL-1 beta, IL-1 alpha and TNF by in-situ hybridisation in synovial sections
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from RA joints. These observations indicate that IL-1 gene expression is 
activated in vivo within the rheumatoid synovium.
The question which one asks is, what is the mechanism of this activation? 
There are a few possibilities. Firstly, purified human C5a has been reported to 
stimulate IL-1 production in human monocytes (Goodman, Glenweth and 
Weigle, 1982) ie. complement activation. Secondly, ICs have the potential to 
stimulate IL-1 production (Arend, Joslin and Massoni, 1985). Moreover ICs 
are known to be produced and phagocytosed locally in the joint. Arend et al. 
(1985) suggest that complement fixation by ICs generates IL-1 inducing 
activity. While Arend et al. (1985) were unable to detect direct stimulation of 
IL-1 production by various forms of ICs in the absence o f complement, other 
investigators have (Dayer et al.. 1980).
Fever, elevated APPs and leucocytosis are some responses to systemic IL-1 that 
make it a key mediator of inflammation. However, clinical observations have 
revealed that not all patients with RA have a characteristic systemic response. 
For instance, fever is often transient and low grade, leucocytosis is not always 
detectable; a wide range of SF leucocyte counts (6,800 to 258,000mm^) has 
been demonstrated, and APPs are not always elevated (Rosin and Goldberg, 
1962). This could be explained by a reduced IL-1 response by SF monocytes. 
The results illustrated in this study would support this possibility.
A  possible explanation for this could be that some inhibitory substance present 
in SF has downregulated the cells’ mechanism for producing IL-1 when in vivo. 
Consequently when stimulated in vitro the cells have an impaired response to 
IL-1 production. At present, no such inhibitory factor has been characterised.
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One possibility could be the acidic pH of SF, which may be detrimental to 
monocytes and their receptors.
The marked leucocytosis characteristic o f a profound bacterial infection may 
not occur in the presence of concurrent RA (Rosin and Goldberg, 1962). 
Consequently, these patients may be more susceptible to bacterial infection in 
joints and tissues affected by rheumatoid changes. Furthermore, Ozaki et al. 
(1987) have encountered debilitated patients who have signs of bacterial 
infection without elevated body temperature. Some clinicians have the view  
that the prognoses of these patients are generally poorer than the prognoses of 
those who manifest fever. In support of this observation, Keenan et al. (1982) 
reported that infected patients who produce EP had a better survival rate than 
those who lack the ability to produce them. This suggests that RA patients 
who do not show a systemic response and develop an infection within a joint 
may be more susceptible to fatal sepsis than those who manifest a systemic 
response.
Wood and his associates (1983) reported that the amount of IL-1 recovered 
from SF did not correlate with the numbers of monocytes observed in the fluid. 
The joint fluid IL-1 may thus be produced not only by free monocytes but by 
those immobilised in the pannus. Therefore, the possibility that in vitro results 
may not necessarily truly reflect what happens in vivo, cannot be dismissed. 
This could be a potential explanation why, in this study, monocytes from SF 
produced less IL-1 than monocytes from the PB, even although high levels of 
IL-1 have been detected in SF from patients with RA (Fontana et al.. 1982).
Since bacterial products are potent stimulators o f IL-1 production by 
macrophages (Wood et al.. 1983), it is possible that the presence o f IL-1 in SF
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may reflect the presence of persistent bacterial debris. The results presented 
herein, that monocytes from SF produce less IL-1 than monocytes from PB 
when stimulated with S. aureus, could be due to previous occupation of 
receptors on SF monocytes by S. aureus from within the joint cavity and 
therefore, fewer free receptors are available for in vitro stimulation.
It was confirmed in these studies that hydrocortisone, in a dose-dependent 
manner, is a highly effective IL-1 inhibitor in vitro. This is also apparently 
true of its action in vivo (Bondy and Bodel, 1971). Therefore, a joint treated 
with a steroid injection may be more susceptible to septic arthritis. 
Therapeutic concentrations of NSAIDs such as indomethacin have been found 
not to reduce the production of IL-1 (Dinarello, 1984a) which is in agreement 
with this study. It would be expected that the disease-modifying drugs, which, 
along with clinical improvement, are associated with a marked and sustained 
fall in the level of APPs, should slow down erosive progression of RA as 
measured x-radiographically. The fall in APPs could be the consequence of 
reduced IL-1 production, since IL-1 is known to induce the production of 
APPs. The results presented herein do not support this theory, as IL-1 
production was not depressed by either SASP or tenidap (a new agent from 
Pfizer), the two representatives of ’2nd-line’ drugs in this study.
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CHAPTER 5 -  DISCUSSION AND FUTURE RESEARCH
The aim of these studies was to investigate a possible association between 
susceptibility of RA patients to bacterial infection (Gristina et al.. 1974) and 
impaired immune responses in these patients. The research herein concentrated 
on two aspects o f immunity in particular; the phagocytic capacity o f PMNs and 
the capacity o f monocytes to produce IL-1.
Rheumatoid arthritis and its therapy provide portals o f entry for invading 
organisms via skin ulcers, joint injections, aspirations and surgery. The first 
line o f non-specific cellular defence, that is PMNs, has been reported to be 
impaired in these patients (Wilton et al.. 1978; Attia et al.. 1982b). Those 
researchers who reported such an intrinsic defect in RA PMNs have been 
criticised for failing to separate PMNs from autologous plasma or SF (Turner et 
al., 1973) and consequently what they detected could have been the result of an 
extrinsic defect. Indeed, investigations on the effect o f RA serum and SF on 
phagocytosis by normal PMNs revealed that the defect in RA PMNs was of an 
extrinsic nature (Turner et al.. 1973).
In this investigation the phagocytic uptake of S. aureus and P. mirabilis by RA 
PMNs was significantly depressed in comparison to normal PMNs. This is 
suggestive o f an intrinsic defect. Serum from seropositive and seronegative RA  
patients did not inhibit the phagocytic uptake o f S. aureus by normal PMNs 
significantly more so than serum from normal subjects. On the other hand SF 
from RA patients did inhibit phagocytic uptake in a dose-dependent manner, 
and significantly more so than SF from patients with other arthritic diseases. 
Since PMNs circulate from serum into SF and back into serum, it is possible
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that the intrinsic defect could be a measurement of the response of PMNs 
which had not yet recovered from the inhibitory effect of RA SF in vivo.
The nature o f the inhibitor(s) of PMN phagocytosis in SF of RA patients 
remains unclear. It is unlikely that inhibition was mediated by simple blockage 
of receptors, as all PMN preparations were washed after exposure to SF. There 
is some evidence that ICs, present in both RA serum and SF, may be 
responsible for the inhibition of PMN phagocytosis (Turner et al.. 1973). 
Phagocytosis o f ICs requires the internalisation of bound C3b and Fc receptors 
which may also involve the removal of unbound receptors for opsonised 
bacteria. Serum from patients with RA was found to contain significantly 
greater concentrations of both IgG and IgM ICs, than normal serum. Yet RA  
sera, in comparison to normal sera did not significantly depress normal PMN 
phagocytic capacities, irrespective of the RF titre. Furthermore, normal PB- 
PMNs incubated with purified RF, did not exhibit defective phagocytic uptake. 
Therefore, the foregoing theory of ICs being responsible for depressed 
phagocytosis seems an unlikely explanation in this study.
The lack of correlation between parameters such as RF titres and levels of 
complement components suggest that inhibitory agents, other than ICs, may be 
involved. Rheumatoid arthritis SF also contains hyaluronic acid and free iron
(Gutteridge £l al., 1982) both of which have a detrimental effect on
phagocytosis (Brandt, 1974; Sweder van Asbeck et al.. 1984). Furthermore, SF 
is known to contain high levels of IL-1 (Wood et al.. 1983). Therefore, it most 
possibly contains other mediators secreted by activated mononuclear phagocytes, 
such as interleukin 6, colony stimulating factor, TNF and gamma interferon 
(Unanue, 1986).
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Further research in this aspect, should involve the characterisation of the 
inhibitory nature of SF. One possibility is to characterise it according to its 
molecular size. Synovial fluids could be run through a sephadex column 
designed to remove a particular molecular weight fraction. The remainder of 
the fluid could be retested in the phagocytic assay to determine its inhibitory 
capacity. By removing a variety of molecular weight fractions and reassaying 
the fluids, one might be able to identify a specific fraction which significantly 
contributes to the inhibitory action of SF. The nature of this fraction could 
then possibly be determined by gel electrophoresis techniques.
It would also be interesting to measure the concentration of hyaluronate, free 
iron and other metal ions in the SFs and to correlate these with the effect of SF 
on PMN phagocytic uptake. Either one of these may contribute to the 
inhibitory action of SF.
Another area o f research which could be pursued would be to investigate the 
effect o f incubating IL-1, IL-6, TNF, colony stimulating factor and gamma 
interferon -  individually and in all possible combinations -  with normal PMNs. 
In this way it is possible to determine whether one of these factors alone is the 
inhibitor or whether they act synergistically or antagonistically to inhibit PMN 
phagocytosis. Synovial fluid from patients with RA may also indirectly inhibit 
phagocytosis by a lack of opsonins. In this study, and others, SF from RA 
patients showed decreased concentrations o f complement components and heat- 
labile opsonic activity.
In terms of providing a mechanistic explanation for the protective effects of 
IL-1, the most obvious possibility might be that IL-1 directly activates 
antibacterial cellular defence mechanisms.
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Ozaki and his colleagues (1987) among others (Minami jgt ah, 1988)
demonstrated that purified recombinant human IL-1 alpha, in a dose-dependent 
manner, significantly increased the survival rate of experimentally infected 
mice. The ineffectiveness of heat-inactivated IL-1 alpha given at the same 
protein concentration on the same schedule as that o f native EL-1 alpha suggests 
that the protective effect of IL-1 against infection was due to specific 
biological activities.
In addition, other studies of in vitro IL-1 production, from blood leucocytes of 
patients with various conditions such as cancer, large tumour burdens, fatal 
sepsis and malnourishment, that have demonstrated reduced IL-1 production 
(Oppenheim, 1986) emphasize its importance.
Interleukin 1 is chemotactic for PMNs, monocytes and lymphocytes 
(Hunninghake et al.. 1987), and local concentrations o f IL-1 in inflammatory 
sites, such as the rheumatoid joint, probably contribute to cellular infiltration. 
Interleukin 1 has been reported to activate PMNs (Murphy, 1985) upon which 
they release toxic oxygen radicals and enzymes into the surrounding mileu. 
These toxic oxygen radicals and proteolytic enzymes cause tissue damage and 
may damage PMN surface Fc receptors thereby preventing them from 
participating in phagocytosis.
Monocytes from the SF of patients with RA have been shown in this study to 
have a lower capacity to produce IL-1 in vitro. This may be the result of pre­
stimulation and exhaustive production in vivo. Although IL-1 is chemotactic 
for PMNs, this study has shown SF from RA patients to be inhibitory to PMN 
phagocytosis. In addition Mowat and Baum (1971) described RA serum to 
inhibit PMN chemotaxis. It is possible that chemotaxis inhibition extends to
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the SF, which would render the joint susceptible to infection not only due to 
impaired PMN phagocytosis but also to a reduced PMN cell population.
Since some microbial surface structures (such as mucopeptide o f S. aureusl act 
to resist phagocytosis (Minami et al.. 1988), higher doses o f IL-1 might be 
necessary to eliminate such organisms. As IL-1 production by SF monocytes is 
lower than that produced by PB monocytes in vitro, these organisms may 
multiply without much interference from IL-1. If this is the case in vivo it is 
interesting to note that S. aureus is one o f the most common organisms to be 
isolated from cases of septic arthritis (Kellgren et al.. 1958; Goldberg and 
Cohen, 1976).
It seems reasonable to suggest that the infecting dose in vivo may be important. 
If large numbers of bacteria infect the joint, it may overcome the capacity of 
IL-1 to protect the host. In addition if  the phagocytic capacity o f PMNs in the 
joint space is depressed as a result o f the inhibitory action of SF, as previously 
reported herein, the joint is consequently rendered more susceptible to infection 
by lower numbers of bacteria.
It would be interesting to isolate monocytes from the SF and measure their 
production of IL-1, produced both spontaneously and after stimulation. The 
same SF could be tested for the presence or absence o f staphylococcal Ags, 
which would be evidence of past or recent infection, and might provide an 
explanation for the changes in IL-1.
Whatever the cause of defective phagocytosis in the joint, and although 
substantial amounts of IL-1 are produced by SF monocytes in comparison to
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normal monocytes, the consequences of this may be tissue damage and a 
susceptibility to infection of the RA patients.
Experience to date with disease-modifying drugs o f RA is that by and large 
they have not significantly compromised the patient, as confirmed in this study. 
This unfortunately is not the case with steroids, which inhibit IL-1 production 
and at high concentrations may possibly be detrimental to PMN phagocytosis. 
The observed increase in susceptibility to infection associated with steroid 
treatment favours the theory that some of the effects o f IL-1 on the host have 
an important and vital role in defence against infection and therefore treatment 
may be contra-indicated. Steroids are administered sparingly now, often as a 
last resort and only to patients with severe persistent arthritis who have been 
unresponsive to alternative therapy.
In summary, although inhibitors o f phagocytosis do exist, as yet to be clearly 
characterised, I feel that future research should be directed towards:
1. Measuring the concentration of hyaluronate and metal ions in SF and 
correlating these to the inhibitory action of SF on PMN phagocytosis,
2. isolation of inhibitors in SF using gel chromatography,
3. studying the dose/response of interleukins on PMN phagocytosis, and
4. investigation of other PMN functions in response to incubation with SF, 
would also be o f interest, eg. chemotaxis and bactericidal activity.
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APPENDIX A
Diagnostic criteria for rheumatoid arthritis according to the American Rheumatism
Association (ARAV
(Taken from Ropes et al. 1959)
Patients described as classical RA satisfied at least 7 o f the following criteria, while
the diagnosis o f definite RA required 5.
1. Morning stiffness.
2. Pain on motion or tenderness in at least one joint.
3. Swelling or soft tissue or fluid (not bony outgrowth alone) in at least one
joint.
4. Swelling of at least one other joint (any interval free o f joint symptoms
between the 2 joint involvements may not be more than 3 months).
5. Symmetrical joint swelling with simultaneous involvement o f the same joint
on both sides of the body.
6. Subcutaneous nodules over bony prominences, on extensor surfaces or in
juxtra articular regions.
7. X-ray changes typical of RA (which must include at least bony 
decalcification localised to or greatest around the involved joints and not just 
degenerative changes.
8. Positive agglutination test - demonstration of rheumatoid factor.
9. Poor mucin precipitate from SF.
10. Characteristic histological changes in synovial membrane with 3 or more of 
the following:
a) marked villous hypertrophy
b) proliferation of superficial synovial cells often with palisading
c) marked infiltration of chronic inflammatory cells.
d) deposition of compact fibrin
e) foci of cell necrosis.
11. Characteristic histological changes in nodules.
Note: for criteria 1-5 the joint signs and symptoms must have been continuous for
at least 6 weeks.
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None of the RA patients displayed any of the features listed below:
1. The typical rash of disseminated lupus erythematosus.
2. High concentrations of lupus eruthematosus cells.
3. Histological evidence of periarteritis nodosa or sarcoid or a positive Kveim
test.
4. Weakness of neck, trunk and pharyngeal muscles, or persistent muscle 
swelling of dermatomyositis.
5. Definite scleroderma.
6. Tophi.
7. Tubercle bacilli in joints or histological evidence o f joint tuberculosis.
8. Homogentisic acid in the urine.
9. Multiple myeloma.
10. Characteristic skin lesions of erythema nodosum.
11. Leukemia or lymphoma.
12. Agammaglobulinaemia.
13. A  clinical picture characteristic o f rheumatic fever, gouty arthritis, acute 
septic arthritis, Reiter’s syndrome, shoulder hand syndrome, hypertrophic 
pulmonary osteoarthropathy or neuroarthropathy.
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APPENDIX B
Standardisation of phagocytosis methodology 
Standardisation of bacteria
One gram-negative and one gram-positive bacteria were used in this work, 
namely:
1. Staphylococcus aureus. Cowan strain
2. Proteus mirabilis. laboratory strain
A  suspension of known concentration had to be determined for each bacterium. 
This was achieved by preparing a series o f culture dilutions, made with a 
constant dilution factor (Miles and Misra., 1938). A  bacterial suspension of 
known optical density was prepared in phosphate buffered saline, and 10-fold  
dilutions were made from this. 10|_l1 from each dilution were then carefully 
dropped onto an agar plate and incubated overnight at 37°C. The following day, 
bacterial colonies were counted and the concentration of bacteria per millilitre 
in the original sample could be calculated.
For example, if  10 colonies were counted at 10“  ^ dilution, the c.f.u./m l would 
be calculated from the following equation:
c.f.u./m l = 10 x 10^ x  10^
Multiply by a factor of 10^ since only added 10|il o f bacterial suspension to the 
plate and the desired concentration is per millilitre.
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This experiment was repeated 8 times for each of the bacteria and the median 
c.f.u./m l calculated and illustrated graphically as shown overleaf.
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5
10 
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I Staphylococcus aureus
% serum used 
as opsonin
5
20
50
75
100
phagocytic uptake 
(%)
34.2 (29.7 -  41.1)
53.1 (31.1 -  65.9)
38.5 (31.0 -  58.1)
12.2 (5.9 - 20.7)
5.9 (1-5 - 22.4)
phagocytic uptake 
(%)
5.0 (1.5 - 9.9)
29.2 (21.4 -  41.2)
57.2 (40.1 -  65.5)
53.3 (49.8 -  60.4)
52.1 (29.9 -  59.9)
II Proteus mirabilis
* Median of 5 separate experiments performed with 5 different 
polymorphonuclear leucocyte.
** Range.
Effect o f the concentration of serum used during opsonisation of,
I. Staphylococcus aureus and II. Proteus mirabilis. on phagocytic uptake.
Phaeocvtic uptake (% )
Bacteria: PMN ratio S.aureus P. mirabilis
1:1 * 62.3 54.1
** (25.5 -  68.1) (34.6 -  67.8)
5:1 43.1
(23.2 -  49.9)
48.6
(21.6 -  54.9)
10:1 24.1
(15.4 -  35.1)
45.9
(14.2 -  57.8)
20:1 10.4
(8.0 -  15.7)
27 2
(15.6 -  37.1)
50:1 5.1
(4.5 -  8.7)
11.0
(10.1 -  21.7)
100:1 3 2
(3.0 -  4.4)
10.6
(5.4 -  17.9)
* Median of 5 experiments with 5 different PMN preparations. 
** Range.
PMN: polymorphonuclear leucocyte.
S. aureus: Staphylococcus aureus 
P. mirabilis: Proteus mirabilis
Effect of bacterial concentration on phagocytic uptake.
% synovial fluid phagocytic uptake %
used as opsonin o f S. aureus (%) precision
10 * 18.7 52.7
** (6.4 -  42.3)
20 20.3 53.6
(10.6 -  48.2)
25 17.6 37.9
(13.8 -  33.7)
50 20.2 31.4
(13.4 -  30.6)
75 21.1 47.0
(6.6 -  35.4)
* Median of 8 experiments performed with 8 different 
polymorphonuclear leucocyte preparations.
** Range.
S. aureus: Staphylococcus aureus.
Effect of the concentration of synovial fluid used during opsonisation of
S. aureus, on phagocytic uptake.
Staphylococcus aureus Proteus mirabilis
♦ 45.4 43.7
** 39.7 -  50.7 37.1 -  49.0
* Median of 5 experiments performed on 5 separate days using polymorphonuclear 
leucocytes from one normal volunteer.
** Range.
Reproducibility o f the phagocytosis assay.
APPENDIX C
Statistical analysis
Non-parametric statistics were used throughout this study as these tests make relatively 
few assumptions about the nature of the population distribution, ie. they take into 
consideration that the data may not be normally distributed. The tests were performed 
using the statgraphics package (version 2.6) on an Amstrad personal computer.
1. The Mann Whitney U test
The Mann Whitney U  test was used to determine whether there was a significant 
difference between the values found in 2 separate sets of data. The 2 samples are 
combined and all sample observations are ranked from smallest to largest. Tied 
observations are assigned the mean of rank positions that they would have occupied if  
there had been no ties. When both nj or n2 is less than 20, the test statistic is
ni (m + 1)
U = n i n2 + ---- -------- -  R i (I)
2
or
n2 (n2 + 1)
U  = n i n2 +  ------------------- -  R2 (H)
2
Where R j = sum of ranks assigned to the group whose sample size is nj and R 2 =
sum of ranks assigned to the group whose sample size is n2. If the U  calculated is
n l n2 ilarger than   than it is U 1 and can be transformed to U  using the formula
2
U = n2 -  U 1 (III)
If U  is equal to or less than the value given in a table of critical values o f U  (Leach, 
1983), then there is a significant difference between the two groups with the level of 
significance indicated at the head of that table.
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When ni or n2 is larger than 20 the probability associated with a value as extreme as 
the observed value o f U may be determined by computing the value of Z.
Z = U -
ni n2
2
(IV)
(ni)(n2)(n1+n2+l)
12
This value is tested by referring to a table o f probabilities (Leach, 1983). If the 
observed value o f U  has an associated probability equal or less than 0.05, then there is 
a significant difference between the 2 groups. If the associated probability is less than
0.01, then the difference is highly significant. If there is a large proportion of ties 
then the corrected formula for Z is
t = the number of observations tied for a given rank.
2. The Wilcoxon rank sum test
The Wilcoxon rank sum test was used to determine whether the values from one 
sample are significantly different from the values from another paired sample. The
n l n2
U  -
2 (V)
Z =
Where N = nj + n2 
t3 - t
T = -----
12
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observations in the two samples are combined into a single series and ranked in order. 
The lowest score starting with a rank of 1, the next getting a rank of 2 and so on. 
When ni and n2 are both less than 26 the test statistic is
S = 2R -  n2 (N + 1)
where R = sum of ranks in smaller sample
N  = total number o f values 
nj = sample size o f larger group 
n2 = sample size o f smaller group
The significance o f S is determined from a table of critical values for S (Leach, 1983).
When nj or n2 is greater than 25 the probability associated with the observed value of 
S may be determined by computing the value of Z.
Z = Sc -  mean 
SD
where Sc = S -l or S+l
c = continuity correction 
mean = mean of S = 0 
SD = standard deviation of S 
=J variance o f S 
= I njn2 (N+l)
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The significance of Z may then be determined by referring to a table of probabilities 
associated with values of Z in the normal distribution (Leach, 1983). If the observed 
value of Z has an associated probability of equal or less then 0.05 then there is a 
significant difference between the two groups.
In the case o f there being many ties the corrected formula for Z is
Z =/s -  2n -  U j -  Uk \ -  mean
2 (k-1)
fn i n2 (N3 - £ U i3)
3N (N -  1)
where k = the number of distinct values on the response variable
U  = the column marginal totals from an ordered contingency table (Leach, 
1983).
3. The Spearman rank correlation
The Spearman rank correlation coefficient was calculated to investigate the degree of 
association between 2 variables. Each observation from each o f the populations (X and 
Y) is ranked from smallest to largest, in order o f magnitude
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relative to all other observations in that one population. If ties occur in either 
population each tied value is assigned the mean of the rank, positions for which it is 
tied. The test statistic is
rs -  1 - 6 ^ d i 2 (V I)
n (n2 -  1)
where di2 = n [Rfxjl -  R(yj)]2
S i
R(x[) = the rank o f the ith value o f x  
R(yj) = the rank of the ith value o f y 
n = the number of paired variables
If there are a large number of ties then the corrected equation is used
(VII)
rs = 2 3  + 2 J
2JSs21y2
n^ -  n v—1
Where x2 = ----------  -  \  Tx
12
y2 = n^ -  nJ  v —>
------------------ ) T y
12 Z _ ,
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Tx and Ty = the number o f x  and y observations that are tied for a particular 
rank.
When the sample size is 30 or less, the probability that the two variables are 
linked together is obtained by comparing the calculated value o f rs, for n pairs 
of observations with tabulated critical values o f rs (Leach, 1983). When the 
sample size is greater than 30 the significance o f a value as large as the 
observed value or rs is determined by calculating t.
and then determining the significance o f that value o f t by referring to a table 
o f critical values o f t (Leach, 1983).
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